<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Clozapine dose for schizophrenia - Subramanian, S - 2017 | Cochrane Library</title> <meta content="Clozapine dose for schizophrenia - Subramanian, S - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009555.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Clozapine dose for schizophrenia - Subramanian, S - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009555.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009555.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Clozapine dose for schizophrenia" name="citation_title"/> <meta content="Selvizhi Subramanian" name="citation_author"/> <meta content="Morecambe Community Mental Health Team" name="citation_author_institution"/> <meta content="Birgit A Völlm" name="citation_author"/> <meta content="University of Nottingham Innovation Park" name="citation_author_institution"/> <meta content="Nick Huband" name="citation_author"/> <meta content="University of Nottingham Innovation Park" name="citation_author_institution"/> <meta content="nick.huband@nottingham.ac.uk" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD009555.pub2" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/06/14" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009555.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009555.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009555.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Agranulocytosis [chemically induced]; Antipsychotic Agents [*administration &amp; dosage, adverse effects, supply &amp; distribution]; Clozapine [*administration &amp; dosage, adverse effects, supply &amp; distribution]; Psychotic Disorders [diagnosis, drug therapy]; Schizophrenia [*drug therapy]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009555.pub2&amp;doi=10.1002/14651858.CD009555.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009555.pub2&amp;doi=10.1002/14651858.CD009555.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009555.pub2&amp;doi=10.1002/14651858.CD009555.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009555.pub2&amp;doi=10.1002/14651858.CD009555.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009555.pub2&amp;doi=10.1002/14651858.CD009555.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009555.pub2&amp;doi=10.1002/14651858.CD009555.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009555.pub2&amp;doi=10.1002/14651858.CD009555.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009555.pub2&amp;doi=10.1002/14651858.CD009555.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009555.pub2&amp;doi=10.1002/14651858.CD009555.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009555.pub2&amp;doi=10.1002/14651858.CD009555.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009555.pub2&amp;doi=10.1002/14651858.CD009555.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009555.pub2&amp;doi=10.1002/14651858.CD009555.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009555.pub2&amp;doi=10.1002/14651858.CD009555.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009555.pub2&amp;doi=10.1002/14651858.CD009555.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009555.pub2&amp;doi=10.1002/14651858.CD009555.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009555.pub2&amp;doi=10.1002/14651858.CD009555.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009555.pub2&amp;doi=10.1002/14651858.CD009555.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009555.pub2&amp;doi=10.1002/14651858.CD009555.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009555.pub2&amp;doi=10.1002/14651858.CD009555.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009555.pub2&amp;doi=10.1002/14651858.CD009555.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009555.pub2&amp;doi=10.1002/14651858.CD009555.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009555.pub2&amp;doi=10.1002/14651858.CD009555.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009555.pub2&amp;doi=10.1002/14651858.CD009555.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="1ljSZou6";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009555\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009555\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009555\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009555\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","ms","hr","pl","fr","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009555.pub2",title:"Clozapine dose for schizophrenia",firstPublishedDate:"Jun 14, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Schizophrenia Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1ljSZou6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009555.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009555.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009555.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009555.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009555.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009555.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009555.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009555.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009555.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009555.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>9466 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009555.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009555.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009555.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009555.pub2/full#CD009555-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009555.pub2/full#CD009555-sec-0193"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009555.pub2/full#CD009555-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009555.pub2/full#CD009555-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009555.pub2/full#CD009555-sec-0039"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009555.pub2/full#CD009555-sec-0040"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009555.pub2/full#CD009555-sec-0115"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009555.pub2/full#CD009555-sec-0174"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009555.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009555.pub2/appendices#CD009555-sec-0205"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009555.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009555.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/table_n/CD009555StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/table_n/CD009555StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009555.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009555.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009555.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009555.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009555.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009555.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Clozapine dose for schizophrenia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009555.pub2/information#CD009555-cr-0002">Selvizhi Subramanian</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009555.pub2/information#CD009555-cr-0003">Birgit A Völlm</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009555.pub2/information#CD009555-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Nick Huband</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/information/en#CD009555-sec-0215">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 14 June 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009555.pub2">https://doi.org/10.1002/14651858.CD009555.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009555-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009555-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009555-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009555-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009555-abs-0002">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009555-abs-0014">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009555-abs-0001" lang="en"> <section id="CD009555-sec-0001"> <h3 class="title" id="CD009555-sec-0001">Background</h3> <p>Schizophrenia and related disorders such as schizophreniform and schizoaffective disorder are serious mental illnesses characterised by profound disruptions in thinking and speech, emotional processes, behaviour and sense of self. Clozapine is useful in the treatment of schizophrenia and related disorders, particularly when other antipsychotic medications have failed. It improves positive symptoms (such as delusions and hallucinations) and negative symptoms (such as withdrawal and poverty of speech). However, it is unclear what dose of clozapine is most effective with the least side effects. </p> </section> <section id="CD009555-sec-0002"> <h3 class="title" id="CD009555-sec-0002">Objectives</h3> <p>To compare the efficacy and tolerability of clozapine at different doses and to identify the optimal dose of clozapine in the treatment of schizophrenia, schizophreniform and schizoaffective disorders. </p> </section> <section id="CD009555-sec-0003"> <h3 class="title" id="CD009555-sec-0003">Search methods</h3> <p>We searched the Cochrane Schizophrenia Group's Study‐Based Register of Trials (August 2011 and 8 December 2016). </p> </section> <section id="CD009555-sec-0004"> <h3 class="title" id="CD009555-sec-0004">Selection criteria</h3> <p>All relevant randomised controlled trials (RCTs), irrespective of blinding status or language, that compared the effects of clozapine at different doses in people with schizophrenia and related disorders, diagnosed by any criteria. </p> </section> <section id="CD009555-sec-0005"> <h3 class="title" id="CD009555-sec-0005">Data collection and analysis</h3> <p>We independently inspected citations from the searches, identified relevant abstracts, obtained full articles of relevant abstracts, and classified trials as included or excluded. We included trials that met our inclusion criteria and reported useable data. For dichotomous data, we calculated the relative risk (RR) and the 95% confidence interval (CI) on an intention‐to‐treat basis based on a random‐effects model. For continuous data, we calculated mean differences (MD) again based on a random‐effects model. We assessed risk of bias for included studies and created 'Summary of findings' tables using GRADE. </p> </section> <section id="CD009555-sec-0006"> <h3 class="title" id="CD009555-sec-0006">Main results</h3> <p>We identified five studies that could be included. Each compared the effects of clozapine at very low dose (up to 149 mg/day), low dose (150 mg/day to 300 mg/day) and standard dose (301 mg/day to 600 mg/day). Four of the five included studies were based on a small number of participants. We rated all the evidence reported for the main outcomes of interest as low or very low quality. No data were available for the main outcomes of global state, service use or quality of life. </p> <p><i>Very low dose compared to low dose</i> </p> <p>We found no evidence of effect on mental state between low and very low doses of clozapine in terms of average Brief Psychiatric Rating Scale‐Anchored (BPRS‐A) endpoint score (1 RCT, n = 31, MD 3.55, 95% CI −4.50 to 11.60, very low quality evidence). One study found no difference between groups in body mass index (BMI) in the short term (1 RCT, n = 59, MD −0.10, 95% CI −0.95 to 0.75, low‐quality evidence). </p> <p><i>Very low dose compared to standard dose</i> </p> <p>We found no evidence of effect on mental state between very low doses and standard doses of clozapine in terms of average BPRS‐A endpoint score (1 RCT, n = 31, MD 6.67, 95% CI −2.09 to 15.43, very low quality evidence). One study found no difference between groups in BMI in the short term (1 RCT, n = 58, MD 0.10, 95% CI −0.76 to 0.96, low‐quality evidence) </p> <p><i>Low dose compared to standard dose</i> </p> <p>We found no evidence of effect on mental state between low doses and standard doses of clozapine in terms of both clinician‐assessed clinical improvement (2 RCTs, n = 141, RR 0.76, 95% CI 0.36 to 1.61, medium‐quality evidence) and clinically important response as more than 30% change in BPRS score (1 RCT, n = 176, RR 0.93, 95% CI 0.78 to 1.10, medium‐quality evidence). One study found no difference between groups in BMI in the short term (1 RCT, n = 57, MD 0.20, 95% CI −0.84 to 1.24, low‐quality evidence). </p> <p>We found some evidence of effect for other adverse effect outcomes; however, the data were again limited. </p> <p><i>Very low dose compared to low dose</i> </p> <p>There was limited evidence that serum triglycerides were lower at low‐dose clozapine compared to very low dose in the short term (1 RCT, n = 59, MD 1.00, 95% CI 0.51 to 1.49). </p> <p><i>Low dose compared to standard dose</i> </p> <p>Weight gain was lower at very low dose compared to standard dose (1 RCT, n = 27, MD −2.70, 95% CI −5.38 to −0.02). Glucose level one hour after meal was also lower at very lose dose (1 RCT, n = 58, MD −1.60, 95% CI −2.90 to −0.30). Total cholesterol levels were higher at very low compared to standard dose (1 RCT, n = 58, n = 58, MD 1.00, 95% CI 0.20 to 1.80). </p> <p><i>Low dose compared to standard dose</i> </p> <p>There was evidence of fewer adverse effects, measured as lower TESS scores, in the low‐dose group in the short term (2 RCTs, n = 266, MD −3.99, 95% CI −5.75 to −2.24); and in one study there was evidence that the incidence of lethargy (RR 0.77, 95% CI 0.60 to 0.97), hypersalivation (RR 0.70, 95% CI 0.57 to 0.84), dizziness (RR 0.56, 95% CI 0.39 to 0.81) and tachycardia (RR 0.57, 95% CI 0.45 to 0.71) was less at low dose compared to standard dose. </p> </section> <section id="CD009555-sec-0007"> <h3 class="title" id="CD009555-sec-0007">Authors' conclusions</h3> <p>We found no evidence of effect on mental state between standard, low and very low dose regimes, but we did not identify any trials on high or very high doses of clozapine. BMI measurements were similar between groups in the short term, although weight gain was less at very low dose compared to standard dose in one study. There was limited evidence that the incidence of some adverse effects was greater at standard dose compared to lower dose regimes. We found very little useful data and the evidence available is generally of low or very low quality. More studies are needed to validate our findings and report on outcomes such as relapse, remission, social functioning, service utilisation, cost‐effectiveness, satisfaction with care, and quality of life. There is a particular lack of medium‐ or long‐term outcome data, and on dose regimes above the standard rate. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009555-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009555-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD009555-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD009555-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009555-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009555-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD009555-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD009555-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD009555-abs-0009">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD009555-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009555-abs-0015">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009555-abs-0004" lang="en"> <h3>Clozapine dose in schizophrenia</h3> <p><i>Background:</i> Schizophrenia is a severe mental illness that affects thinking and perception. People with schizophrenia often experience profound disruptions in their speech, emotional processes, behaviour and sense of self. Antipsychotic medication can be a helpful treatment for schizophrenia; however, taking antipsychotic medication can have unpleasant effects. Clozapine is an antipsychotic drug that can be useful in treating schizophrenia, particularly when other antipsychotic medications have not worked. It is unclear, however, what dose of clozapine is most effective with the least side effects. This review investigates the effects of receiving clozapine at four different dose levels (high dose, standard dose, low dose, very low dose). </p> <p><i>Searching:</i> An electronic search for studies that randomised people with schizophrenia to receive different doses of clozapine was run in August 2011 and again on 8 December 2016. </p> <p><i>Results</i>: We found five studies with 452 participants which met our inclusion criteria. Each compared the effects of clozapine at very low dose (up to 149 mg/day), low dose (150 mg/day to 300 mg/day) and standard dose (301 mg/day to 600 mg/day). None of the studies examined the effects of clozapine at higher than the standard dose. There was nothing to choose between standard, low and very low doses in terms of body mass index (BMI) measurements in the short term. However, weight gain was greater in those receiving the standard dose compared to those receiving the low dose. The incidence of unpleasant side effects (which included feeling lethargic, producing too much saliva, and feeling dizzy) was less at low dose compared to standard dose. </p> <p><i>Quality of evidence:</i> For main outcomes the quality was low or very low. </p> <p><i>Conclusions:</i> We found no evidence that might indicate the best dose of clozapine for patients with schizophrenia. Careful consideration has to be given to balancing the advantages and disadvantages of different doses in relation to weight gain and other side effects. Overall measurements of BMI were similar between groups; however, some side effects appear to be lower at lower doses. Overall, this review highlights the lack of evidence‐based information available for addressing the question of what dose of clozapine is most effective with the least side effects. There is a need for large, well‐designed and well‐reported randomised clinical trials to address this question. There is a particular need for such trials to look at longer‐term outcomes, and to examine the effects of clozapine when given at greater than the standard dose. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009555-sec-0193" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009555-sec-0193"></div> <h3 class="title" id="CD009555-sec-0194">Implications for practice</h3> <section id="CD009555-sec-0194"> <section id="CD009555-sec-0195"> <h5 class="title">1. For people with schizophrenia</h5> <p>We found no evidence relating dose to clinical response in the short or medium term. A standard dose (301 mg/day to 600 mg/day) helps in improvement of illness but causes more adverse effects than lower doses. Evidence from our review indicates that the very low dose of clozapine (&lt; 150 mg/day) is associated with least side effects. Evidence supports that the low dose (150 mg/day to 300 mg/day) could be the optimal dose to see a clinical response with fewest side effects. Standard dose appears to be associated with more side effects than the other two groups which might necessitate close monitoring of weight, lipid profile and glucose. We could not reach a conclusion on high dose and very high dose of clozapine. Hence, in practice, every patient needs to be titrated on the most appropriate dose of clozapine necessary to gain a response, guided by close monitoring for emergence of side effects. </p> </section> <section id="CD009555-sec-0196"> <h5 class="title">2. For clinicians</h5> <p>Based on effects on mental state, we found no evidence on the optimal dosing of clozapine. Careful consideration has to be given to balancing the advantages and disadvantages of different dosing schemes, in particular in relation to side effects which seem to be lower at lower doses. We were unable to identify any trials on high and very high doses of clozapine. </p> </section> <section id="CD009555-sec-0197"> <h5 class="title">3. For managers or policy makers</h5> <p>More studies are needed to replicate and validate findings so far, and to ascertain effects on outcomes such as relapse, remission, social functioning, quality of life, service utilisation, cost‐effectiveness, satisfaction with care, quality of life. There is a particular lack of medium‐ or long‐term outcome data and on above‐standard dosing regimes. </p> </section> </section> <h3 class="title" id="CD009555-sec-0198">Implications for research</h3> <section id="CD009555-sec-0198"> <section id="CD009555-sec-0199"> <h5 class="title">1. General</h5> <p>Much more data would have been available if the recommendations of the CONSORT statement had been anticipated by the trialists (<a href="./references#CD009555-bbs2-0074" title="MoherD , SchulzKF , AltmanD . The CONSORT statement: revised recommendations for improving the quality of reports of parallel‐group randomized trials. JAMA2001;285(15):1987‐91. ">Moher 2001</a>). Allocation concealment is essential for the result of a trial to be considered valid and gives the assurance that selection bias is kept to the minimum. Well‐described and tested blinding could have encouraged confidence in the control of performance and detection bias. It is also important to know how many, and from which groups, people were withdrawn in order to evaluate exclusion bias. It would also have been helpful if authors had presented data in a useful manner which reflects association between intervention and outcome, for example relative risk, odds ratio, risk or mean differences, as well as raw numbers. Binary outcomes should be calculated in preference to continuous results, as they are easier to interpret. If P values are used, the exact value should be reported. </p> </section> <section id="CD009555-sec-0200"> <h5 class="title">2. Specific</h5> <section id="CD009555-sec-0201"> <h6 class="title">2.1 Reviews</h6> <p>Inspection of the table of excluded studies does not suggest any particular need for additional review topics in relation to clozapine dose since data from any new eligible report will be included in updates of this review. </p> <p>A number of the excluded studies examined adverse effects of clozapine at differing dose regimes, but could not be included because they reported results by serum clozapine level and not by clozapine dose. There may therefore be value in additionally reviewing those studies that focus on serum clozapine levels under a separate or modified protocol. </p> <p><b>Excluded studies in relation to other Cochrane Reviews</b> </p> <p> <div class="table" id="CD009555-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Excluded study</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Comparison</i> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b><i>Existing Cochrane review</i> </b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009555-bbs2-0007" title="deLeonJ , Odom‐WhiteA , StanillaJ , JoiassenR , SimpsonGM . Does clozapine induce akathisia?. Schizophrenia Research1995;15(1‐2):207. ">de Leon 1995a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Akathisia at three clozapine dose levels</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None currently</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009555-bbs2-0009" title="deLeonJ , Odom‐WhiteA , JosiassenRC , DiazFJ , CooperTB , SimpsonGM . Serum antimuscarinic activity during clozapine treatment. Journal of Clinical Psychopharmacology2003;23(4):336‐41. ">de Leon 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Muscarinic side effects at three clozapine dose levels</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None currently</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009555-bbs2-0010" title="deLeonJ , DiazFJ , JosiassenRC , SimpsonGM . Possible individual and gender differences in the small increases in plasma prolactin levels seen during clozapine treatment. European Archives of Psychiatry and Clinical Neuroscience2004;254(5):318‐25. [MEDLINE: 15365707] ">de Leon 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serum prolactin level at three clozapine dose levels</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None currently</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009555-bbs2-0012" title="HanYC , ShiSS , XuRJ , ShangFZ . Controlled clinical trial of high versus low dose clozapine combined with sulpiride for schizophrenia. Shandong Archives of Psychiatry [山东精神医学]2001;14(2):138‐9. ">Han 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two different dose levels of clozapine with an adjunctive medication (sulpiride)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009555-bbs2-0092" title="WangJ , OmoriIM , FentonM , SoaresBGO . Sulpiride augmentation for schizophrenia. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD008125.pub2] ">Wang 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009555-bbs2-0003" title="LiuSF , WangY , WangDP , WeiP , WangSG , MaHJ , et al. Effects of different doses clozapine on glucose metabolism in male schizophrenics. Chinese Journal of New Drugs and Clinical Remedies2005;24(2):98‐101. LiuSF , WeiP , WangSG , WangDP , WangY , MaHJ , et al. Effects of varied dosage of clozapine on blood lipid and glucometabolism in schizophrenia. Chinese Journal of Psychiatry2005;38(2):82‐5. ">Liu 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BPRS and TESS scores at three clozapine dose levels</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None currently</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009555-bbs2-0017" title="NairCJ , deLeonJ , SimpsonGM , JosiassenRC . Therapeutic effects of clozapine on tardive dyskinesia. Cognitive and Behavioral Practice1998;5:119–27. ">Nair 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Those with and without probable tardive dyskinesia at three clozapine dose levels</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None currently</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009555-bbs2-0018" title="NairCJ , JosiassenRC , AbrahamG , StanillaJK , TracyJI , SimpsonGM . Does akathisia influence psychopathology in psychotic patients treated with clozapine?. Biological Psychiatry1999;45:1376–83. ">Nair 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Those with and without probable tardive dyskinesia at three clozapine dose levels</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None currently</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009555-bbs2-0019" title="PotkinSG , BeraR , GulasekaramB . High and low dose of clozapine compared in a double‐blind study. Schizophrenia Research1993;9:246‐7. ">Potkin 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BPRS, CGI &amp; EPS scores at two clozapine dose levels</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None currently</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009555-bbs2-0020" title="PotkinSG , BeraR , GulasekaramB , CostaJ , HayesS , JinY , et al. Plasma clozapine concentrations predict clinical response in treatment‐resistant schizophrenia. Journal of Clinical Psychiatry1994;55(Suppl B):133‐6. [MEDLINE: 7961557] ">Potkin 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BPRS scores at two clozapine dose levels</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None currently</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009555-bbs2-0021" title="TangY , PengC , XiaoH . Research for clozapine in schizophrenia and the relationship between plasma clozapine concentration and clinical response. Journal of Clinical Psychological Medicine [临床精神医学杂志]2000;10(6):335‐7. ">Tang 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical response at three plasma clozapine concentration levels</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None currently</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009555-bbs2-0022" title="VanderZwaagC , McGeeM , McEvoyJP , FreudenreichO , WilsonWH , CooperTB . Response of patients with treatment‐refractory schizophrenia to clozapine within three serum level ranges. American Journal of Psychiatry1996;153(12):1579‐84. [MEDLINE: 8942454] ">VanderZwaag 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BPRS scores at three different serum clozapine levels.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None currently</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009555-bbs2-0023" title="FreudenreichO , WeinerRD , McEvoyJP . Clozapine‐induced electroencephalogram changes as a function of clozapine serum levels. Biological Psychiatry1997;42(2):132‐7. ">VanderZwaag 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BPRS scores at three different serum clozapine levels.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None currently</p> </td> </tr> </tbody> </table> </div> </p> </section> <section id="CD009555-sec-0202"> <h6 class="title">2.2 Trials</h6> <p>Clozapine is usually reserved for people suffering from treatment‐resistant illnesses. In spite of clozapine being in use for a very long time, there are still insufficient trials to clearly evidence which dose of clozapine is optimal for people suffering from schizophrenia and schizophreniform psychosis, to gain response to illness, attain remission and improve quality of life. </p> <p>We consider an ‘ideal’ study might have the following characteristics.</p> <p> <ul id="CD009555-list-0002"> <li> <p>Participants: adults diagnosed with schizophrenia or schizoaffective disorder. Random allocation with 150 participants per arm and 100% follow‐up. </p> </li> <li> <p>Intervention: three contrasting levels of clozapine dose – high (601 mg/day to 900 mg/day), standard (301 mg/day to 600 mg/day) and low (150 mg/day to 300 mg/day). </p> </li> <li> <p>Blinding: participants, clinical staff and researchers blinded to allocation status.</p> </li> <li> <p>Outcomes: functioning (clinically significant response in social or life skills), clinical response (e.g. clinically significant response in mental state), service utilisation (e.g. time to hospitalisation, number of days hospitalised), quality of life, relapse, satisfaction with care, and any clinically important adverse effects (e.g. weight gain, prolactin increase). </p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009555-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009555-sec-0029"></div> <div class="table" id="CD009555-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Clozapine: very low dose (up to 149 mg/day) versus low dose (150 mg/day to 300 mg/day) for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150‐300 mg/day) for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> <br/> <b>Intervention:</b> Clozapine: very low dose (up to 149 mg/day) versus low dose (150 mg/day to 300 mg/day) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Clozapine: very low dose (up to 149 mg/day) versus low dose (150 mg/day to 300 mg/day)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: clinically important response, as defined by individual studies</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: clinically important response, as defined by individual studies *</b> </p> <p>Follow‐up: 16 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean clinical response: mental state ‐ average scores ‐ medium term endpoint (BPRS‐A, high = worse) in the intervention group was<br/> <b>3.55 higher</b> <br/> (4.50 to 11.60 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>* Pre‐defined outcome not reported: Mental state measured as average endpoint scores (BPRS‐A, high = worse). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Functioning: clinically important change in general functioning, as defined by individual studies</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effect: clinically important adverse effect (weight ‐ BMI)</b> <br/> Follow‐up: 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean adverse effect ‐ any clinically important specific adverse effects ‐ BMI in the intervention group was<br/> <b>0.1 lower</b> <br/> (0.95 lower to 0.75 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Service use: number of days hospitalised</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Service use: time to hospitalisation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life: clinically important change in general quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias: rated as 'serious' (downgraded by 1) due to attrition bias, reporting bias, and sponsorship by Novartis Pharmaceuticals.<br/> <sup>2</sup> Indirectness: rated 'serious' (downgraded by 1) as proxy measure of pre‐defined outcome<br/> <sup>3</sup> Imprecision: rated 'serious' (downgraded by 1) as only one study providing data, small number of participants (less than 200) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009555-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Clozapine: very low dose (up to 149 mg/day) versus standard dose (301 mg/day to 600 mg/day) for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus STANDARD DOSE (301‐600 mg/day) for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> <br/> <b>Intervention:</b> Clozapine: very low dose (up to 149 mg/day) versus standard dose (301 mg/day to 600 mg/day) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Clozapine: very low dose (up to 149 mg/day) versus standard dose (301 mg/day to 600 mg/day)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: clinically important response, as defined by individual studies</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: clinically important response, as defined by individual studies *</b> </p> <p>Follow‐up: 16 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean clinical response: mental state ‐ average scores ‐ medium term endpoint (BPRS‐A, high = worse) in the intervention group was<br/> <b>6.67 higher</b> <br/> (2.09 to 15.43 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>* Pre‐defined outcome not reported: Mental state measured as average endpoint scores (BPRS‐A, high = worse). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Functioning: clinically important change in general functioning, as defined by individual studies</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effect: clinically important adverse effect (weight ‐ BMI)</b> <br/> Follow‐up: 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean adverse effect ‐ any clinically important specific adverse effects ‐ BMI in the intervention group was<br/> <b>0.1 higher</b> <br/> (0.76 lower to 0.96 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Service use: number of days hospitalised</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Service use: time to hospitalisation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life: clinically important change in general quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias: rated as 'serious' (downgraded by 1) due to attrition bias, reporting bias, and sponsorship by Novartis Pharmaceuticals.<br/> <sup>2</sup> Indirectness: rated 'serious' (downgraded by 1) as proxy measure of pre‐defined outcome<br/> <sup>3</sup> Imprecision: rated 'serious' (downgraded by 1) as only one study providing data, small number of participants (less than 200) </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009555-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Clozapine: low dose (150 mg/day to 300 mg/day) versus standard dose (301 mg/day to 600 mg/day) for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Clozapine: low dose (150 mg/day to 300 mg/day) versus standard dose (301 mg/day to 600 mg/day) for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> <br/> <b>Intervention:</b> Clozapine: low dose (150 mg/day to 300 mg/day) versus standard dose (301 mg/day to 600 mg/day) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Clozapine: low dose (150 mg/day to 300 mg/day) versus standard dose (301 mg/day to 600 mg/day)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Global state: clinically important response, as defined by individual studies</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Mental state: clinically important response in mental state</b> <br/> BPRS score &gt;30% change<br/> Follow‐up: 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.93</b> <br/> (0.78 to 1.1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>176<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/> low <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>186 per 1000</b> <br/> (156 to 220) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>465 per 1000</b> <br/> (390 to 550) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>800 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>744 per 1000</b> <br/> (624 to 880) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Functioning: clinically important change in general functioning, as defined by individual studies</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effect: clinically important adverse effect ( weight ‐ BMI)</b> <br/> Follow‐up: 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean adverse effect ‐ any clinically important specific adverse effects ‐ BMI in the intervention group was<br/> <b>0.2 higher</b> <br/> (0.84 lower to 1.24 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Service use: number of days hospitalised</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Service use: time to hospitalisation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life: clinically important change in general quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias rated as 'serious' (downgraded by 1) as allocation concealment, blinding status and trial sponsorship unclear<br/> <sup>2</sup> Indirectness: rated 'serious' (downgraded by 1) as proxy measure of pre‐defined outcome </p> <p><sup>3</sup> Imprecision: rated as 'serious' (downgraded by 1) as only one study providing data, small number of participants (less than 200) </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009555-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009555-sec-0030"></div> <p>Schizophrenia is a serious mental illness characterised by profound disruptions in thinking and speech, emotional processes, behaviour and sense of self (<a href="./references#CD009555-bbs2-0093" title="World Health Organisation. Health topics, mental health, schizophrenia. www.who.int/mental_health/management/schizophrenia/en/ (accessed 9 March 2013). ">WHO 2013</a>). It can have great impact in terms of both human suffering and societal expenditure (<a href="./references#CD009555-bbs2-0089" title="vanOsJ , KapurS . Schizophrenia. Lancet2009;374(9690):635–45. [PUBMED: 19700006] ">van Os 2009</a>). It is among the world's top ten causes of long‐term disability, leading to problems in social and occupational functioning and self‐care (<a href="./references#CD009555-bbs2-0073" title="MueserKT , McGurkSR . Schizophrenia. Lancet2004;363(9426):2063–72. [PUBMED: 15207959] ">Meuser 2004</a>). Before the introduction of clozapine, doctors largely relied on first generation (typical) antipsychotics, such as chlorpromazine, to control persisting symptoms and to prevent further exacerbations or relapse of illness (<a href="./references#CD009555-bbs2-0060" title="KaneJM . Treatment programme and long term outcome in chronic schizophrenia. Acta Psychiatrica Scandinavica Supplementum1990;358:151–7. ">Kane 1990</a>). Clozapine is the first second generation (atypical) antipsychotic drug introduced to the market. Arnt suggested that second generation antipsychotics are those that do not cause movement disorders (catalepsy) in rats at clinically effective doses (<a href="./references#CD009555-bbs2-0027" title="ArntJ , SkarsfeldtT . Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 199;8(18):63–101. ">Arnt 1998</a>). When clozapine was introduced it proved to be superior in controlling treatment‐resistant illness, with fewer extrapyramidal side effects (EPSEs) than typical antipsychotics such as chlorpromazine (<a href="./references#CD009555-bbs2-0059" title="KaneJ , HonigfeldG , SingerJ , MeltzerH . Clozapine for the treatment resistant schizophrenic: a double‐blind comparison with chlorpromazine. Archives of General Psychiatry1988;45(9):789–96. ">Kane 1988</a>). However, clozapine was largely withdrawn from use in 1975 following the death of some patients due to the development of agranulocytosis. This withdrawal, however, was not followed worldwide. For example, Scandinavia, Germany and China continued to use clozapine. Subsequent studies demonstrated that clozapine could be administered safely when patients are carefully monitored for side effects such as agranulocytosis (<a href="./references#CD009555-bbs2-0059" title="KaneJ , HonigfeldG , SingerJ , MeltzerH . Clozapine for the treatment resistant schizophrenic: a double‐blind comparison with chlorpromazine. Archives of General Psychiatry1988;45(9):789–96. ">Kane 1988</a>; <a href="./references#CD009555-bbs2-0075" title="NaheedM , GreenB . Focus on clozapine. Current Medical Research and Opinion2001;17(3):223–9. ">Naheed 2001</a>). Following this, clozapine was reintroduced in the USA in 1990 with hopes that it would improve quality of life, cognitive functioning and movement disorders, and also reduce negative symptoms such as poverty of speech, blunting of affect, lack of volition and social withdrawal in the management of treatment‐resistant schizophrenia. During this reintroduction, some safeguards were put in place; for example, clozapine is recommended to be used only in treatment‐resistant schizophrenia along with regular monitoring for side effects such as agranulocytosis. </p> <section id="CD009555-sec-0031"> <h3 class="title" id="CD009555-sec-0031">Description of the condition</h3> <section id="CD009555-sec-0032"> <h4 class="title">1. Schizophrenia</h4> <p><a href="./references#CD009555-bbs2-0093" title="World Health Organisation. Health topics, mental health, schizophrenia. www.who.int/mental_health/management/schizophrenia/en/ (accessed 9 March 2013). ">WHO 2013</a> estimates that about 24 million people worldwide are affected by schizophrenia. The symptoms typically emerge in late adolescence or early adulthood. It is unclear as to what exactly causes schizophrenia, but both genetic and environmental factors are thought to play a role. <a href="./references#CD009555-bbs2-0093" title="World Health Organisation. Health topics, mental health, schizophrenia. www.who.int/mental_health/management/schizophrenia/en/ (accessed 9 March 2013). ">WHO 2013</a> identified a low incidence of 3 per 100,000, whereas <a href="./references#CD009555-bbs2-0072" title="McGrathJ , SahaS , ChantD , WelhamJ . Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiologic Reviews2008;30:67‐76. [DOI: 10.1093/epirev/mxn001] ">McGrath 2008</a> identified the median incidence of schizophrenia as 15.2 per 100,000 people. <a href="./references#CD009555-bbs2-0080" title="SahaS , ChantD , WelhamJ , McGrathJ . A systematic review of the prevalence of schizophrenia. PLoS Medicine2005;2(5):e141. ">Saha 2005</a> found no significant difference in prevalence between urban, rural, and mixed sites. The prevalence of schizophrenia in migrants is higher compared to native‐born individuals and is lower in poorer countries than in richer countries. <a href="./references#CD009555-bbs2-0080" title="SahaS , ChantD , WelhamJ , McGrathJ . A systematic review of the prevalence of schizophrenia. PLoS Medicine2005;2(5):e141. ">Saha 2005</a> identified the median point prevalence of schizophrenia (the proportion of people who suffer from schizophrenia at a specific point in time) as 4.6 per 1000; the median lifetime prevalence for persons (the number of people in the population who have ever manifested the disease) was 4.0 per 1000; and the lifetime morbid risk (the likelihood of a particular individual developing schizophrenia in their lifetime) as 7.2 per 1000. Acute schizophrenia predominantly manifests itself with positive symptoms such as abnormal experiences; these include abnormal perceptions in the absence of a stimulus (hallucinations), false fixed beliefs (delusions), and disordered thinking. Chronic schizophrenia typically manifests itself with negative symptoms. Though there is no complete agreement as to the specification of negative symptoms, it is generally agreed that they include poverty of speech, blunting of affect, lack of volition and social withdrawal (<a href="./references#CD009555-bbs2-0051" title="GelderMJ , MayouR , CowenP . Oxford Shorter Textbook of Psychiatry. 4th Edition. New York, USA: Oxford University Press, 2001. ">Gelder 2001</a>). More than 50% of people with schizophrenia are not receiving appropriate care and about 90% of people with untreated schizophrenia live in developing countries (<a href="./references#CD009555-bbs2-0093" title="World Health Organisation. Health topics, mental health, schizophrenia. www.who.int/mental_health/management/schizophrenia/en/ (accessed 9 March 2013). ">WHO 2013</a>). Most cases of schizophrenia can be treated and those affected can lead a productive life and be integrated in society. The incidence of treatment resistance in schizophrenia is about 20% (<a href="./references#CD009555-bbs2-0065" title="KerwinR , BolonnaA . Management of clozapine‐resistant schizophrenia. Advances in Psychiatric Treatment2005;11:101‐106. [DOI: 10.1192/apt.11.2.101] ">Kerwin 2005</a>). Clozapine reduces psychotic symptoms in 30% to 60% of such schizophrenia patients who have failed to respond to adequate trials of other antipsychotics (<a href="./references#CD009555-bbs2-0035" title="BuchananRW . Clozapine: efficacy and Safety. Schizophrenia Bulletin1995;21(4):579‐91. ">Buchanan 1995</a>). </p> </section> <section id="CD009555-sec-0033"> <h4 class="title">2. Schizophreniform disorder</h4> <p>According to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, schizophreniform disorder is a condition with symptoms similar to schizophrenia but lasting less than six months (<a href="./references#CD009555-bbs2-0045" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM‐IV‐TR. American Psychiatric Association, 2000. ">DSM‐IV</a>). In 1937 and 1939, follow‐up studies were undertaken on patients who initially presented with symptoms similar to schizophrenia. Two different outcomes were identified in those patients. One group, whose symptoms were typical of schizophrenia, were identified as having a poor prognosis. The other group, whose symptoms were similar to those of schizophrenia but who had prominent affective symptoms, had a better outcome; Langfeldt introduced the concept of schizophreniform psychoses to describe this latter group (<a href="./references#CD009555-bbs2-0078" title="NoreikK , AstrupC , DalgardOS , HolmboeR . A prolonged follow‐up of acute schizophrenic and schizophreniform psychoses. Acta Psychiatrica Scandinavica1967;43(4):432–43. ">Noreik 1967</a>; <a href="./references#CD009555-bbs2-0052" title="GuldbergCA , DahlAA , HansenH , BergemAL . Were Langfeldt's schizophreniform psychoses really affective?. Psychopathology1991;24(5):270‐6. ">Guldberg 1991</a>). Langfeldt’s original schizophreniform cases were reviewed by other researchers using DSM‐III and International Statistical Classification of Diseases and Related Health Problems, Ninth Revision (ICD‐9) criteria. They concluded that most of the original schizophreniform cases described by Langfeldt possibly appeared to more closely resemble affective disorders with psychoses, rather than schizophrenia‐like illness (<a href="./references#CD009555-bbs2-0031" title="BergemAL , DahlAA , GuldbergC , HansenH . Langfeldt's schizophreniform psychoses fifty years later. British Journal of Psychiatry1990;157:351‐4. ">Bergem 1990</a>; <a href="./references#CD009555-bbs2-0052" title="GuldbergCA , DahlAA , HansenH , BergemAL . Were Langfeldt's schizophreniform psychoses really affective?. Psychopathology1991;24(5):270‐6. ">Guldberg 1991</a>). <a href="./references#CD009555-bbs2-0045" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM‐IV‐TR. American Psychiatric Association, 2000. ">DSM‐IV</a> uses schizophreniform disorder to define a disorder that would otherwise meet the diagnostic criteria for schizophrenia but lasts less than six months (<a href="./references#CD009555-bbs2-0051" title="GelderMJ , MayouR , CowenP . Oxford Shorter Textbook of Psychiatry. 4th Edition. New York, USA: Oxford University Press, 2001. ">Gelder 2001</a>). There are currently no reliable data on prevalence rates of schizophreniform disorder (<a href="./references#CD009555-bbs2-0062" title="SadockBJ , Sadock VA(editors) . Kaplan &amp; Sadock's Comprehensive Text Book of Psychiatry. 8th Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2005. ">Kaplan 2005</a>). Treatment is similar to that of schizophrenia. Good prognostic factors for schizophreniform illness include episodic illness, recurrent course and a family history of mood disorders (<a href="./references#CD009555-bbs2-0030" title="BenazziF . Outcome of schizophreniform disorder. Current Psychiatry Reports2003;5(3):192‐6. ">Benazzi 2003</a>). </p> </section> <section id="CD009555-sec-0034"> <h4 class="title">3. Schizoaffective disorder</h4> <p>In 1933 Jacob Kasanin coined the term schizoaffective psychosis (<a href="./references#CD009555-bbs2-0063" title="KasaninJ . The acute schizoaffective psychoses. American Journal of Psychiatry1933;90:97‐126. ">Kasanin 1933</a>). Schizoaffective psychosis can be considered as a syndrome on the continuum between schizophrenia and mood disorders (such as depression and bipolar affective disorder) and presents with symptoms of both these illnesses (<a href="./references#CD009555-bbs2-0040" title="DanileviciūteV . Schizoaffective disorder: clinical symptoms and present‐day approach to treatment. Medicina (Kaunas)2002;38(11):1057‐65. ">Danileviciūte 2002</a>). <a href="./references#CD009555-bbs2-0058" title="World Health Organization. The ICD‐10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. 10th Edition. World Health Organization, 2004. ">ICD‐10</a> considers schizoaffective disorder as an episodic disorder in which both affective and schizophrenic symptoms are prominent but which does not justify a diagnosis of either schizophrenia or a depressive or manic episode. Studies on schizoaffective disorder suggest that it is relatively common in clinical settings. Among admissions to inpatient mental health facilities for functional psychosis, 10% to 30% comprise schizoaffective disorder. The lifetime prevalence of schizoaffective disorder is estimated to be between 0.5% and 0.8% and the illness typically presents with an episodic course (<a href="./references#CD009555-bbs2-0029" title="AzorinJM , KaladjianA , FakraE . Current issues on schizoaffective disorder. Encephale2005;31(3):359‐65. ">Azorin 2005</a>). Psychotic features may include both positive and negative symptoms along with affective symptoms. Outcome is predicted by premorbid functioning, number of past episodes, persistence of psychotic features and degree of cognitive impairment. <a href="./references#CD009555-bbs2-0090" title="VietaE . Developing an individualized treatment plan for patients with schizoaffective disorder: from pharmacotherapy to psychoeducation. Journal of Clinical Psychiatry2010;71(Suppl 2):14‐9. ">Vieta 2010</a> suggests that bipolar‐type schizoaffective illness can be treated with second generation antipsychotics, either alone or in conjunction with a mood stabiliser. The depressive type of schizoaffective disorder can be treated with a second generation antipsychotic in conjunction with either an antidepressant or a mood stabiliser. Electroconvulsive therapy (ECT) can be considered in refractory cases. Prognosis appears to be better than for schizophrenia, but worse than for affective disorder (<a href="./references#CD009555-bbs2-0029" title="AzorinJM , KaladjianA , FakraE . Current issues on schizoaffective disorder. Encephale2005;31(3):359‐65. ">Azorin 2005</a>). </p> </section> </section> <section id="CD009555-sec-0035"> <h3 class="title" id="CD009555-sec-0035">Description of the intervention</h3> <p>Prescribing of clozapine requires a number of preparatory steps. For example, before initiation of clozapine a base line physical examination should be performed with an ECG and base line blood tests, including full blood count. Patients must be registered with the clozapine patient monitoring services, and full blood count must be monitored once a week for the first 18 weeks, thereafter fortnightly for 34 weeks and then once in every four weeks for the period of time clozapine is taken. For adults over 16 years of age, clozapine should be started at a very low dose, e.g. 12.5 mg once or twice a day. On the second day, 25 mg to 50 mg is given, and, if well tolerated, the dose can be gradually increased in steps of 25 mg to 50 mg daily over 14 to 21 days up to 300 mg daily in divided doses. If necessary, the dose can be increased further. Elderly people may need slower titration. During initiation and titration, pulse and blood pressure (in standing and lying position) should be monitored regularly to identify persistent tachycardia and postural hypotension. If clozapine, for whatever reason, was omitted for a period of 48 hours, it should be restarted from lowest dose and titrated upwards. Adverse effects of clozapine include constipation, troublesome hypersalivation, tachycardia, ECG changes, hypertension, drowsiness, dizziness, headache, tremor, seizures, fatigue, impaired temperature regulation, urinary incontinence, urinary retention, leukopenia, eosinophilia, leucocytosis, and, less commonly, agranulocytosis, and other cardiovascular and respiratory side effects (<a href="./references#CD009555-bbs2-0033" title="British National Formulary. Royal Pharmaceutical Society. London: BMJ Group, Pharmaceutical Press, Sep 2012:229‐230. ">BNF 2012</a>). </p> <section id="CD009555-sec-0036"> <h4 class="title">Accessibility of clozapine</h4> <p>Upon reintroduction of clozapine in the USA in 1990, clozapine was recommended to be used only in treatment‐resistant schizophrenia, along with regular monitoring for side effects such as agranulocytosis. The British National Formulary currently recommends clozapine be used only in "schizophrenia (including psychosis in Parkinson’s disease) in patients unresponsive to, or intolerant of, conventional antipsychotic drugs" (<a href="./references#CD009555-bbs2-0033" title="British National Formulary. Royal Pharmaceutical Society. London: BMJ Group, Pharmaceutical Press, Sep 2012:229‐230. ">BNF 2012</a>). The National Institute for Health and Care Excellence recommends clozapine in people suffering from schizophrenia who did not respond adequately to sequential use of adequate doses of at least two different antipsychotic drugs, at least one of which should be a non‐clozapine second‐generation antipsychotic (<a href="./references#CD009555-bbs2-0076" title="National Institute for Health and Clinical Excellence (NICE). NICE clinical guideline 82: Schizophrenia core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. www.nice.org.uk/guidance/CG82 (accessed 24 February 2017). ">NICE</a>). Clozapine is made available only through the manufacturer's proprietary monitoring system, and all the UK manufacturers of clozapine such as Novartis (Clozaril), Merz (Denzapine), and Teva (Zaponex) require that the patients, prescribers and supplying pharmacists be registered with their relevant patient monitoring service. Through shared care arrangements with local community pharmacies dispensing clozapine, it is possible in the UK to initiate clozapine treatment in the community after registration with the patient monitoring services is completed (<a href="./references#CD009555-bbs2-0038" title="The College of Mental Health Pharmacy. www.cmhp.org.uk (accessed 5 August 2011). ">CMHP</a>). However, general practitioners generally do not prescribe clozapine in the UK. <a href="./references#CD009555-bbs2-0025" title="AitchisonK , KerwinR . Cost‐effectiveness of clozapine. A UK clinic‐based study. British Journal of Psychiatry1997;171:125‐30. ">Aitchison 1997</a> suggested that the costs of prescribing clozapine could be recouped on savings in future inpatient care. <a href="./references#CD009555-bbs2-0091" title="WangPS , GanzDA , BennerJS , GlynnRJ , AvornJ . Should clozapine continue to be restricted to third‐line status for schizophrenia?: A decision‐analytic model. Journal of Mental Health Policy and Economics2004;7(2):77‐85. ">Wang 2004</a> indicated that if clozapine was made available as a first‐line antipsychotic, it might possibly lead to small gains in life expectancy, at moderate but acceptable costs. <a href="./references#CD009555-bbs2-0061" title="KaneJM . A user guide to clozapine. Acta Psychiatrica Scandinavica2011; Vol. 123, issue 6:407‐8. ">Kane 2011</a> opined that clozapine still remains strikingly under‐utilised and that many practitioners across the world and across different clinical settings do not use clozapine even when indicated. </p> </section> </section> <section id="CD009555-sec-0037"> <h3 class="title" id="CD009555-sec-0037">How the intervention might work</h3> <p>Clozapine (<a href="#CD009555-fig-0001">Figure 1</a>) was the first atypical antipsychotic to show definite benefit in treatment of patients where symptoms failed to respond to typical agents. Clozapine has the highest affinity for dopamine D4, 5‐HT1C, 5‐HT2, alpha 1, muscarinic and histamine H1 receptors, but moderate affinity is also seen for many other receptor subtypes (<a href="./references#CD009555-bbs2-0039" title="CowardDM . General pharmacology of clozapine. British Journal of Psychiatry Supplement1992;17:5‐11. ">Coward 1992</a>). Clozapine causes fewer extrapyramidal side effects (EPSEs) than typical antipsychotics (<a href="./references#CD009555-bbs2-0059" title="KaneJ , HonigfeldG , SingerJ , MeltzerH . Clozapine for the treatment resistant schizophrenic: a double‐blind comparison with chlorpromazine. Archives of General Psychiatry1988;45(9):789–96. ">Kane 1988</a>). Clozapine appears to be more active at the limbic site than the striatal site and this might explain its low extrapyramidal side effect profile. It is metabolized mainly in the liver. Norclozapine is an active metabolite of clozapine. Monitoring the plasma levels of clozapine and norclozapine helps to assess compliance. It is suggested that the therapeutic response is associated with clozapine blood levels between 200 ng/ml and 400 ng/ml (<a href="./references#CD009555-bbs2-0066" title="KronigMH , MunneRA , SzymanskiS , SaffermanAZ , PollackS , CooperT , et al. Plasma clozapine levels and clinical response for treatment‐refractory schizophrenic patients. American Journal of Psychiatry1995;152:179‐82. ">Kronig 1995</a>). Chemicals that affect cytochrome enzymes can reduce or increase plasma clozapine concentration. </p> <div class="figure" id="CD009555-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Clozapine structure" data-id="CD009555-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Clozapine structure</p> </div> </div> </div> </section> <section id="CD009555-sec-0038"> <h3 class="title" id="CD009555-sec-0038">Why it is important to do this review</h3> <p>Different guidelines suggest different dosing for clozapine. For example, <a href="./references#CD009555-bbs2-0033" title="British National Formulary. Royal Pharmaceutical Society. London: BMJ Group, Pharmaceutical Press, Sep 2012:229‐230. ">BNF 2012</a> recommends a usual dose of 200 mg/day to 450 mg/day and the maximum daily dose of 900 mg. Merz, the UK manufacturer of Denzapine, also advises the prescription of clozapine at a dose between 200 mg/day and 450 mg/day, with maximum doses up to 900 mg/day. Novartis, the UK manufacturer of Clozaril, suggests that while many patients may respond adequately at doses between 300 mg/day and 600 mg/day, it may be necessary to raise the dose to the 600 mg/day to 900 mg/day range to obtain an acceptable response. <a href="./references#CD009555-bbs2-0062" title="SadockBJ , Sadock VA(editors) . Kaplan &amp; Sadock's Comprehensive Text Book of Psychiatry. 8th Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2005. ">Kaplan 2005</a> suggests that daily doses between 250 mg/day and 450 mg/day are usually considered adequate and daily dosage above 600 mg/day is seldom indicated. <a href="./references#CD009555-bbs2-0082" title="SmythR , BurnsJ , DarjeeR , McIntoshA . Oxford Handbook of Psychiatry. New York: Oxford University Press Inc., 2007. ">Semple 2007</a> advises that usual doses of 200 mg to 450 mg daily can be used, and that an increase in frequency of seizures occurs at doses greater than 600 mg/day. <a href="./references#CD009555-bbs2-0084" title="StahlSM . Essential Psychopharmacology. Cambridge, New York, USA: Cambridge University Press, 2006. ">Stahl 2006</a> suggests using 300 mg/day to 450 mg/day with a maximum of 900 mg/day, and that doses of more than 550 mg/day may require concomitant anticonvulsant medications to reduce the risk of seizures. Plasma levels may help guide dosing, with studies suggesting that maximal clinical efficacy may be achieved when plasma levels of clozapine are between 200 ng/ml and 400 ng/ml (typically associated with a dose of 300 mg/day to 400 mg/day (<a href="./references#CD009555-bbs2-0066" title="KronigMH , MunneRA , SzymanskiS , SaffermanAZ , PollackS , CooperT , et al. Plasma clozapine levels and clinical response for treatment‐refractory schizophrenic patients. American Journal of Psychiatry1995;152:179‐82. ">Kronig 1995</a>; <a href="./references#CD009555-bbs2-0005" title="SimpsonGM . Correction. American Journal of Psychiatry2001;158(5):834. SimpsonGM , JosiassenRC , StanillaJK , deLeonJ , NairC , AbrahamG , et al. Double blind study of clozapine dose response in chronic schizophrenia. American Journal of Psychiatry1999;156(11):1744‐50. [MEDLINE: 10553738] deLeonJ , DiazFJ , JosiassenRC , CooperTB , SimpsonGM . Weight gain during a double‐blind multidosage clozapine study. Journal of Clinical Psychopharmacology2007;27(1):22‐7. [MEDLINE: 17224708] ">Simpson 1999</a>). However, it is important to note that the relationship between the dose of clozapine and the resulting serum level is weak (<a href="./references#CD009555-bbs2-0087" title="TaylorD , DuncanD . The use of clozapine plasma levels in optimising therapy. Psychiatric Bulletin1995;19:753‐55. ">Taylor 1995</a>). This could be a reason why there is wide variation of the clinically effective dose in different individuals. It is still unclear as to what dose of clozapine is most effective with the least side effects. It must be borne in mind as well that patient non‐compliance can be as high as 50% under outpatient conditions and this could be due to drug‐related side effects (<a href="./references#CD009555-bbs2-0050" title="GaebelW . Towards the improvement of compliance: the significance of psycho‐education and new antipsychotic drugs. International Clinical Psychopharmacology1997;12(Suppl 1):S37–42. ">Gaebel 1997</a>), and lead to relapse. Clozapine produces severe adverse effects. Hence we will review the evidence for doses of clozapine that are both tolerable and effective in the management of schizophrenia, schizophreniform and schizoaffective disorders. This is one of a series of reviews on the effects of clozapine (<a href="#CD009555-tbl-0004">Table 1</a>). </p> <div class="table" id="CD009555-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Other reviews in the clozapine series</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Title</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reference</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clozapine versus other atypical antipsychotics for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009555-bbs2-0028" title="Asenjo LobosC , KomossaK , Rummel‐KlugeC , HungerH , SchmidF , SchwarzS , et al. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2010, Issue 11. [DOI: 10.1002/14651858.CD006633.pub2; PUBMED: 21069690] ">Asenjo 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009555-bbs2-0037" title="CiprianiA , BosoM , BarbuiC . Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD006324.pub2; PUBMED: 19588385] ">Cipriani 2009</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clozapine versus typical neuroleptic medication for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009555-bbs2-0048" title="EssaliA , Al‐Haj HaasanN , LiC , RathboneJ . Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD000059.pub2; PUBMED: 19160174] ">Essali 2009</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pharmacological interventions for clozapine‐induced hypersalivation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009555-bbs2-0086" title="SyedR , AuK , CahillC , DugganL , HeY , UduV , et al. Pharmacological interventions for clozapine‐induced hypersalivation. Cochrane Database of Systematic Reviews2008, Issue 3. [DOI: 10.1002/14651858.CD005579.pub2; PUBMED: 18646130] ">Syed 2008</a> </p> </td> </tr> </tbody> </table> </div> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009555-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009555-sec-0039"></div> <p>To compare the efficacy and tolerability of clozapine at different doses and to identify the optimal dose of clozapine in the treatment of schizophrenia, schizophreniform and schizoaffective disorders. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009555-sec-0040" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009555-sec-0040"></div> <section id="CD009555-sec-0041"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009555-sec-0042"> <h4 class="title">Types of studies</h4> <p>We included all relevant randomised controlled trials, reporting useable data, that compared different doses of clozapine, irrespective of blinding status and published language. Where people were given additional treatments along with clozapine, we included the trial only if the adjunct treatment was equal in both groups and only the clozapine doses were randomised. We included studies on treatment‐resistant illnesses and took the opportunity to examine clozapine’s effect on the course of the illness (for example acute, partial remission, remission, first episode). We excluded case series and non‐randomised trials, and quasi‐randomised trials where, for example, allocation is undertaken on alternate days of the week or by alphabetical order. </p> </section> <section id="CD009555-sec-0043"> <h4 class="title">Types of participants</h4> <p>We included studies on people with schizophrenia, schizophreniform disorder and schizoaffective disorder diagnosed by any criteria. We decided to include schizophreniform and schizoaffective disorders as these conditions may be caused by similar disease processes and may require similar treatment approaches (<a href="./references#CD009555-bbs2-0036" title="CarpenterWTJr , BuchananRW . Schizophrenia. New England Journal of Medicine1994;330:681–90. ">Carpenter 1994</a>). </p> </section> <section id="CD009555-sec-0044"> <h4 class="title">Types of interventions</h4> <p>We compared the efficacy of different doses of clozapine in different arms in the same trial. We did not compare efficacy of clozapine to any other antipsychotic or to placebo or to any other medications. The intervention of interest was clozapine: oral formulation, any dose, comparison of different doses. We predefined the dosage categories as follows.<br/> <br/> 1. Very low dose clozapine: up to 149 mg/day.<br/> 2. Low‐dose clozapine: 150 mg/day to 300 mg/day.<br/> 3. Standard‐dose clozapine: 301 mg/day to 600 mg/day.<br/> 4. High‐dose clozapine: 601 mg/day to 900 mg/day.<br/> 5. Very high dose clozapine: 901 mg/day and above. </p> </section> <section id="CD009555-sec-0045"> <h4 class="title">Types of outcome measures</h4> <p>We grouped outcomes into short term (up to 12 weeks), medium term (13 to 26 weeks) and long term (more than 26 weeks). </p> <section id="CD009555-sec-0046"> <h5 class="title">Primary outcomes</h5> <section id="CD009555-sec-0047"> <h6 class="title">1. Global state</h6> <p>Clinically important response as defined by the individual studies (e.g. global impression "much improved" or 50% reduction on a rating scale). </p> </section> </section> <section id="CD009555-sec-0048"> <h5 class="title">Secondary outcomes</h5> <section id="CD009555-sec-0049"> <h6 class="title">1. Global state</h6> <p>1.1 Relapse (as defined by the individual studies).<br/> 1.2 Average endpoint global state score.<br/> 1.3 Average change in global state scores.<br/> 1.4 Needing additional medication. </p> </section> <section id="CD009555-sec-0050"> <h6 class="title">2. Mental state</h6> <p>2.1 Clinically important change in general mental state score.<br/> 2.2 Average endpoint general mental state score.<br/> 2.3 Average change in general mental state scores.<br/> 2.4 Clinically important change in specific symptoms (e.g. positive symptoms of schizophrenia, negative symptoms of schizophrenia).<br/> 2.5 Average endpoint specific symptom score.<br/> 2.6 Average change in specific symptom scores.<br/> 2.7 Healthy days. </p> </section> <section id="CD009555-sec-0051"> <h6 class="title">3. Death</h6> <p>3.1 Suicide.<br/> 3.2 Natural causes. </p> </section> <section id="CD009555-sec-0052"> <h6 class="title">4. Leaving the studies early</h6> <p>4.1 Any reason.<br/> 4.2 Specific reason (as described by individual studies; for example: adverse events, treatment inefficacy). </p> </section> <section id="CD009555-sec-0053"> <h6 class="title">5. Behaviour</h6> <p>5.1 Clinically important change in general behaviour.<br/> 5.2 Average endpoint general behaviour score.<br/> 5.3 Average change in general behaviour scores.<br/> 5.4 Clinically important change in specific aspects of behaviour.<br/> 5.5 Average endpoint specific aspects of behaviour.<br/> 5.6 Average change in specific aspects of behaviour. </p> </section> <section id="CD009555-sec-0054"> <h6 class="title">6. Functioning</h6> <p>6.1 Clinically important change in general functioning.<br/> 6.2 Average endpoint general functioning score.<br/> 6.3 Average change in general functioning scores.<br/> 6.4 No clinically important change in specific aspects of functioning, such as social or life skills.<br/> 6.5 Average endpoint specific aspects of functioning, such as social or life skills.<br/> 6.6 Average change in specific aspects of functioning, such as social or life skills. </p> </section> <section id="CD009555-sec-0055"> <h6 class="title">7. Cognitive functioning</h6> <p>7.1 Clinically important change in overall cognitive functioning.<br/> 7.2 Average endpoint overall cognitive functioning score.<br/> 7.3 Average change in overall cognitive functioning score.<br/> 7.4 Clinically important change in specific aspects of cognitive functioning.<br/> 7.5 Average endpoint specific aspects of cognitive functioning.<br/> 7.6 Average change in specific aspects of cognitive functioning. </p> </section> <section id="CD009555-sec-0056"> <h6 class="title">8. Quality of life</h6> <p>8.1 Clinically important change in general quality of life.<br/> 8.2 Average endpoint general quality of life score.<br/> 8.3 Average change in general quality of life score.<br/> 8.4 Clinically important change in specific aspects of quality of life.<br/> 8.5 Average endpoint specific aspects of quality of life.<br/> 8.6 Average change in specific aspects of quality of life. </p> </section> <section id="CD009555-sec-0057"> <h6 class="title">9. Adverse effects</h6> <p>9.1 Number of participants with at least one adverse effect.<br/> 9.2 Clinically important specific adverse effects (such as effects on white blood cell count, cardiac effects, movement disorders, hypersalivation, seizures, prolactin increase and metabolic side effects (such as weight gain, hyperlipidaemia and hyperglycaemia)).<br/> 9.3 Clinically important general adverse effects.<br/> 9.4 Average endpoint general adverse effect score.<br/> 9.5 Average change in general adverse effect score.<br/> 9.6 Average endpoint specific adverse effect score.<br/> 9.7 Average change in specific adverse effect score.<br/> 9.8 Use of any drugs for adverse effects. </p> </section> <section id="CD009555-sec-0058"> <h6 class="title">10. Satisfaction with treatment</h6> <p>10.1 Recipient of care not satisfied with treatment.<br/> 10.2 Recipient of care average satisfaction score.<br/> 10.3 Recipient of care average change in satisfaction score.<br/> 10.4 Carer not satisfied with treatment.<br/> 10.5 Carer average satisfaction score.<br/> 10.6 Carer average change in satisfaction score. </p> </section> <section id="CD009555-sec-0059"> <h6 class="title">11. Service use</h6> <p>11.1 Number of patients hospitalised.<br/> 11.2 Number of days hospitalised.<br/> 11.3 Time to hospitalisation.<br/> 11.4 Number of patients discharged or readmitted (as defined in individual trial). </p> </section> <section id="CD009555-sec-0060"> <h6 class="title">12. Economic outcomes</h6> <p>12.1 Direct costs.<br/> 12.2 Indirect costs. </p> </section> <section id="CD009555-sec-0061"> <h6 class="title">13. 'Summary of findings' table</h6> <p>We used the GRADE approach to interpret findings (<a href="./references#CD009555-bbs2-0081" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In Higgins JPT, Green S editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011</a>); and GRADE Profiler (<a href="http://ims.cochrane.org/revman/gradepro" target="_blank">GRADEpro GDT</a>) to import data from <a href="http://ims.cochrane.org/revman" target="_blank">Review Manager 5</a> (RevMan 5) to create 'Summary of findings' tables. These tables provide outcome‐specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined and the sum of available data on all outcomes we rated as important to patient care and decision making. We selected the following outcomes for inclusion in the <a href="./full#CD009555-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD009555-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD009555-tbl-0003">summary of findings Table 3</a>. </p> <p> <ol id="CD009555-list-0001"> <li> <p>Global state: clinically important response, as defined by individual studies.</p> </li> <li> <p>Mental state: clinically important response, as defined by individual studies.</p> </li> <li> <p>Functioning: clinically important change in general functioning, including social or life skills, as defined by individual studies. </p> </li> <li> <p>Adverse effect: clinically important adverse effect.</p> </li> <li> <p>Service use: number of days hospitalised.</p> </li> <li> <p>Service use: time to hospitalisation.</p> </li> <li> <p>Quality of life: clinically important change in general quality of life.</p> </li> </ol> </p> </section> </section> </section> </section> <section id="CD009555-sec-0062"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD009555-sec-0063"> <h4 class="title">Electronic searches</h4> <section id="CD009555-sec-0064"> <h5 class="title">Cochrane Schizophrenia Group’s Study‐Based Register of Trials</h5> <p>On 8 December 2016, the information specialist searched the register using the following search strategy: </p> <p>Dosage ‐ Clozapine in Intervention Field of STUDY</p> <p>In a study‐based register such as this, searching the major concept retrieves all the synonyms and relevant studies because all the studies have already been organised based on their interventions and linked to the relevant topics. </p> <p>This register is compiled by systematic searches of major resources (including AMED, BIOSIS, CINAHL, Embase, MEDLINE, PsycINFO, PubMed, and registries of clinical trials) and their monthly updates, handsearches, grey literature, and conference proceedings (see <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html" target="_blank">Group’s Module</a>). There is no language, date, document type, or publication status limitations for inclusion of records in the register. </p> <p>For previous searches, please see <a href="./appendices#CD009555-sec-0206">Appendix 1</a>. </p> </section> </section> <section id="CD009555-sec-0065"> <h4 class="title">Searching other resources</h4> <section id="CD009555-sec-0066"> <h5 class="title">1. Reference searching</h5> <p>We searched the reference lists of each included paper, but failed to find any new studies. </p> </section> <section id="CD009555-sec-0067"> <h5 class="title">2. Personal contact</h5> <p>Where possible, we contacted the first author of trials or citations for missing information on unpublished data or trials. Where contact with the first author was not possible through the Cochrane Schizophrenia Group, we attempted to contact the other authors. At the time of writing, we have not received any of the missing data we requested, though one author indicated he will send the requested information at a future date. We have discussed this in detail under relevant Results sections. </p> </section> </section> </section> <section id="CD009555-sec-0068"> <h3 class="title" id="CD009555-sec-0068">Data collection and analysis</h3> <section id="CD009555-sec-0069"> <h4 class="title">Selection of studies</h4> <p>One review author (SS) inspected citations from the searches, identified relevant abstracts, obtained full articles of all relevant abstracts, and classified studies as 'included', 'excluded', or 'with information missing'. We placed the last under 'pending classification' and contacted the authors for further clarification. A second review author (BV) independently inspected a random 20% of citations to ensure reliability. </p> </section> <section id="CD009555-sec-0070"> <h4 class="title">Data extraction and management</h4> <section id="CD009555-sec-0071"> <h5 class="title">1.1 Data extraction</h5> <p>One review author (SS) extracted data from all included reports. To ensure reliability, a second review author (BV) independently extracted data from a random 25% sample of these reports. There was no disagreement. Had there been disagreement, we would have documented decisions and contacted authors of studies for clarification where necessary. We extracted data presented in graphs and figures only, whenever possible. We attempted to contact authors in order to obtain missing information or clarification whenever necessary. </p> </section> <section id="CD009555-sec-0072"> <h5 class="title">1.2 Forms</h5> <p>We extracted data onto standard forms.</p> </section> <section id="CD009555-sec-0073"> <h5 class="title">2. Data management</h5> <section id="CD009555-sec-0074"> <h6 class="title">2.1 Scale‐derived data</h6> <p>We included continuous data from rating scales only if (a) the psychometric properties of the measuring instrument had been described in a peer‐reviewed journal (<a href="./references#CD009555-bbs2-0071" title="MarshallM , LockwoodA , BradleyC , AdamsCE , JoyC , FentonM . Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry2000;176:249‐52. ">Marshall 2000</a>), and (b) the measuring instrument had not been written or modified by one of the trialists for that particular trial. Ideally the measuring instrument should either be: </p> <p>(a) a self‐report;</p> <p>(b) an instrument completed by an independent rater or relative (not the therapist);</p> <p>(c) a global assessment of an area of functioning and not sub‐scores which are not, in themselves, validated or shown to be reliable. However there are exceptions: we included sub‐scores from mental state scales measuring positive and negative symptoms of schizophrenia. </p> <p>We realise that this is not often reported clearly and we note in <a href="#CD009555-sec-0116">Description of studies</a> if this was the case or not. </p> </section> <section id="CD009555-sec-0075"> <h6 class="title">2.2 Endpoint versus change data</h6> <p>There are advantages of both endpoint and change data. Change data can remove a component of between‐person variability from the analysis. On the other hand, calculation of change needs two assessments (baseline and endpoint) which can be difficult in unstable and difficult‐to‐measure conditions such as schizophrenia. We primarily used endpoint data, and only used change data if the former were not available. We combined endpoint and change data in the analysis by the use throughout of mean differences (MD) rather than standardised mean differences (<a href="./references#CD009555-bbs2-0042" title="DeeksJJ , HigginsJPT , Altman DGeditor(s) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Deeks 2011</a>). </p> </section> <section id="CD009555-sec-0076"> <h6 class="title">2.3 Skewed data</h6> <p>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non‐parametric data, we aimed to apply the following standards to all data before inclusion: a) standard deviations and means are reported in the paper or obtainable from the authors; b) when a scale starts from the finite number zero, the standard deviation, when multiplied by two, is less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution (<a href="./references#CD009555-bbs2-0026" title="AltmanDG , BlandJM . Detecing skewness from summary information. BMJ1996;313(7066):1200. [OLZ020600] ">Altman 1996</a>); c) if a scale started from a positive value (such as the PANSS which can have values from 30 to 210), the calculation described above was modified to take the scale starting point into account. In these cases skew is present if 2SD &gt; (S −S min), where S is the mean score and S min is the minimum score. Endpoint scores on scales often have a finite start and end point and the above rules can be applied. We did not come across skewed endpoint data in our review, but if we had then we would have entered skewed endpoint data from studies of fewer than 200 participants as other data within the <a href="./references#CD009555-sec-0204" title="">Data and analyses</a> section rather than into a statistical analysis. Skewed endpoint data would pose fewer problems when looking at means if the sample size is large, and we would have then entered these into syntheses. </p> <p>When continuous data are presented on a scale that includes a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not, and we would have entered skewed change data into statistical analysis. </p> </section> <section id="CD009555-sec-0077"> <h6 class="title">2.4 Common measure</h6> <p>To facilitate comparison between trials, where possible we tried to convert variables reported in different metrics (e.g. days spent in hospital as mean days per year or per week or per month) to a common metric (e.g. mean days per month). </p> </section> <section id="CD009555-sec-0078"> <h6 class="title">2.5 Conversion of continuous to binary</h6> <p>Where possible, we would have converted outcome measures to dichotomous data. This would have been done by identifying cut‐off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It is generally assumed that if there is a 50% reduction in a scale‐derived score such as the Brief Psychiatric Rating Scale (BPRS, <a href="./references#CD009555-bbs2-0079" title="OverallJE , GorhamDR . The brief psychiatric rating scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>) or the Positive and Negative Syndrome Scale (PANSS, <a href="./references#CD009555-bbs2-0064" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>), this could be considered as a clinically significant response (<a href="./references#CD009555-bbs2-0068" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry2005;187:366‐71. [PUBMED: 16199797] ">Leucht 2005a</a>; <a href="./references#CD009555-bbs2-0069" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelRR . What does the PANSS mean?. Schizophrenia Research2005;79(2‐3):231‐8. [PUBMED: 15982856] ">Leucht 2005b</a>). If data based on these thresholds had not been available, we would have used the primary cut‐off presented by the original authors. Where data on clinical improvement was presented as 'very effective', 'effective' and 'no improvement', we grouped these to form the dichotomous outcome of 'effective'/'no improvement'. </p> </section> <section id="CD009555-sec-0079"> <h6 class="title">2.6 Direction of graphs</h6> <p>Where possible, we entered data in such a way that the area to the left of the line of no effect indicates a favourable outcome for lower dose of clozapine. </p> </section> </section> </section> <section id="CD009555-sec-0080"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>One review author (SS) independently assessed risk of bias by using criteria described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> to assess trial quality (<a href="./references#CD009555-bbs2-0056" title="HigginsJPT , AltmanDG , Sterne JACeditor(s) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011b</a>). A second review author (BV) randomly checked 25% to ensure reliability. This set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the article such as sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting. There was no disagreement. If there had been disagreement, we would have resolved it by further discussion. The level of risk of bias is noted in both the text of the review and in the 'Summary of findings' table. </p> </section> <section id="CD009555-sec-0081"> <h4 class="title">Measures of treatment effect</h4> <section id="CD009555-sec-0082"> <h5 class="title">1. Binary data</h5> <p>For binary outcomes we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive than odds ratios (<a href="./references#CD009555-bbs2-0034" title="BoisselJP , CucheratM , LiW , ChatellierG , GueyffierF , BuyseM , et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'etude des Indices d'efficacite]. Therapie1999;54(4):405‐11. [PUBMED: 10667106] ">Boissel 1999</a>); and that odds ratios tend to be interpreted as RR by clinicians (<a href="./references#CD009555-bbs2-0041" title="DeeksJ . Issues in the selection for meta‐analyses of binary data. 8th International Cochrane Colloquium; 2000 Oct 25‐28; Cape Town. Cape Town: The Cochrane Collaboration, 2000. ">Deeks 2000</a>). The number needed to treat for an additional beneficial outcome/harmful outcome (NNTB/NNTH) statistic with its confidence intervals is intuitively attractive to clinicians but is problematic both in its accurate calculation in meta‐analyses and interpretation (<a href="./references#CD009555-bbs2-0057" title="HuttonJL . Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology2009;146(1):27‐30. ">Hutton 2009</a>). For binary data presented in the 'Summary of findings' table/s, where possible we calculated illustrative comparative risks. </p> </section> <section id="CD009555-sec-0083"> <h5 class="title">2. Continuous data</h5> <p>We estimated mean difference (MD) between groups for continuous outcomes. We preferred not to calculate effect size measures (standardised mean difference (SMD)). However, if very similar scales had been used, we would have presumed there was a small difference in measurement and would have calculated effect size and transformed the effect back to the units of one or more of the specific instruments. </p> </section> </section> <section id="CD009555-sec-0084"> <h4 class="title">Unit of analysis issues</h4> <section id="CD009555-sec-0085"> <h5 class="title">1. Cluster trials</h5> <p>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data poses problems. Firstly, authors often fail to account for intra‐class correlation in clustered studies, leading to a 'unit of analysis' error (<a href="./references#CD009555-bbs2-0043" title="DivineGW , BrownJT , FrazierLM . The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine1992;7(6):623‐9. ">Divine 1992</a>), whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type I errors (<a href="./references#CD009555-bbs2-0032" title="BlandJM . Statistics notes. Trials randomised in clusters. BMJ1997;315:600. ">Bland 1997</a>; <a href="./references#CD009555-bbs2-0053" title="GullifordMC . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149(9):876‐83. ">Gulliford 1999</a>). </p> <p>There were no cluster trials included in our review. If there had been cluster studies, then where clustering was not accounted for in primary studies we would have presented data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we will contact first authors of studies to obtain intra‐class correlation coefficients for their clustered data and adjust for this by using accepted methods (<a href="./references#CD009555-bbs2-0053" title="GullifordMC . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149(9):876‐83. ">Gulliford 1999</a>). </p> <p>If clustering had been incorporated into the analysis of primary studies, we would have presented these data as if from a non‐cluster randomised study, but would have adjusted for the clustering effect. Statistical advice has been sought in the past: it was advised that binary data should be presented in a report and divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the intra‐class correlation coefficient (ICC): [Design effect = 1 + (m − 1) * ICC] (<a href="./references#CD009555-bbs2-0044" title="DonnerA , KlarN . Issues in the meta‐analysis of cluster randomized trials. Statistics in Medicine2002;21(19):2971‐80. ">Donner 2002</a>). If the ICC had not been reported we would have assumed it to be 0.1 (<a href="./references#CD009555-bbs2-0088" title="UkoumunneOC , GullifordMC , ChinnS , SterneJAC , BurneyPGJ . Methods for evaluating area‐wide and organisation‐based intervention in health and health care: a systematic review. Health Technology Assessment1999;3(5):1‐75. ">Ukoumunne 1999</a>). If cluster studies had been appropriately analysed taking into account intra‐class correlation coefficients and relevant data documented in the report, synthesis with other studies might have been possible using the generic inverse variance technique. </p> </section> <section id="CD009555-sec-0086"> <h5 class="title">2. Cross‐over trials</h5> <p>We only used data from the first phase of cross‐over studies. A major concern of cross‐over trials is the carry‐over effect. It occurs if an effect (e.g. pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase participants can differ systematically from their initial state despite a wash‐out phase. For the same reason cross‐over trials are not appropriate if the condition of interest is unstable (<a href="./references#CD009555-bbs2-0047" title="ElbourneD , AltmanDG , HigginsJPT , CurtinaF , WorthingtondHV , VaileA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>). Because both these effects are very likely in severe mental illness, we decided to use data from the first phase of cross‐over studies only. In our review, the <a href="./references#CD009555-bbs2-0005" title="SimpsonGM . Correction. American Journal of Psychiatry2001;158(5):834. SimpsonGM , JosiassenRC , StanillaJK , deLeonJ , NairC , AbrahamG , et al. Double blind study of clozapine dose response in chronic schizophrenia. American Journal of Psychiatry1999;156(11):1744‐50. [MEDLINE: 10553738] deLeonJ , DiazFJ , JosiassenRC , CooperTB , SimpsonGM . Weight gain during a double‐blind multidosage clozapine study. Journal of Clinical Psychopharmacology2007;27(1):22‐7. [MEDLINE: 17224708] ">Simpson 1999</a> trial was conducted in three phases of 16 weeks each, lasting for a total of 48 weeks with the last two phases being crossed over. For this trial we included the data from the first 16 weeks only (i.e. before cross‐over occurred). </p> </section> <section id="CD009555-sec-0087"> <h5 class="title">3. Studies with multiple treatment groups</h5> <p>There was no relevant additional treatment in any of the included trials. If a study had involved additional treatment arms, we would have presented the additional arms in comparisons only if relevant and would not have reproduced data from irrelevant arms. For binary data, we would simply have added these and combined within a two‐by‐two table. For continuous data, we would have combined the data following the formula in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009555-bbs2-0055" title="HigginsJPT , GreenS editor(s) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011a</a>). In cases where a study had two intervention arms which both fell within a single‐dosage category defined in <a href="#CD009555-sec-0044">Types of interventions</a> (for example, in <a href="./references#CD009555-bbs2-0002" title="ChenYH , CaoQ , ChenWQ . The effect of clozapine for patients with schizophrenia: a clinical trial [氯氮平治疗精神分裂症患者的临床研究]. Modern Diagnosis and Treatment [现代诊断与治疗]2013, issue 15:3460‐1. ">Chen 2013</a> where both the 301 mg/day to 400 mg/day intervention and the 401 mg/day to 500 mg/day intervention fell within the ‘standard’ dose category), means and standard deviations were combined for continuous outcomes using methods described in section 7.7.3.8 of <a href="./references#CD009555-bbs2-0055" title="HigginsJPT , GreenS editor(s) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011a</a>. </p> </section> </section> <section id="CD009555-sec-0088"> <h4 class="title">Dealing with missing data</h4> <section id="CD009555-sec-0089"> <h5 class="title">1. Overall loss of credibility</h5> <p>At some degree of loss of follow‐up, data must lose credibility (<a href="./references#CD009555-bbs2-0095" title="XiaJ , AdamsCE , BhagatN , BhagatV , BhoopathiP , El‐SayehH , et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin2009;33(7):254‐7. ">Xia 2009</a>). If more than 50% of data had been unaccounted for in any particular outcome, we had decided neither to reproduce these data nor to use them within our analyses. In this review, however, loss of data was never more than 50% for any outcome or in any arm. If the loss of data had been more than 50% but the total loss had been less than 50%, we would have marked such data with (*) to indicate that the result might have been prone to bias. </p> </section> <section id="CD009555-sec-0090"> <h5 class="title">2. Binary</h5> <p>Those who left the study early were all assumed to have the same outcome as those who completed, with the exception of the outcomes of death and adverse effects. </p> </section> <section id="CD009555-sec-0091"> <h5 class="title">3. Continuous</h5> <section id="CD009555-sec-0092"> <h6 class="title">3.1 Attrition</h6> <p>Had attrition for a continuous outcome been between 0% and 50% and completer‐only data had been reported, we would have reproduced these data. </p> </section> <section id="CD009555-sec-0093"> <h6 class="title">3.2 Standard deviations</h6> <p>In our review, there were few data whose standard deviations (SDs) were missing. We tried to obtain the missing values from the authors, but were unsuccessful. Where there are missing measures of variance for continuous data, but an exact standard error (SE) and confidence intervals available for group means, and either P value or t value available for differences in mean, we can calculate them according to the rules described in the <i>Cochrane Handbook for Systematic reviews of Interventions</i> (<a href="./references#CD009555-bbs2-0055" title="HigginsJPT , GreenS editor(s) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011a</a>): When only the standard error (SE) is reported, SDs are calculated by the formula SD = SE * square root (n). The <i>Cochrane Handbook for Systematic reviews of Interventions</i> (<a href="./references#CD009555-bbs2-0055" title="HigginsJPT , GreenS editor(s) . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Higgins 2011a</a>) present detailed formulae for estimating SDs from P values, t or F values, confidence intervals, ranges or other statistics. If these formulae do not apply, we could calculate the SDs according to a validated imputation method which is based on the SDs of the other included studies (<a href="./references#CD009555-bbs2-0049" title="FurukawaTA , BarbuiC , CiprianiA , BrambillaP , WatanabeN . Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology2006;59(1):7‐10. ">Furukawa 2006</a>). Although some of these imputation strategies can introduce error, the alternative would be to exclude a given study’s outcome and thus to lose information. We examined the validity of the imputations in a sensitivity analysis excluding imputed values. In our review we needed to exclude some outcome data as suggested by this last option. </p> </section> <section id="CD009555-sec-0094"> <h6 class="title">3.3 Last observation carried forward</h6> <p>We anticipated that in some studies the method of last observation carried forward (LOCF) would have been reported. As with all methods of imputation to deal with missing data, LOCF introduces uncertainty about the reliability of the results (<a href="./references#CD009555-bbs2-0070" title="LeuchtS , EngelRR , BaumlJ , DavisJM . Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophrenia Bulletin2007;33(1):183‐91. [PUBMED: 16905632] ">Leucht 2007</a>). We found no cases where less than 50% of the LOCF data were available; if we had, we would have reproduced these data and indicated that they were based on LOCF assumptions<i>.</i> </p> </section> </section> </section> <section id="CD009555-sec-0095"> <h4 class="title">Assessment of heterogeneity</h4> <section id="CD009555-sec-0096"> <h5 class="title">1. Clinical heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data to judge clinical heterogeneity. We inspected all studies for clearly outlying people or situations which we had not predicted would arise, but we did not come across any such outlying conditions. </p> </section> <section id="CD009555-sec-0097"> <h5 class="title">2. Methodological heterogeneity</h5> <p>We considered all included studies initially without seeing comparison data to judge methodological heterogeneity. We simply inspected all studies for clearly outlying methods which we had not predicted would arise, but we did not come across any such outlying methods. </p> </section> <section id="CD009555-sec-0098"> <h5 class="title">3. Statistical heterogeneity</h5> <section id="CD009555-sec-0099"> <h6 class="title">3.1 Visual inspection</h6> <p>We visually inspected the graphs to investigate the possibility of statistical heterogeneity.</p> </section> <section id="CD009555-sec-0100"> <h6 class="title">3.2 Employing the I² statistic</h6> <p>We investigated heterogeneity between studies by considering the I² method alongside the Chi² P value. The I² provides an estimate of the percentage of inconsistency thought to be due to chance (<a href="./references#CD009555-bbs2-0054" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>). The importance of the observed value of I² depends on (i) magnitude and direction of effects, and (ii) strength of evidence for heterogeneity (e.g. P value from Chi²  test, or a confidence interval for I²). I² estimates greater than or equal to 50% and accompanied by a statistically significant Chi² statistic are interpreted as evidence of substantial levels of heterogeneity (<a href="./references#CD009555-bbs2-0042" title="DeeksJJ , HigginsJPT , Altman DGeditor(s) . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Deeks 2011</a>). If substantial levels of heterogeneity had been found in the primary outcome, we would have explored reasons for heterogeneity (<a href="#CD009555-sec-0105">Subgroup analysis and investigation of heterogeneity</a>). </p> </section> </section> </section> <section id="CD009555-sec-0101"> <h4 class="title">Assessment of reporting biases</h4> <section id="CD009555-sec-0102"> <h5 class="title">1. Protocol versus full study</h5> <p>We attempted to locate protocols of the included randomised trials but were unsuccessful. We therefore compared the outcomes listed in the Methods section of the trial report with those actually reported in the results. </p> </section> <section id="CD009555-sec-0103"> <h5 class="title">2. Funnel plot</h5> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<a href="./references#CD009555-bbs2-0046" title="EggerM , Davey‐SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315(7109):629‐34. ">Egger 1997</a>). These are described in Chapter 10 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009555-bbs2-0085" title="SterneJAC , EggerM , MoherD editor(s) . Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org. ">Sterne 2011</a>). We are aware that funnel plots may be useful in investigating reporting biases but have limited power to detect small‐study effects. We did not use funnel plots as there were only three randomised controlled studies included in this review<i>.</i> </p> </section> </section> <section id="CD009555-sec-0104"> <h4 class="title">Data synthesis</h4> <p>We understand that there is no closed argument in favour of either a fixed‐effect or a random‐effects model. The random‐effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This often seems to be true to us and the random‐effects model takes into account differences between studies even if there is no statistically significant heterogeneity. There is, however, a disadvantage to the random‐effects model: it adds weight to small studies, which often are the most biased ones. Depending on the direction of effect, these studies can either inflate or deflate the effect size. We chose a random‐effects model for all analyses. The reader is, however, able to choose to inspect the data using the fixed‐effect model by opening this review in RevMan 5 format and selecting to view by "fixed effect" model under the properties section of each graph. </p> </section> <section id="CD009555-sec-0105"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <section id="CD009555-sec-0106"> <h5 class="title">1. Subgroup analyses</h5> <p>We had planned to report data on subgroups of participants (for example, those who received additional medications or had additional diagnoses), but we did not encounter such subgroups. </p> <section id="CD009555-sec-0107"> <h6 class="title">1.1 Clinical state, stage or problem</h6> <p>This review provides an overview of the effects of clozapine for people with schizophrenia, schizophreniform and schizoaffective disorder. Our aim was also to report data on subgroups of people in the same clinical state, stage and with similar problems (for example patients in agitated state, partial remission, remission or first episode), but we did not come across any such subgroups. </p> </section> </section> <section id="CD009555-sec-0108"> <h5 class="title">2. Investigation of heterogeneity</h5> <p>We report if inconsistency was high. First, we investigated whether data were entered correctly. Secondly, if the data were correct, we visually inspected the graphs and successively removed outlying studies to see if heterogeneity was restored. For this review we decided that we would present the data if this occurred in no more than 10% of the total weighting of the summary findings. If not, we would not pool data but would only discuss the issues. If unanticipated clinical or methodological heterogeneity had been obvious, we would have stated the hypotheses regarding these for future reviews or versions of this review and would not have undertaken analyses relating to these. </p> </section> </section> <section id="CD009555-sec-0109"> <h4 class="title">Sensitivity analysis</h4> <section id="CD009555-sec-0110"> <h5 class="title">1. Implication of randomisation</h5> <p> We would have included in a sensitivity analysis primary outcomes data from studies where randomisation was implied but was not clearly described, but we did not come across such studies. If there had been no substantive difference when the implied randomised studies were added to those with better description of randomisation, then we would have employed all data from these studies. </p> </section> <section id="CD009555-sec-0111"> <h5 class="title">2. Assumptions for lost binary data</h5> <p>Where assumptions were made regarding participants lost to follow‐up (see <a href="#CD009555-sec-0088">Dealing with missing data</a>) we would have compared the findings of the primary outcomes when we used our assumption compared with completer data only. If there had been a substantial difference, we would have reported the results and discussed them but would have continued to employ our assumption. Where assumptions were made regarding missing SDs data (see <a href="#CD009555-sec-0088">Dealing with missing data</a>), we would have compared the findings on primary outcomes when we used our assumption compared with completer data only. We would have undertaken a sensitivity analysis testing as to how prone results would have been to change with completer data only compared to the imputed data using the above assumption. If there would have been a substantial difference, we would have reported these results and discussed them but would have continued to employ our assumption. We did not have to make such assumptions in our review. </p> </section> <section id="CD009555-sec-0112"> <h5 class="title">3. Risk of bias</h5> <p>We analysed the effects of excluding trials that were judged to be at high risk of bias across one or more of the domains — randomisation, allocation concealment, blinding and outcome reporting and other bias — for the meta‐analyses of the primary outcome. If the exclusion of trials at high risk of bias did not substantially alter the direction of effect or the precision of the effect estimates, then we included data from these trials in the analysis. </p> </section> <section id="CD009555-sec-0113"> <h5 class="title">4. Imputed values</h5> <p>We did not include any cluster trials. If any had been included, we would have undertaken sensitivity analysis to assess the effects of including data from trials where we had used imputed values for ICCs in calculating the design effect. If substantial differences in the direction or precision of effect estimates in any of the sensitivity analyses had been noted, we would not have pooled data, but would have presented them separately. </p> </section> <section id="CD009555-sec-0114"> <h5 class="title">5. Fixed‐effect and random‐effects</h5> <p>We synthesised all data using a random‐effects model.</p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009555-sec-0115" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009555-sec-0115"></div> <section id="CD009555-sec-0116"> <h3 class="title">Description of studies</h3> <p>For substantive description of studies please also see <a href="./references#CD009555-sec-0221" title="">Characteristics of included studies</a>, <a href="./references#CD009555-sec-0222" title="">Characteristics of excluded studies</a> and Characteristics of ongoing studies. </p> <section id="CD009555-sec-0117"> <h4 class="title">Results of the search</h4> <p>The search strategy yielded 122 citations. One was a duplicate. We closely inspected 23 full‐text reports; and after excluding 18 full‐text reports, we included five studies in the review. A random 20% of the citations were independently reviewed by one review author (BV) to increase reliability. Details of the search results are illustrated in the PRISMA table (<a href="#CD009555-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD009555-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD009555-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD009555-sec-0118"> <h4 class="title">Included studies</h4> <p>We included five studies with a total of 452 participants.</p> <section id="CD009555-sec-0119"> <h5 class="title">1. Study length</h5> <p><a href="./references#CD009555-bbs2-0001" title="ChenYG , ZhaoJP , XieGR , ChenJD , ZhuRH , LiaoJD , et al. A study on serum concentration and clinical response of clozapine with different dose administration for treatment of schizophrenia. Chinese Journal of Psychiatry1998;31(2):104‐7. ">Chen 1998</a> and <a href="./references#CD009555-bbs2-0002" title="ChenYH , CaoQ , ChenWQ . The effect of clozapine for patients with schizophrenia: a clinical trial [氯氮平治疗精神分裂症患者的临床研究]. Modern Diagnosis and Treatment [现代诊断与治疗]2013, issue 15:3460‐1. ">Chen 2013</a> were short‐term trials lasting six weeks. <a href="./references#CD009555-bbs2-0004" title="ShengXQ , HuaK , YanH , LuoLH . Clozapine therapy in schizophrenia. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]1990; Vol. 16, issue 2:90‐2. ">Sheng 1990</a> and <a href="./references#CD009555-bbs2-0003" title="LiuSF , WangY , WangDP , WeiP , WangSG , MaHJ , et al. Effects of different doses clozapine on glucose metabolism in male schizophrenics. Chinese Journal of New Drugs and Clinical Remedies2005;24(2):98‐101. LiuSF , WeiP , WangSG , WangDP , WangY , MaHJ , et al. Effects of varied dosage of clozapine on blood lipid and glucometabolism in schizophrenia. Chinese Journal of Psychiatry2005;38(2):82‐5. ">Liu 2005</a> were also short term (12 weeks). The <a href="./references#CD009555-bbs2-0005" title="SimpsonGM . Correction. American Journal of Psychiatry2001;158(5):834. SimpsonGM , JosiassenRC , StanillaJK , deLeonJ , NairC , AbrahamG , et al. Double blind study of clozapine dose response in chronic schizophrenia. American Journal of Psychiatry1999;156(11):1744‐50. [MEDLINE: 10553738] deLeonJ , DiazFJ , JosiassenRC , CooperTB , SimpsonGM . Weight gain during a double‐blind multidosage clozapine study. Journal of Clinical Psychopharmacology2007;27(1):22‐7. [MEDLINE: 17224708] ">Simpson 1999</a> trial was originally conducted in three phases of 16 weeks each, lasting for a total of 48 weeks. However, after the first 16 weeks, the non‐responders in the trial were crossed over to other arms and hence they were not randomised anymore after the initial 16 weeks. So, as per protocol, we included the results of only the first 16 weeks (medium term: 13 to 26 weeks) from these citations. There were no long‐term studies (&gt; 26 weeks). </p> </section> <section id="CD009555-sec-0120"> <h5 class="title">2. Design</h5> <p>All included studies were randomised controlled trials. <a href="./references#CD009555-bbs2-0001" title="ChenYG , ZhaoJP , XieGR , ChenJD , ZhuRH , LiaoJD , et al. A study on serum concentration and clinical response of clozapine with different dose administration for treatment of schizophrenia. Chinese Journal of Psychiatry1998;31(2):104‐7. ">Chen 1998</a> is a randomised controlled trial comparing the efficacy of clozapine at doses of 200 mg and 500 mg; details of blinding status and of any sponsorship are unclear. <a href="./references#CD009555-bbs2-0003" title="LiuSF , WangY , WangDP , WeiP , WangSG , MaHJ , et al. Effects of different doses clozapine on glucose metabolism in male schizophrenics. Chinese Journal of New Drugs and Clinical Remedies2005;24(2):98‐101. LiuSF , WeiP , WangSG , WangDP , WangY , MaHJ , et al. Effects of varied dosage of clozapine on blood lipid and glucometabolism in schizophrenia. Chinese Journal of Psychiatry2005;38(2):82‐5. ">Liu 2005</a> is a randomised controlled trial comparing clozapine at doses of less than 150 mg/day, 150 mg/day to 300 mg/day and more than 300 mg/day, in which participants were allocated using a random number table; details of blinding status and of any sponsorship are unclear. <a href="./references#CD009555-bbs2-0002" title="ChenYH , CaoQ , ChenWQ . The effect of clozapine for patients with schizophrenia: a clinical trial [氯氮平治疗精神分裂症患者的临床研究]. Modern Diagnosis and Treatment [现代诊断与治疗]2013, issue 15:3460‐1. ">Chen 2013</a> is a randomised trial comparing doses of 200 mg/day to 300 mg/day, 301 mg/day to 400 mg/day and 401 mg/day to 500 mg/day. <a href="./references#CD009555-bbs2-0004" title="ShengXQ , HuaK , YanH , LuoLH . Clozapine therapy in schizophrenia. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]1990; Vol. 16, issue 2:90‐2. ">Sheng 1990</a> is a randomised trial comparing doses of 300 mg/day and 600 mg/day. <a href="./references#CD009555-bbs2-0005" title="SimpsonGM . Correction. American Journal of Psychiatry2001;158(5):834. SimpsonGM , JosiassenRC , StanillaJK , deLeonJ , NairC , AbrahamG , et al. Double blind study of clozapine dose response in chronic schizophrenia. American Journal of Psychiatry1999;156(11):1744‐50. [MEDLINE: 10553738] deLeonJ , DiazFJ , JosiassenRC , CooperTB , SimpsonGM . Weight gain during a double‐blind multidosage clozapine study. Journal of Clinical Psychopharmacology2007;27(1):22‐7. [MEDLINE: 17224708] ">Simpson 1999</a> is an implied randomised controlled trial comparing the efficacy of clozapine at different doses of 100 mg/day, 300 mg/day and 600 mg/day in 50 patients. The trial was sponsored by Novartis Pharmaceuticals and conducted between 1992 and 1995; the participants stayed in the research centre for four weeks for adaptation (naturalistic baseline with no modification in their treatment regimen) and underwent a four‐week haloperidol treatment followed by a one‐week wash out before the first phase of clozapine treatment. </p> </section> <section id="CD009555-sec-0121"> <h5 class="title">3. Participants</h5> <p>A total of 452 participants were included in the five trials. <a href="./references#CD009555-bbs2-0001" title="ChenYG , ZhaoJP , XieGR , ChenJD , ZhuRH , LiaoJD , et al. A study on serum concentration and clinical response of clozapine with different dose administration for treatment of schizophrenia. Chinese Journal of Psychiatry1998;31(2):104‐7. ">Chen 1998</a> conducted their study on a total of 176 male and female patients, aged between 17 and 55 years, suffering from schizophrenia and with illness duration of 8 (± 11 months) on average. <a href="./references#CD009555-bbs2-0003" title="LiuSF , WangY , WangDP , WeiP , WangSG , MaHJ , et al. Effects of different doses clozapine on glucose metabolism in male schizophrenics. Chinese Journal of New Drugs and Clinical Remedies2005;24(2):98‐101. LiuSF , WeiP , WangSG , WangDP , WangY , MaHJ , et al. Effects of varied dosage of clozapine on blood lipid and glucometabolism in schizophrenia. Chinese Journal of Psychiatry2005;38(2):82‐5. ">Liu 2005</a> included 87 male patients aged between 18 and 45 years and used CCMD‐3 to diagnose patients suffering from schizophrenia. <a href="./references#CD009555-bbs2-0002" title="ChenYH , CaoQ , ChenWQ . The effect of clozapine for patients with schizophrenia: a clinical trial [氯氮平治疗精神分裂症患者的临床研究]. Modern Diagnosis and Treatment [现代诊断与治疗]2013, issue 15:3460‐1. ">Chen 2013</a> and <a href="./references#CD009555-bbs2-0004" title="ShengXQ , HuaK , YanH , LuoLH . Clozapine therapy in schizophrenia. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]1990; Vol. 16, issue 2:90‐2. ">Sheng 1990</a> randomised 90 and 51 patients with schizophrenia, respectively. <a href="./references#CD009555-bbs2-0005" title="SimpsonGM . Correction. American Journal of Psychiatry2001;158(5):834. SimpsonGM , JosiassenRC , StanillaJK , deLeonJ , NairC , AbrahamG , et al. Double blind study of clozapine dose response in chronic schizophrenia. American Journal of Psychiatry1999;156(11):1744‐50. [MEDLINE: 10553738] deLeonJ , DiazFJ , JosiassenRC , CooperTB , SimpsonGM . Weight gain during a double‐blind multidosage clozapine study. Journal of Clinical Psychopharmacology2007;27(1):22‐7. [MEDLINE: 17224708] ">Simpson 1999</a> was conducted on a total of 22 males and 28 females with a mean age of 44.8 years (range 35 to 54) suffering from schizophrenia, treatment refractory or schizoaffective disorder, diagnosed by DSM‐III‐R criteria. Mean illness duration was 25.1 years (range 1 to 38 years) and the median number of psychiatric hospitalisations was five (range 1 to 25). Patients had not shown a satisfactory clinical response to treatment with at least three neuroleptic drugs (each given for at least six weeks in doses equivalent to 1000 mg/day of chlorpromazine). </p> </section> <section id="CD009555-sec-0122"> <h5 class="title">4. Settings</h5> <p><a href="./references#CD009555-bbs2-0005" title="SimpsonGM . Correction. American Journal of Psychiatry2001;158(5):834. SimpsonGM , JosiassenRC , StanillaJK , deLeonJ , NairC , AbrahamG , et al. Double blind study of clozapine dose response in chronic schizophrenia. American Journal of Psychiatry1999;156(11):1744‐50. [MEDLINE: 10553738] deLeonJ , DiazFJ , JosiassenRC , CooperTB , SimpsonGM . Weight gain during a double‐blind multidosage clozapine study. Journal of Clinical Psychopharmacology2007;27(1):22‐7. [MEDLINE: 17224708] ">Simpson 1999</a> used a research ward inpatient setting in a State hospital in the USA. <a href="./references#CD009555-bbs2-0003" title="LiuSF , WangY , WangDP , WeiP , WangSG , MaHJ , et al. Effects of different doses clozapine on glucose metabolism in male schizophrenics. Chinese Journal of New Drugs and Clinical Remedies2005;24(2):98‐101. LiuSF , WeiP , WangSG , WangDP , WangY , MaHJ , et al. Effects of varied dosage of clozapine on blood lipid and glucometabolism in schizophrenia. Chinese Journal of Psychiatry2005;38(2):82‐5. ">Liu 2005</a> was conducted in an inpatient setting in a medical college. The settings for <a href="./references#CD009555-bbs2-0001" title="ChenYG , ZhaoJP , XieGR , ChenJD , ZhuRH , LiaoJD , et al. A study on serum concentration and clinical response of clozapine with different dose administration for treatment of schizophrenia. Chinese Journal of Psychiatry1998;31(2):104‐7. ">Chen 1998</a>, <a href="./references#CD009555-bbs2-0002" title="ChenYH , CaoQ , ChenWQ . The effect of clozapine for patients with schizophrenia: a clinical trial [氯氮平治疗精神分裂症患者的临床研究]. Modern Diagnosis and Treatment [现代诊断与治疗]2013, issue 15:3460‐1. ">Chen 2013</a> and <a href="./references#CD009555-bbs2-0004" title="ShengXQ , HuaK , YanH , LuoLH . Clozapine therapy in schizophrenia. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]1990; Vol. 16, issue 2:90‐2. ">Sheng 1990</a> were unclear. </p> </section> <section id="CD009555-sec-0123"> <h5 class="title">5. Interventions</h5> <p>We classified interventions into five groups according to clozapine dosage. <a href="./references#CD009555-bbs2-0003" title="LiuSF , WangY , WangDP , WeiP , WangSG , MaHJ , et al. Effects of different doses clozapine on glucose metabolism in male schizophrenics. Chinese Journal of New Drugs and Clinical Remedies2005;24(2):98‐101. LiuSF , WeiP , WangSG , WangDP , WangY , MaHJ , et al. Effects of varied dosage of clozapine on blood lipid and glucometabolism in schizophrenia. Chinese Journal of Psychiatry2005;38(2):82‐5. ">Liu 2005</a> administered clozapine at less than 150 mg/day (very low dose), at 150 mg/day to 300 mg/day (low dose) and at more than 300 mg/day (standard dose). <a href="./references#CD009555-bbs2-0005" title="SimpsonGM . Correction. American Journal of Psychiatry2001;158(5):834. SimpsonGM , JosiassenRC , StanillaJK , deLeonJ , NairC , AbrahamG , et al. Double blind study of clozapine dose response in chronic schizophrenia. American Journal of Psychiatry1999;156(11):1744‐50. [MEDLINE: 10553738] deLeonJ , DiazFJ , JosiassenRC , CooperTB , SimpsonGM . Weight gain during a double‐blind multidosage clozapine study. Journal of Clinical Psychopharmacology2007;27(1):22‐7. [MEDLINE: 17224708] ">Simpson 1999</a> administered clozapine at 100 mg/day (very low dose), 300 mg/day (low dose) and 600 mg/day (standard dose). <a href="./references#CD009555-bbs2-0001" title="ChenYG , ZhaoJP , XieGR , ChenJD , ZhuRH , LiaoJD , et al. A study on serum concentration and clinical response of clozapine with different dose administration for treatment of schizophrenia. Chinese Journal of Psychiatry1998;31(2):104‐7. ">Chen 1998</a> administered clozapine at 200 mg/day (low dose) and at 500 mg/day (standard dose). <a href="./references#CD009555-bbs2-0002" title="ChenYH , CaoQ , ChenWQ . The effect of clozapine for patients with schizophrenia: a clinical trial [氯氮平治疗精神分裂症患者的临床研究]. Modern Diagnosis and Treatment [现代诊断与治疗]2013, issue 15:3460‐1. ">Chen 2013</a> administered doses of 200 mg/day to 300 mg/day, 301 mg/day to 400 mg/day and 401 mg/day to 500 mg/day. <a href="./references#CD009555-bbs2-0004" title="ShengXQ , HuaK , YanH , LuoLH . Clozapine therapy in schizophrenia. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]1990; Vol. 16, issue 2:90‐2. ">Sheng 1990</a> administered doses of 300 mg/day and 600 mg/day. No trial administered clozapine at more than 601 mg/day (high dose) or more than 901 mg/day (very high dose). </p> </section> <section id="CD009555-sec-0124"> <h5 class="title">6. Outcomes</h5> <section id="CD009555-sec-0125"> <h6 class="title">6.1 Rating scales</h6> <p>Details of the scales that provided usable data are shown below. Reasons for exclusions of data and/or scales are given under ‘Outcomes’ in the <a href="./references#CD009555-sec-0221" title="">Characteristics of included studies</a> table. </p> <section id="CD009555-sec-0126"> <p><b>6.1.1 Mental state</b></p> <p>6.1.1.1 Brief Psychiatric Rating Scale ‒ BPRS (<a href="./references#CD009555-bbs2-0079" title="OverallJE , GorhamDR . The brief psychiatric rating scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>) </p> <p>The BPRS is an 18‐item scale measuring positive symptoms, general psychopathology and affective symptoms. High scores indicate more severe symptoms. The original scale has 16 items that are rated in interview format using Likert scale ratings from 1 (‘absent’) to 7 (‘very severe’) with scores ranging from 0 to 112. A revised 18‐item scale is commonly used with scores ranging from 0 to 126. The BPRS‐A is an anchored version of the BPRS. It describes expected symptoms and problems for each of the seven rating options for each item. As such, it is thought that the BPRS‐A anchor points provide an increased level of standardisation, leading to an improvement in rater reliability (<a href="./references#CD009555-bbs2-0094" title="WoernerMG , MannuzzaS , KaneJM . Anchoring the BPRS: an aid to improved reliability. Psychopharmacology Bulletin1988;24(1):112‐7. ">Woerner 1988</a>). The BPRS‐A and its subscales have been validated (<a href="./references#CD009555-bbs2-0067" title="LacharD , BailleySE , RhoadesHM , EspadasA , AponteM , CowanKA , et al. New subscales for an anchored version of the Brief Psychiatric Rating Scale: construction, reliability, and validity in acute psychiatric admissions. Psychological Assessment2001;13(3):384‐95. ">Lachar 2001</a>). <a href="./references#CD009555-bbs2-0001" title="ChenYG , ZhaoJP , XieGR , ChenJD , ZhuRH , LiaoJD , et al. A study on serum concentration and clinical response of clozapine with different dose administration for treatment of schizophrenia. Chinese Journal of Psychiatry1998;31(2):104‐7. ">Chen 1998</a> and <a href="./references#CD009555-bbs2-0005" title="SimpsonGM . Correction. American Journal of Psychiatry2001;158(5):834. SimpsonGM , JosiassenRC , StanillaJK , deLeonJ , NairC , AbrahamG , et al. Double blind study of clozapine dose response in chronic schizophrenia. American Journal of Psychiatry1999;156(11):1744‐50. [MEDLINE: 10553738] deLeonJ , DiazFJ , JosiassenRC , CooperTB , SimpsonGM . Weight gain during a double‐blind multidosage clozapine study. Journal of Clinical Psychopharmacology2007;27(1):22‐7. [MEDLINE: 17224708] ">Simpson 1999</a> reported data on the BPRS‐A. </p> </section> <section id="CD009555-sec-0127"> <p><b>6.1.2 Adverse events</b></p> <p>6.1.2.1 Treatment‐Emergent Signs and Symptoms ‐ TESS (<a href="./references#CD009555-bbs2-0077" title="National Institute of Mental Health (NIMH). TESS (treatment emergent symptoms scale). Psychopharmacology Bulletin1985;22:1069‐72. ">NIMH 1985</a>) </p> <p>This checklist assesses a variety of characteristics for each adverse event, including severity, relationship to the drug, temporal characteristics (timing after a dose, duration and pattern during the day), contributing factors, course, and action taken to counteract the effect. Symptoms can be listed a priori or can be recorded as observed by the investigator. A low score indicates low levels of adverse effects. <a href="./references#CD009555-bbs2-0001" title="ChenYG , ZhaoJP , XieGR , ChenJD , ZhuRH , LiaoJD , et al. A study on serum concentration and clinical response of clozapine with different dose administration for treatment of schizophrenia. Chinese Journal of Psychiatry1998;31(2):104‐7. ">Chen 1998</a> and <a href="./references#CD009555-bbs2-0002" title="ChenYH , CaoQ , ChenWQ . The effect of clozapine for patients with schizophrenia: a clinical trial [氯氮平治疗精神分裂症患者的临床研究]. Modern Diagnosis and Treatment [现代诊断与治疗]2013, issue 15:3460‐1. ">Chen 2013</a> reported data on this outcome. </p> </section> </section> </section> </section> <section id="CD009555-sec-0128"> <h4 class="title">Excluded studies</h4> <p>Of the 122 references identified using the search strategy, one was a duplicate. We closely inspected 28 reports and excluded 23. <a href="./references#CD009555-bbs2-0013" title="LiuSF , MuJL , ZhangYJ , WangSG , WeiP , WangDP , et al. Effect of clozapine of different dosages on the cognitive function in patients with schizophrenia assessed by the changes of p300 potentials. Chinese Journal of Clinical Rehabilitation2005;9(8):56‐7. ">Liu 2005a</a> and <a href="./references#CD009555-bbs2-0021" title="TangY , PengC , XiaoH . Research for clozapine in schizophrenia and the relationship between plasma clozapine concentration and clinical response. Journal of Clinical Psychological Medicine [临床精神医学杂志]2000;10(6):335‐7. ">Tang 2000</a> were not randomised trials. All data were missing in <a href="./references#CD009555-bbs2-0007" title="deLeonJ , Odom‐WhiteA , StanillaJ , JoiassenR , SimpsonGM . Does clozapine induce akathisia?. Schizophrenia Research1995;15(1‐2):207. ">de Leon 1995a</a> and <a href="./references#CD009555-bbs2-0010" title="deLeonJ , DiazFJ , JosiassenRC , SimpsonGM . Possible individual and gender differences in the small increases in plasma prolactin levels seen during clozapine treatment. European Archives of Psychiatry and Clinical Neuroscience2004;254(5):318‐25. [MEDLINE: 15365707] ">de Leon 2004</a> and we contacted the author who confirmed that no further data were available. <a href="./references#CD009555-bbs2-0009" title="deLeonJ , Odom‐WhiteA , JosiassenRC , DiazFJ , CooperTB , SimpsonGM . Serum antimuscarinic activity during clozapine treatment. Journal of Clinical Psychopharmacology2003;23(4):336‐41. ">de Leon 2003</a> was excluded as the data on serum antimuscarinic activity was missing at 16 weeks before the cross‐over point. <a href="./references#CD009555-bbs2-0019" title="PotkinSG , BeraR , GulasekaramB . High and low dose of clozapine compared in a double‐blind study. Schizophrenia Research1993;9:246‐7. ">Potkin 1993</a> and <a href="./references#CD009555-bbs2-0020" title="PotkinSG , BeraR , GulasekaramB , CostaJ , HayesS , JinY , et al. Plasma clozapine concentrations predict clinical response in treatment‐resistant schizophrenia. Journal of Clinical Psychiatry1994;55(Suppl B):133‐6. [MEDLINE: 7961557] ">Potkin 1994</a> also had all data missing from the reports and no data were useable; we contacted the author regarding the missing data but no response has been received at the time of writing. We excluded <a href="./references#CD009555-bbs2-0012" title="HanYC , ShiSS , XuRJ , ShangFZ . Controlled clinical trial of high versus low dose clozapine combined with sulpiride for schizophrenia. Shandong Archives of Psychiatry [山东精神医学]2001;14(2):138‐9. ">Han 2001</a> as different doses of sulpiride were prescribed in the clozapine arms. <a href="./references#CD009555-bbs2-0022" title="VanderZwaagC , McGeeM , McEvoyJP , FreudenreichO , WilsonWH , CooperTB . Response of patients with treatment‐refractory schizophrenia to clozapine within three serum level ranges. American Journal of Psychiatry1996;153(12):1579‐84. [MEDLINE: 8942454] ">VanderZwaag 1996</a> and <a href="./references#CD009555-bbs2-0023" title="FreudenreichO , WeinerRD , McEvoyJP . Clozapine‐induced electroencephalogram changes as a function of clozapine serum levels. Biological Psychiatry1997;42(2):132‐7. ">VanderZwaag 1997</a> compared the effectiveness of different serum clozapine levels, but not the effects of different doses of clozapine. <a href="./references#CD009555-bbs2-0017" title="NairCJ , deLeonJ , SimpsonGM , JosiassenRC . Therapeutic effects of clozapine on tardive dyskinesia. Cognitive and Behavioral Practice1998;5:119–27. ">Nair 1998</a> and <a href="./references#CD009555-bbs2-0018" title="NairCJ , JosiassenRC , AbrahamG , StanillaJK , TracyJI , SimpsonGM . Does akathisia influence psychopathology in psychotic patients treated with clozapine?. Biological Psychiatry1999;45:1376–83. ">Nair 1999</a> were excluded because the authors compared those with and without probable tardive dyskinesia in subgroups of 23 and 33 participants respectively from the <a href="./references#CD009555-bbs2-0005" title="SimpsonGM . Correction. American Journal of Psychiatry2001;158(5):834. SimpsonGM , JosiassenRC , StanillaJK , deLeonJ , NairC , AbrahamG , et al. Double blind study of clozapine dose response in chronic schizophrenia. American Journal of Psychiatry1999;156(11):1744‐50. [MEDLINE: 10553738] deLeonJ , DiazFJ , JosiassenRC , CooperTB , SimpsonGM . Weight gain during a double‐blind multidosage clozapine study. Journal of Clinical Psychopharmacology2007;27(1):22‐7. [MEDLINE: 17224708] ">Simpson 1999</a> trial, but provided no additional data relevant to this review. </p> <section id="CD009555-sec-0129"> <h5 class="title">Studies awaiting classification</h5> <p><a href="./references#CD009555-bbs2-0024" title="AbrahamG , NairC , TracyJI , SimpsonGM . The effects of clozapine on symptom clusters in treatment‐refractory patients. Journal of Clinical Psychopharmacology1997;17(1):49‐53. [MEDLINE: 9004057] ">Abraham 1997</a> is a report of a trial conducted from 1992 to 1995, reported in detail in <a href="./references#CD009555-bbs2-0005" title="SimpsonGM . Correction. American Journal of Psychiatry2001;158(5):834. SimpsonGM , JosiassenRC , StanillaJK , deLeonJ , NairC , AbrahamG , et al. Double blind study of clozapine dose response in chronic schizophrenia. American Journal of Psychiatry1999;156(11):1744‐50. [MEDLINE: 10553738] deLeonJ , DiazFJ , JosiassenRC , CooperTB , SimpsonGM . Weight gain during a double‐blind multidosage clozapine study. Journal of Clinical Psychopharmacology2007;27(1):22‐7. [MEDLINE: 17224708] ">Simpson 1999</a> where it is mentioned that global state was measured using the Clinical Global Impression (CGI) and these data would be discussed in <a href="./references#CD009555-bbs2-0024" title="AbrahamG , NairC , TracyJI , SimpsonGM . The effects of clozapine on symptom clusters in treatment‐refractory patients. Journal of Clinical Psychopharmacology1997;17(1):49‐53. [MEDLINE: 9004057] ">Abraham 1997</a>. However, <a href="./references#CD009555-bbs2-0024" title="AbrahamG , NairC , TracyJI , SimpsonGM . The effects of clozapine on symptom clusters in treatment‐refractory patients. Journal of Clinical Psychopharmacology1997;17(1):49‐53. [MEDLINE: 9004057] ">Abraham 1997</a> only retrospectively analysed the data on responders and non‐responders; four participants responded, but it was unclear from the report which groups they belonged to and the CGI data for the dosage groups were also missing. We contacted the main trialist who indicated he would provide the missing data, but this has not been received at the time of writing. If we receive this subsequently, we will include it in an update of this review. </p> </section> <section id="CD009555-sec-0130"> <h5 class="title">Ongoing studies</h5> <p>We did not identify any ongoing studies.</p> </section> </section> </section> <section id="CD009555-sec-0131"> <h3 class="title">Risk of bias in included studies</h3> <p>None of the studies explicitly described the allocation process fully. Some of the studies were selective in presenting their data on outcomes. Some of the outcomes in the trials could not be used and we have not received missing data we requested from the authors of the trials. <a href="./references#CD009555-bbs2-0005" title="SimpsonGM . Correction. American Journal of Psychiatry2001;158(5):834. SimpsonGM , JosiassenRC , StanillaJK , deLeonJ , NairC , AbrahamG , et al. Double blind study of clozapine dose response in chronic schizophrenia. American Journal of Psychiatry1999;156(11):1744‐50. [MEDLINE: 10553738] deLeonJ , DiazFJ , JosiassenRC , CooperTB , SimpsonGM . Weight gain during a double‐blind multidosage clozapine study. Journal of Clinical Psychopharmacology2007;27(1):22‐7. [MEDLINE: 17224708] ">Simpson 1999</a> was a trial sponsored by a clozapine drug company. See <a href="#CD009555-fig-0003">Figure 3</a>, <a href="#CD009555-fig-0004">Figure 4</a>. </p> <div class="figure" id="CD009555-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009555-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD009555-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009555-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD009555-sec-0132"> <h4 class="title">Allocation</h4> <p>All five studies were described as randomised. Allocation in <a href="./references#CD009555-bbs2-0003" title="LiuSF , WangY , WangDP , WeiP , WangSG , MaHJ , et al. Effects of different doses clozapine on glucose metabolism in male schizophrenics. Chinese Journal of New Drugs and Clinical Remedies2005;24(2):98‐101. LiuSF , WeiP , WangSG , WangDP , WangY , MaHJ , et al. Effects of varied dosage of clozapine on blood lipid and glucometabolism in schizophrenia. Chinese Journal of Psychiatry2005;38(2):82‐5. ">Liu 2005</a> was via a random number generator. <a href="./references#CD009555-bbs2-0005" title="SimpsonGM . Correction. American Journal of Psychiatry2001;158(5):834. SimpsonGM , JosiassenRC , StanillaJK , deLeonJ , NairC , AbrahamG , et al. Double blind study of clozapine dose response in chronic schizophrenia. American Journal of Psychiatry1999;156(11):1744‐50. [MEDLINE: 10553738] deLeonJ , DiazFJ , JosiassenRC , CooperTB , SimpsonGM . Weight gain during a double‐blind multidosage clozapine study. Journal of Clinical Psychopharmacology2007;27(1):22‐7. [MEDLINE: 17224708] ">Simpson 1999</a>, <a href="./references#CD009555-bbs2-0004" title="ShengXQ , HuaK , YanH , LuoLH . Clozapine therapy in schizophrenia. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]1990; Vol. 16, issue 2:90‐2. ">Sheng 1990</a>, <a href="./references#CD009555-bbs2-0002" title="ChenYH , CaoQ , ChenWQ . The effect of clozapine for patients with schizophrenia: a clinical trial [氯氮平治疗精神分裂症患者的临床研究]. Modern Diagnosis and Treatment [现代诊断与治疗]2013, issue 15:3460‐1. ">Chen 2013</a> and <a href="./references#CD009555-bbs2-0001" title="ChenYG , ZhaoJP , XieGR , ChenJD , ZhuRH , LiaoJD , et al. A study on serum concentration and clinical response of clozapine with different dose administration for treatment of schizophrenia. Chinese Journal of Psychiatry1998;31(2):104‐7. ">Chen 1998</a> did not describe the methods used to generate the allocation sequence. None of the studies reported on how the results of allocation were concealed. </p> </section> <section id="CD009555-sec-0133"> <h4 class="title">Blinding</h4> <p><a href="./references#CD009555-bbs2-0005" title="SimpsonGM . Correction. American Journal of Psychiatry2001;158(5):834. SimpsonGM , JosiassenRC , StanillaJK , deLeonJ , NairC , AbrahamG , et al. Double blind study of clozapine dose response in chronic schizophrenia. American Journal of Psychiatry1999;156(11):1744‐50. [MEDLINE: 10553738] deLeonJ , DiazFJ , JosiassenRC , CooperTB , SimpsonGM . Weight gain during a double‐blind multidosage clozapine study. Journal of Clinical Psychopharmacology2007;27(1):22‐7. [MEDLINE: 17224708] ">Simpson 1999</a> was described as a double‐blind trial with assessors blinded and all patients receiving the same number of identical capsules every time, although the authors appear not to have tested the success of blinding for participants or evaluators. This may increase the risk of observer bias with potential for overestimation of positive effects and underestimation of negative ones. <a href="./references#CD009555-bbs2-0001" title="ChenYG , ZhaoJP , XieGR , ChenJD , ZhuRH , LiaoJD , et al. A study on serum concentration and clinical response of clozapine with different dose administration for treatment of schizophrenia. Chinese Journal of Psychiatry1998;31(2):104‐7. ">Chen 1998</a> and <a href="./references#CD009555-bbs2-0003" title="LiuSF , WangY , WangDP , WeiP , WangSG , MaHJ , et al. Effects of different doses clozapine on glucose metabolism in male schizophrenics. Chinese Journal of New Drugs and Clinical Remedies2005;24(2):98‐101. LiuSF , WeiP , WangSG , WangDP , WangY , MaHJ , et al. Effects of varied dosage of clozapine on blood lipid and glucometabolism in schizophrenia. Chinese Journal of Psychiatry2005;38(2):82‐5. ">Liu 2005</a> did not report if their trials were blinded. <a href="./references#CD009555-bbs2-0002" title="ChenYH , CaoQ , ChenWQ . The effect of clozapine for patients with schizophrenia: a clinical trial [氯氮平治疗精神分裂症患者的临床研究]. Modern Diagnosis and Treatment [现代诊断与治疗]2013, issue 15:3460‐1. ">Chen 2013</a> and <a href="./references#CD009555-bbs2-0004" title="ShengXQ , HuaK , YanH , LuoLH . Clozapine therapy in schizophrenia. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]1990; Vol. 16, issue 2:90‐2. ">Sheng 1990</a> did not report how blinding took place. Blinding may be less important for objective outcomes such as death, but the studies included here reported only subjective outcomes. </p> </section> <section id="CD009555-sec-0134"> <h4 class="title">Incomplete outcome data</h4> <p><a href="./references#CD009555-bbs2-0001" title="ChenYG , ZhaoJP , XieGR , ChenJD , ZhuRH , LiaoJD , et al. A study on serum concentration and clinical response of clozapine with different dose administration for treatment of schizophrenia. Chinese Journal of Psychiatry1998;31(2):104‐7. ">Chen 1998</a>, <a href="./references#CD009555-bbs2-0002" title="ChenYH , CaoQ , ChenWQ . The effect of clozapine for patients with schizophrenia: a clinical trial [氯氮平治疗精神分裂症患者的临床研究]. Modern Diagnosis and Treatment [现代诊断与治疗]2013, issue 15:3460‐1. ">Chen 2013</a> and <a href="./references#CD009555-bbs2-0004" title="ShengXQ , HuaK , YanH , LuoLH . Clozapine therapy in schizophrenia. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]1990; Vol. 16, issue 2:90‐2. ">Sheng 1990</a> appear to have had no loss to follow up. <a href="./references#CD009555-bbs2-0003" title="LiuSF , WangY , WangDP , WeiP , WangSG , MaHJ , et al. Effects of different doses clozapine on glucose metabolism in male schizophrenics. Chinese Journal of New Drugs and Clinical Remedies2005;24(2):98‐101. LiuSF , WeiP , WangSG , WangDP , WangY , MaHJ , et al. Effects of varied dosage of clozapine on blood lipid and glucometabolism in schizophrenia. Chinese Journal of Psychiatry2005;38(2):82‐5. ">Liu 2005</a> reported on three participants who left the study early with clear reasons for doing so. <a href="./references#CD009555-bbs2-0005" title="SimpsonGM . Correction. American Journal of Psychiatry2001;158(5):834. SimpsonGM , JosiassenRC , StanillaJK , deLeonJ , NairC , AbrahamG , et al. Double blind study of clozapine dose response in chronic schizophrenia. American Journal of Psychiatry1999;156(11):1744‐50. [MEDLINE: 10553738] deLeonJ , DiazFJ , JosiassenRC , CooperTB , SimpsonGM . Weight gain during a double‐blind multidosage clozapine study. Journal of Clinical Psychopharmacology2007;27(1):22‐7. [MEDLINE: 17224708] ">Simpson 1999</a> reported the number leaving the study early and explicitly described that their last observations were carried forward; however, data on the scale for the Assessment of Negative Symptoms (SANS) were not reported. de Leon 2007 reported data on patients who completed the <a href="./references#CD009555-bbs2-0005" title="SimpsonGM . Correction. American Journal of Psychiatry2001;158(5):834. SimpsonGM , JosiassenRC , StanillaJK , deLeonJ , NairC , AbrahamG , et al. Double blind study of clozapine dose response in chronic schizophrenia. American Journal of Psychiatry1999;156(11):1744‐50. [MEDLINE: 10553738] deLeonJ , DiazFJ , JosiassenRC , CooperTB , SimpsonGM . Weight gain during a double‐blind multidosage clozapine study. Journal of Clinical Psychopharmacology2007;27(1):22‐7. [MEDLINE: 17224708] ">Simpson 1999</a> trial. However the number of patients on whom measures were reported differed slightly from week to week, and it is unclear why the number of patients on whom measurements were reported at each week differed, who had missed their measurements and why the measurements were not taken. </p> </section> <section id="CD009555-sec-0135"> <h4 class="title">Selective reporting</h4> <p><a href="./references#CD009555-bbs2-0005" title="SimpsonGM . Correction. American Journal of Psychiatry2001;158(5):834. SimpsonGM , JosiassenRC , StanillaJK , deLeonJ , NairC , AbrahamG , et al. Double blind study of clozapine dose response in chronic schizophrenia. American Journal of Psychiatry1999;156(11):1744‐50. [MEDLINE: 10553738] deLeonJ , DiazFJ , JosiassenRC , CooperTB , SimpsonGM . Weight gain during a double‐blind multidosage clozapine study. Journal of Clinical Psychopharmacology2007;27(1):22‐7. [MEDLINE: 17224708] ">Simpson 1999</a> did not report on SANS. <a href="./references#CD009555-bbs2-0004" title="ShengXQ , HuaK , YanH , LuoLH . Clozapine therapy in schizophrenia. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]1990; Vol. 16, issue 2:90‐2. ">Sheng 1990</a> did not report BPRS or TESS scores. <a href="./references#CD009555-bbs2-0005" title="SimpsonGM . Correction. American Journal of Psychiatry2001;158(5):834. SimpsonGM , JosiassenRC , StanillaJK , deLeonJ , NairC , AbrahamG , et al. Double blind study of clozapine dose response in chronic schizophrenia. American Journal of Psychiatry1999;156(11):1744‐50. [MEDLINE: 10553738] deLeonJ , DiazFJ , JosiassenRC , CooperTB , SimpsonGM . Weight gain during a double‐blind multidosage clozapine study. Journal of Clinical Psychopharmacology2007;27(1):22‐7. [MEDLINE: 17224708] ">Simpson 1999</a> reported responders' and non‐responders' data only at 48 weeks, which is after the cross‐over point at 16 weeks. No data is reported before the cross‐over. </p> </section> </section> <section id="CD009555-sec-0136"> <h3 class="title" id="CD009555-sec-0136">Effects of interventions</h3> <p>See: <a href="./full#CD009555-tbl-0001"><b>Summary of findings for the main comparison</b> Clozapine: very low dose (up to 149 mg/day) versus low dose (150 mg/day to 300 mg/day) for schizophrenia</a>; <a href="./full#CD009555-tbl-0002"><b>Summary of findings 2</b> Clozapine: very low dose (up to 149 mg/day) versus standard dose (301 mg/day to 600 mg/day) for schizophrenia</a>; <a href="./full#CD009555-tbl-0003"><b>Summary of findings 3</b> Clozapine: low dose (150 mg/day to 300 mg/day) versus standard dose (301 mg/day to 600 mg/day) for schizophrenia</a> </p> <p>In the text below, data from <a href="./references#CD009555-bbs2-0005" title="SimpsonGM . Correction. American Journal of Psychiatry2001;158(5):834. SimpsonGM , JosiassenRC , StanillaJK , deLeonJ , NairC , AbrahamG , et al. Double blind study of clozapine dose response in chronic schizophrenia. American Journal of Psychiatry1999;156(11):1744‐50. [MEDLINE: 10553738] deLeonJ , DiazFJ , JosiassenRC , CooperTB , SimpsonGM . Weight gain during a double‐blind multidosage clozapine study. Journal of Clinical Psychopharmacology2007;27(1):22‐7. [MEDLINE: 17224708] ">Simpson 1999</a> have been adjusted in accordance with the published corrections (<a href="./references#CD009555-bbs2-0083" title="SimpsonGM . Correction. American Journal of Psychiatry2001;158(5):834. ">Simpson 2001</a>). Specifically, the standard errors for BPRS‐A endpoint scores which were originally reported by the authors as if they were standard deviations have been converted to standard deviations. </p> <section id="CD009555-sec-0137"> <h4 class="title">Comparison 1: clozapine: very low dose (up to 149 mg/day) versus low dose (150 mg/day to 300 mg/day) </h4> <section id="CD009555-sec-0138"> <h5 class="title">1.1 Mental state: average endpoint scores (BPRS‐A, high = poor) – medium term</h5> <p><a href="./references#CD009555-bbs2-0005" title="SimpsonGM . Correction. American Journal of Psychiatry2001;158(5):834. SimpsonGM , JosiassenRC , StanillaJK , deLeonJ , NairC , AbrahamG , et al. Double blind study of clozapine dose response in chronic schizophrenia. American Journal of Psychiatry1999;156(11):1744‐50. [MEDLINE: 10553738] deLeonJ , DiazFJ , JosiassenRC , CooperTB , SimpsonGM . Weight gain during a double‐blind multidosage clozapine study. Journal of Clinical Psychopharmacology2007;27(1):22‐7. [MEDLINE: 17224708] ">Simpson 1999</a> found no significant difference in endpoint mental state scores at 16 weeks measured using the BPRS‐A (n = 31, MD 3.55, 95% CI −4.50 to 11.60; <a href="./references#CD009555-fig-0005" title="">Analysis 1.1</a>). </p> </section> <section id="CD009555-sec-0139"> <h5 class="title">1.2 Adverse effects: 1a. weight ‐ BMI (kg/m²) – short term</h5> <p><a href="./references#CD009555-bbs2-0003" title="LiuSF , WangY , WangDP , WeiP , WangSG , MaHJ , et al. Effects of different doses clozapine on glucose metabolism in male schizophrenics. Chinese Journal of New Drugs and Clinical Remedies2005;24(2):98‐101. LiuSF , WeiP , WangSG , WangDP , WangY , MaHJ , et al. Effects of varied dosage of clozapine on blood lipid and glucometabolism in schizophrenia. Chinese Journal of Psychiatry2005;38(2):82‐5. ">Liu 2005</a> found no significant difference in BMI at the end of six weeks in the very low dose group compared to the low dose group (n = 59, MD −0.10, 95% CI −0.95 to 0.75; <a href="./references#CD009555-fig-0006" title="">Analysis 1.2</a>). </p> </section> <section id="CD009555-sec-0140"> <h5 class="title">1.3 Adverse effects: 1b. weight gain (kg; average)</h5> <p><a href="./references#CD009555-bbs2-0005" title="SimpsonGM . Correction. American Journal of Psychiatry2001;158(5):834. SimpsonGM , JosiassenRC , StanillaJK , deLeonJ , NairC , AbrahamG , et al. Double blind study of clozapine dose response in chronic schizophrenia. American Journal of Psychiatry1999;156(11):1744‐50. [MEDLINE: 10553738] deLeonJ , DiazFJ , JosiassenRC , CooperTB , SimpsonGM . Weight gain during a double‐blind multidosage clozapine study. Journal of Clinical Psychopharmacology2007;27(1):22‐7. [MEDLINE: 17224708] ">Simpson 1999</a> (reported in de Leon 2007) found no significant difference between the groups in weight gain at week 12 (n = 27, 1 RCT, MD −1.10, 95% CI −3.93 to 1.73; <a href="./references#CD009555-fig-0007" title="">Analysis 1.3</a>). There was similarly no significant difference between the groups in weight gain at 16 weeks (n = 28, 1 RCT, MD −1.30, 95% CI −4.86 to 2.26; <a href="./references#CD009555-fig-0007" title="">Analysis 1.3</a>). </p> </section> <section id="CD009555-sec-0141"> <h5 class="title">1.4 Adverse effects: 1c. weight – body weight at endpoint (kg; average) – short term</h5> <p><a href="./references#CD009555-bbs2-0003" title="LiuSF , WangY , WangDP , WeiP , WangSG , MaHJ , et al. Effects of different doses clozapine on glucose metabolism in male schizophrenics. Chinese Journal of New Drugs and Clinical Remedies2005;24(2):98‐101. LiuSF , WeiP , WangSG , WangDP , WangY , MaHJ , et al. Effects of varied dosage of clozapine on blood lipid and glucometabolism in schizophrenia. Chinese Journal of Psychiatry2005;38(2):82‐5. ">Liu 2005</a> found no significant difference in body weight between the groups at the end of six weeks (n = 59, 1 RCT, MD 0.00, 95% CI −3.92 to 3.92; <a href="./references#CD009555-fig-0008" title="">Analysis 1.4</a>). </p> <p>One study, <a href="./references#CD009555-bbs2-0003" title="LiuSF , WangY , WangDP , WeiP , WangSG , MaHJ , et al. Effects of different doses clozapine on glucose metabolism in male schizophrenics. Chinese Journal of New Drugs and Clinical Remedies2005;24(2):98‐101. LiuSF , WeiP , WangSG , WangDP , WangY , MaHJ , et al. Effects of varied dosage of clozapine on blood lipid and glucometabolism in schizophrenia. Chinese Journal of Psychiatry2005;38(2):82‐5. ">Liu 2005</a>, reported on two other adverse effects. </p> </section> <section id="CD009555-sec-0142"> <h5 class="title">1.5 Adverse effects: 2a. metabolic – blood glucose – before and after meal</h5> <p>No difference between the groups were found before a meal (n = 59, 1 RCT, MD −0.40, 95% CI −1.06 to 0.26), one hour after meal (n = 59, 1 RCT, MD −0.70, 95% CI −2.01 to 0.61), two hours after meal (n = 59, 1 RCT, MD 0.30, 95% CI −0.98 to 1.58) and three hours after meal (n = 59, 1 RCT, MD −0.70, 95% CI −1.59 to 0.19). There was no significant difference in the overall analysis (n = 59, 1 RCT, MD −0.43, 95% CI −0.89 to 0.03; <a href="./references#CD009555-fig-0009" title="">Analysis 1.5</a>). </p> </section> <section id="CD009555-sec-0143"> <h5 class="title">1.6 Adverse effects: 2b. metabolic ‐ lipid profile ‐ short term</h5> <p>Participants on low‐dose clozapine had significantly lower serum triglycerides than those on a very low dose (n = 59, 1 RCT, MD 1.00, 95% CI 0.51 to 1.49). Otherwise there was no significant difference between the groups in terms of serum total cholesterol (n = 59, 1 RCT, MD 0.50, 95% CI −0.12 to 1.12), high density lipoprotein (HDL) (n = 59, 1 RCT, MD 0.04, 95% CI −0.14 to 0.22), low density lipoprotein (LDL) (n = 59, 1 RCT, MD 0.10, 95% CI −0.36 to 0.56), Apo‐A1 (n = 59, 1 RCT, MD 0.05, 95% CI −0.10 to 0.20) and Apo‐B (n = 59, 1 RCT, MD 0.13, 95% CI −0.16 to 0.42). All <a href="./references#CD009555-fig-0010" title="">Analysis 1.6</a>. </p> </section> <section id="CD009555-sec-0144"> <h5 class="title">1.7 Leaving the study early</h5> <p><a href="./references#CD009555-bbs2-0005" title="SimpsonGM . Correction. American Journal of Psychiatry2001;158(5):834. SimpsonGM , JosiassenRC , StanillaJK , deLeonJ , NairC , AbrahamG , et al. Double blind study of clozapine dose response in chronic schizophrenia. American Journal of Psychiatry1999;156(11):1744‐50. [MEDLINE: 10553738] deLeonJ , DiazFJ , JosiassenRC , CooperTB , SimpsonGM . Weight gain during a double‐blind multidosage clozapine study. Journal of Clinical Psychopharmacology2007;27(1):22‐7. [MEDLINE: 17224708] ">Simpson 1999</a> found no significant difference in numbers leaving the study early between the groups in the medium term for any reason (n = 31, 1 RCT, RR 6.00, 95% CI 0.31 to 115.56; <a href="./references#CD009555-fig-0011" title="">Analysis 1.7</a>). <a href="./references#CD009555-bbs2-0003" title="LiuSF , WangY , WangDP , WeiP , WangSG , MaHJ , et al. Effects of different doses clozapine on glucose metabolism in male schizophrenics. Chinese Journal of New Drugs and Clinical Remedies2005;24(2):98‐101. LiuSF , WeiP , WangSG , WangDP , WangY , MaHJ , et al. Effects of varied dosage of clozapine on blood lipid and glucometabolism in schizophrenia. Chinese Journal of Psychiatry2005;38(2):82‐5. ">Liu 2005</a> reported no significant difference between the groups in the short term due to specific side effects (n = 60, 1 RCT, RR 0.33, 95% CI 0.01 to 7.87; <a href="./references#CD009555-fig-0011" title="">Analysis 1.7</a>). The overall analysis showed no significant difference in the numbers leaving the study early between the very low dose and the low‐dose groups in the short and medium term (n = 91, 2 RCTs, RR 1.50, 95% CI 0.09 to 25.41; <a href="./references#CD009555-fig-0011" title="">Analysis 1.7</a>). </p> </section> <section id="CD009555-sec-0145"> <h5 class="title">Missing outcomes</h5> <p>For this comparison, no studies reported on global state, death, behaviour, functioning, quality of life, satisfaction with treatment, service use and economic costs. </p> </section> </section> <section id="CD009555-sec-0146"> <h4 class="title">Comparison 2: clozapine: very low dose (up to 149 mg/day) versus standard dose (301 mg/day to 600 mg/day) </h4> <section id="CD009555-sec-0147"> <h5 class="title">2.1 Mental state: average endpoint scores (BPRS‐A, high = poor) – medium term</h5> <p><a href="./references#CD009555-bbs2-0005" title="SimpsonGM . Correction. American Journal of Psychiatry2001;158(5):834. SimpsonGM , JosiassenRC , StanillaJK , deLeonJ , NairC , AbrahamG , et al. Double blind study of clozapine dose response in chronic schizophrenia. American Journal of Psychiatry1999;156(11):1744‐50. [MEDLINE: 10553738] deLeonJ , DiazFJ , JosiassenRC , CooperTB , SimpsonGM . Weight gain during a double‐blind multidosage clozapine study. Journal of Clinical Psychopharmacology2007;27(1):22‐7. [MEDLINE: 17224708] ">Simpson 1999</a> found no significant difference in mean endpoint BPRS‐A scores at 16 weeks (n = 31, 1 RCT, MD 6.67, 95% CI −2.09 to 15.43; <a href="./references#CD009555-fig-0012" title="">Analysis 2.1</a>). </p> </section> <section id="CD009555-sec-0148"> <h5 class="title">2.2 Adverse effects: 1a. weight – BMI (in kg/m²) – short term</h5> <p><a href="./references#CD009555-bbs2-0003" title="LiuSF , WangY , WangDP , WeiP , WangSG , MaHJ , et al. Effects of different doses clozapine on glucose metabolism in male schizophrenics. Chinese Journal of New Drugs and Clinical Remedies2005;24(2):98‐101. LiuSF , WeiP , WangSG , WangDP , WangY , MaHJ , et al. Effects of varied dosage of clozapine on blood lipid and glucometabolism in schizophrenia. Chinese Journal of Psychiatry2005;38(2):82‐5. ">Liu 2005</a> found no significant difference in body mass index (BMI) at the end of six weeks in the very low dose group compared to the standard‐dose group (n = 58, 1 RCT, MD 0.10, 95% CI −0.76 to 0.96; <a href="./references#CD009555-fig-0013" title="">Analysis 2.2</a>). </p> </section> <section id="CD009555-sec-0149"> <h5 class="title">2.3 Adverse effects: 1b. weight – weight gain (kg; average)</h5> <p><a href="./references#CD009555-bbs2-0005" title="SimpsonGM . Correction. American Journal of Psychiatry2001;158(5):834. SimpsonGM , JosiassenRC , StanillaJK , deLeonJ , NairC , AbrahamG , et al. Double blind study of clozapine dose response in chronic schizophrenia. American Journal of Psychiatry1999;156(11):1744‐50. [MEDLINE: 10553738] deLeonJ , DiazFJ , JosiassenRC , CooperTB , SimpsonGM . Weight gain during a double‐blind multidosage clozapine study. Journal of Clinical Psychopharmacology2007;27(1):22‐7. [MEDLINE: 17224708] ">Simpson 1999</a> (reported by de Leon 2007) found significantly lower weight gain in the very low dose group at 12 weeks (n = 27, 1 RCT, MD −2.70, 95% CI −5.38 to −0.02), although no significant difference between the groups at 16 weeks (n = 28, 1 RCT, MD −3.10, 95% CI −6.73 to 0.53; <a href="./references#CD009555-fig-0014" title="">Analysis 2.3</a>). </p> </section> <section id="CD009555-sec-0150"> <h5 class="title">2.4 Adverse effects: 1c. body weight at endpoint – short term (kg; average)</h5> <p><a href="./references#CD009555-bbs2-0003" title="LiuSF , WangY , WangDP , WeiP , WangSG , MaHJ , et al. Effects of different doses clozapine on glucose metabolism in male schizophrenics. Chinese Journal of New Drugs and Clinical Remedies2005;24(2):98‐101. LiuSF , WeiP , WangSG , WangDP , WangY , MaHJ , et al. Effects of varied dosage of clozapine on blood lipid and glucometabolism in schizophrenia. Chinese Journal of Psychiatry2005;38(2):82‐5. ">Liu 2005</a> found no significant difference in body weight between the groups at six weeks (n = 58, 1 RCT, MD 1.00, 95% CI −2.66 to 4.66; <a href="./references#CD009555-fig-0015" title="">Analysis 2.4</a>). </p> </section> <section id="CD009555-sec-0151"> <h5 class="title">2.5 Adverse effects: 2a. metabolic – blood glucose – short term</h5> <p><a href="./references#CD009555-bbs2-0003" title="LiuSF , WangY , WangDP , WeiP , WangSG , MaHJ , et al. Effects of different doses clozapine on glucose metabolism in male schizophrenics. Chinese Journal of New Drugs and Clinical Remedies2005;24(2):98‐101. LiuSF , WeiP , WangSG , WangDP , WangY , MaHJ , et al. Effects of varied dosage of clozapine on blood lipid and glucometabolism in schizophrenia. Chinese Journal of Psychiatry2005;38(2):82‐5. ">Liu 2005</a> found that glucose level one hour after a meal was significantly less in the very low dose group (n = 58, 1 RCT, MD −1.60, 95% CI −2.90 to −0.30). There was no significant difference between the groups before meal (n = 58, 1 RCT, MD −0.10, 95% CI −0.68 to 0.48), two hours after meal (n = 58, 1 RCT, MD −0.60, 95% CI −1.89 to 0.69) or three hours after meal (n = 58, 1 RCT, MD −0.30, 95% CI −1.55 to 0.95). There was no significant difference in the overall analysis between the groups (n = 58, 1 RCT, MD −0.49, 95% CI −1.12 to 0.13). All <a href="./references#CD009555-fig-0016" title="">Analysis 2.5</a>. </p> </section> <section id="CD009555-sec-0152"> <h5 class="title">2.6 Adverse effects: 2b. lipid profile – short term</h5> <p><a href="./references#CD009555-bbs2-0003" title="LiuSF , WangY , WangDP , WeiP , WangSG , MaHJ , et al. Effects of different doses clozapine on glucose metabolism in male schizophrenics. Chinese Journal of New Drugs and Clinical Remedies2005;24(2):98‐101. LiuSF , WeiP , WangSG , WangDP , WangY , MaHJ , et al. Effects of varied dosage of clozapine on blood lipid and glucometabolism in schizophrenia. Chinese Journal of Psychiatry2005;38(2):82‐5. ">Liu 2005</a> found that standard dose was associated with significantly lower serum levels of total cholesterol (n = 58, 1 RCT, MD 1.00, 95% CI 0.20 to 1.80), triglycerides (n = 58, 1 RCT, MD 1.30, 95% CI 0.81 to 1.79) and Apo‐B (n = 58, 1 RCT, MD 0.23, 95% CI 0.01 to 0.45). No significant difference was found between the groups in high density lipoprotein (HDL) (n = 58, 1 RCT, MD 0.10, 95% CI −0.13 to 0.33), low density lipoprotein (LDL) (n = 58, 1 RCT, MD 0.00, 95% CI −0.39 to 0.39) or Apo‐A1 levels (n = 58, 1 RCT, MD 0.04, 95% CI −0.10 to 0.18). All <a href="./references#CD009555-fig-0017" title="">Analysis 2.6</a>. </p> </section> <section id="CD009555-sec-0153"> <h5 class="title">2.7 Leaving the study early</h5> <p><a href="./references#CD009555-bbs2-0005" title="SimpsonGM . Correction. American Journal of Psychiatry2001;158(5):834. SimpsonGM , JosiassenRC , StanillaJK , deLeonJ , NairC , AbrahamG , et al. Double blind study of clozapine dose response in chronic schizophrenia. American Journal of Psychiatry1999;156(11):1744‐50. [MEDLINE: 10553738] deLeonJ , DiazFJ , JosiassenRC , CooperTB , SimpsonGM . Weight gain during a double‐blind multidosage clozapine study. Journal of Clinical Psychopharmacology2007;27(1):22‐7. [MEDLINE: 17224708] ">Simpson 1999</a> found no significant difference in numbers leaving the study early for any reason between the groups in the medium term (n = 31, 1 RCT, RR 1.21, 95% CI 0.20 to 7.55). <a href="./references#CD009555-bbs2-0003" title="LiuSF , WangY , WangDP , WeiP , WangSG , MaHJ , et al. Effects of different doses clozapine on glucose metabolism in male schizophrenics. Chinese Journal of New Drugs and Clinical Remedies2005;24(2):98‐101. LiuSF , WeiP , WangSG , WangDP , WangY , MaHJ , et al. Effects of varied dosage of clozapine on blood lipid and glucometabolism in schizophrenia. Chinese Journal of Psychiatry2005;38(2):82‐5. ">Liu 2005</a> reported no significant difference between the groups in numbers leaving the study early due to specific physical side effects in the short term (n = 60, 1 RCT, RR 0.20, 95% CI 0.01 to 4.00). The overall analysis showed no significant difference between the groups (n = 91, 2 RCTs, RR 0.73, 95% CI 0.14 to 3.72; <a href="./references#CD009555-fig-0018" title="">Analysis 2.7</a>). </p> </section> <section id="CD009555-sec-0154"> <h5 class="title">Missing outcomes</h5> <p>For this comparison, no studies reported on global state, death, behaviour, functioning, quality of life, satisfaction with treatment, service use and economic costs. </p> </section> </section> <section id="CD009555-sec-0155"> <h4 class="title">Comparison 3: clopazine: low dose (150 mg/day to 300 mg/day) versus standard dose (301 mg/day to 600 mg/day) </h4> <section id="CD009555-sec-0156"> <h5 class="title">3.1 Mental state: 1a. clinically important response (BPRS score &gt; 30% change)</h5> <p><a href="./references#CD009555-bbs2-0001" title="ChenYG , ZhaoJP , XieGR , ChenJD , ZhuRH , LiaoJD , et al. A study on serum concentration and clinical response of clozapine with different dose administration for treatment of schizophrenia. Chinese Journal of Psychiatry1998;31(2):104‐7. ">Chen 1998</a> found no significant difference in curative rate between the groups (n = 176, 1 RCT, RR 0.93, 95% CI 0.78 to 1.10; <a href="./references#CD009555-fig-0019" title="">Analysis 3.1</a>). </p> </section> <section id="CD009555-sec-0157"> <h5 class="title">3.2 Mental state: 1b. average endpoint score (BPRS‐A total, high = poor)</h5> <p><a href="./references#CD009555-bbs2-0001" title="ChenYG , ZhaoJP , XieGR , ChenJD , ZhuRH , LiaoJD , et al. A study on serum concentration and clinical response of clozapine with different dose administration for treatment of schizophrenia. Chinese Journal of Psychiatry1998;31(2):104‐7. ">Chen 1998</a> reported no significant difference between the groups for total scores at week 6 (n = 176, 1 RCT, MD 1.70, 95% CI −1.26 to 4.66; <a href="./references#CD009555-fig-0020" title="">Analysis 3.2</a>). <a href="./references#CD009555-bbs2-0005" title="SimpsonGM . Correction. American Journal of Psychiatry2001;158(5):834. SimpsonGM , JosiassenRC , StanillaJK , deLeonJ , NairC , AbrahamG , et al. Double blind study of clozapine dose response in chronic schizophrenia. American Journal of Psychiatry1999;156(11):1744‐50. [MEDLINE: 10553738] deLeonJ , DiazFJ , JosiassenRC , CooperTB , SimpsonGM . Weight gain during a double‐blind multidosage clozapine study. Journal of Clinical Psychopharmacology2007;27(1):22‐7. [MEDLINE: 17224708] ">Simpson 1999</a> reported no significant difference between the groups for total scores at 16 weeks (n = 34, 1 RCT, MD 3.12, 95% CI −4.20 to 10.44; <a href="./references#CD009555-fig-0020" title="">Analysis 3.2</a>). </p> </section> <section id="CD009555-sec-0158"> <h5 class="title">3.3 Mental state: 1c. average endpoint score (BPRS‐A, subscores, high = poor)</h5> <section id="CD009555-sec-0159"> <h6 class="title">3.3.1 Anxiety</h6> <p><a href="./references#CD009555-bbs2-0001" title="ChenYG , ZhaoJP , XieGR , ChenJD , ZhuRH , LiaoJD , et al. A study on serum concentration and clinical response of clozapine with different dose administration for treatment of schizophrenia. Chinese Journal of Psychiatry1998;31(2):104‐7. ">Chen 1998</a> found no significant difference between the groups at week 6 (n = 176, 1 RCT, MD 0.00, 95% CI −0.09 to 0.09; <a href="./references#CD009555-fig-0021" title="">Analysis 3.3</a>). </p> </section> <section id="CD009555-sec-0160"> <h6 class="title">3.3.2 Blunted Affect</h6> <p><a href="./references#CD009555-bbs2-0001" title="ChenYG , ZhaoJP , XieGR , ChenJD , ZhuRH , LiaoJD , et al. A study on serum concentration and clinical response of clozapine with different dose administration for treatment of schizophrenia. Chinese Journal of Psychiatry1998;31(2):104‐7. ">Chen 1998</a> found no significant difference between the groups at week 6 (n = 176, 1 RCT, MD 0.00, 95% CI −0.18 to 0.18; <a href="./references#CD009555-fig-0021" title="">Analysis 3.3</a>). </p> </section> <section id="CD009555-sec-0161"> <h6 class="title">3.3.3 Conceptual Disorganisation</h6> <p><a href="./references#CD009555-bbs2-0001" title="ChenYG , ZhaoJP , XieGR , ChenJD , ZhuRH , LiaoJD , et al. A study on serum concentration and clinical response of clozapine with different dose administration for treatment of schizophrenia. Chinese Journal of Psychiatry1998;31(2):104‐7. ">Chen 1998</a> found no significant difference between the groups at week 6 (n = 176, 1 RCT, MD 0.20, 95% CI −0.02 to 0.42, <a href="./references#CD009555-fig-0020" title="">Analysis 3.2</a>.5). </p> </section> <section id="CD009555-sec-0162"> <h6 class="title">3.3.4 Excitement</h6> <p><a href="./references#CD009555-bbs2-0001" title="ChenYG , ZhaoJP , XieGR , ChenJD , ZhuRH , LiaoJD , et al. A study on serum concentration and clinical response of clozapine with different dose administration for treatment of schizophrenia. Chinese Journal of Psychiatry1998;31(2):104‐7. ">Chen 1998</a> found no significant difference between the groups at week 6 (n = 176, 1 RCT, MD 0.00, 95% CI −0.10 to 0.10; <a href="./references#CD009555-fig-0021" title="">Analysis 3.3</a>). </p> </section> <section id="CD009555-sec-0163"> <h6 class="title">3.3.5 Uncooperativeness</h6> <p><a href="./references#CD009555-bbs2-0001" title="ChenYG , ZhaoJP , XieGR , ChenJD , ZhuRH , LiaoJD , et al. A study on serum concentration and clinical response of clozapine with different dose administration for treatment of schizophrenia. Chinese Journal of Psychiatry1998;31(2):104‐7. ">Chen 1998</a> found no significant difference between the groups at week 6 (n = 176, 1 RCT, MD 0.00, 95% CI −0.21 to 0.21; <a href="./references#CD009555-fig-0021" title="">Analysis 3.3</a>). </p> </section> </section> <section id="CD009555-sec-0164"> <h5 class="title">3.4 Mental state: 1d. clinical improvement (clinician assessed)</h5> <p>There was no significant difference between groups at 12 weeks (<a href="./references#CD009555-bbs2-0001" title="ChenYG , ZhaoJP , XieGR , ChenJD , ZhuRH , LiaoJD , et al. A study on serum concentration and clinical response of clozapine with different dose administration for treatment of schizophrenia. Chinese Journal of Psychiatry1998;31(2):104‐7. ">Chen 1998</a>; <a href="./references#CD009555-bbs2-0002" title="ChenYH , CaoQ , ChenWQ . The effect of clozapine for patients with schizophrenia: a clinical trial [氯氮平治疗精神分裂症患者的临床研究]. Modern Diagnosis and Treatment [现代诊断与治疗]2013, issue 15:3460‐1. ">Chen 2013</a>) (n = 141, 2 RCTs, RR 0.76, 95% CI 0.36 to 1.61; <a href="./references#CD009555-fig-0022" title="">Analysis 3.4</a>). </p> </section> <section id="CD009555-sec-0165"> <h5 class="title">3.5 Adverse effects: 1a. weight – BMI (in kg/m²) – short term</h5> <p><a href="./references#CD009555-bbs2-0003" title="LiuSF , WangY , WangDP , WeiP , WangSG , MaHJ , et al. Effects of different doses clozapine on glucose metabolism in male schizophrenics. Chinese Journal of New Drugs and Clinical Remedies2005;24(2):98‐101. LiuSF , WeiP , WangSG , WangDP , WangY , MaHJ , et al. Effects of varied dosage of clozapine on blood lipid and glucometabolism in schizophrenia. Chinese Journal of Psychiatry2005;38(2):82‐5. ">Liu 2005</a> found no significant difference in body mass index at the end of six weeks in the low dose group compared to the standard dose group (n = 57, 1 RCT, MD 0.20, 95% CI −0.84 to 1.24; <a href="./references#CD009555-fig-0023" title="">Analysis 3.5</a>) </p> </section> <section id="CD009555-sec-0166"> <h5 class="title">3.6 Adverse effects: 1b. weight – weight gain (kg; average)</h5> <p><a href="./references#CD009555-bbs2-0005" title="SimpsonGM . Correction. American Journal of Psychiatry2001;158(5):834. SimpsonGM , JosiassenRC , StanillaJK , deLeonJ , NairC , AbrahamG , et al. Double blind study of clozapine dose response in chronic schizophrenia. American Journal of Psychiatry1999;156(11):1744‐50. [MEDLINE: 10553738] deLeonJ , DiazFJ , JosiassenRC , CooperTB , SimpsonGM . Weight gain during a double‐blind multidosage clozapine study. Journal of Clinical Psychopharmacology2007;27(1):22‐7. [MEDLINE: 17224708] ">Simpson 1999</a> (reported in de Leon 2007) found no significant difference in weight gain between the groups at week 12 (n = 30, 1 RCT, MD −1.60, 95% CI −4.47 to 1.27) or week 16 (n = 30, MD −1.80, 95% CI −5.38 to 1.78; <a href="./references#CD009555-fig-0024" title="">Analysis 3.6</a>). </p> </section> <section id="CD009555-sec-0167"> <h5 class="title">3.7 Adverse effects: 1c. body weight at endpoint (kg; average) – short term</h5> <p><a href="./references#CD009555-bbs2-0003" title="LiuSF , WangY , WangDP , WeiP , WangSG , MaHJ , et al. Effects of different doses clozapine on glucose metabolism in male schizophrenics. Chinese Journal of New Drugs and Clinical Remedies2005;24(2):98‐101. LiuSF , WeiP , WangSG , WangDP , WangY , MaHJ , et al. Effects of varied dosage of clozapine on blood lipid and glucometabolism in schizophrenia. Chinese Journal of Psychiatry2005;38(2):82‐5. ">Liu 2005</a> found no significant difference in body weight between the groups in the short term (n = 57, 1 RCT, MD 1.00, 95% CI −3.42 to 5.42; <a href="./references#CD009555-fig-0023" title="">Analysis 3.5</a>.4). </p> </section> <section id="CD009555-sec-0168"> <h5 class="title">3.8 Adverse effects: 2a. metabolic – blood glucose – short term</h5> <p><a href="./references#CD009555-bbs2-0003" title="LiuSF , WangY , WangDP , WeiP , WangSG , MaHJ , et al. Effects of different doses clozapine on glucose metabolism in male schizophrenics. Chinese Journal of New Drugs and Clinical Remedies2005;24(2):98‐101. LiuSF , WeiP , WangSG , WangDP , WangY , MaHJ , et al. Effects of varied dosage of clozapine on blood lipid and glucometabolism in schizophrenia. Chinese Journal of Psychiatry2005;38(2):82‐5. ">Liu 2005</a> found no significant difference in glucose levels between the groups before meal (n = 57, 1 RCT, MD 0.30, 95% CI −0.23 to 0.83; <a href="./references#CD009555-fig-0026" title="">Analysis 3.8</a>), one hour after meal (n = 57, 1 RCT, MD −0.90, 95% CI −2.33 to 0.53; <a href="./references#CD009555-fig-0026" title="">Analysis 3.8</a>), two hours after meal (n = 57, 1 RCT, MD −0.90, 95% CI −2.14 to 0.34; <a href="./references#CD009555-fig-0026" title="">Analysis 3.8</a>), three hours after meal (n = 57, 1 RCT, MD 0.40, 95% CI −0.84 to 1.64; <a href="./references#CD009555-fig-0026" title="">Analysis 3.8</a>). There was no difference between the groups in the overall analysis (1 RCT, MD −0.12, 95% CI −0.79 to 0.56; <a href="./references#CD009555-fig-0026" title="">Analysis 3.8</a>). </p> </section> <section id="CD009555-sec-0169"> <h5 class="title">3.9 Adverse effects: 2b. metabolic – lipid profile – short term</h5> <p><a href="./references#CD009555-bbs2-0003" title="LiuSF , WangY , WangDP , WeiP , WangSG , MaHJ , et al. Effects of different doses clozapine on glucose metabolism in male schizophrenics. Chinese Journal of New Drugs and Clinical Remedies2005;24(2):98‐101. LiuSF , WeiP , WangSG , WangDP , WangY , MaHJ , et al. Effects of varied dosage of clozapine on blood lipid and glucometabolism in schizophrenia. Chinese Journal of Psychiatry2005;38(2):82‐5. ">Liu 2005</a> found no significant difference between the groups in serum total cholesterol (n = 57, 1 RCT, MD 0.50, 95% CI −0.29 to 1.29; <a href="./references#CD009555-fig-0027" title="">Analysis 3.9</a>), triglycerides (n = 57, 1 RCT, MD 0.30, 95% CI −0.12 to 0.72; <a href="./references#CD009555-fig-0027" title="">Analysis 3.9</a>), high density lipoprotein (HDL) (n = 57, 1 RCT, MD 0.06, 95% CI −0.16 to 0.28; <a href="./references#CD009555-fig-0027" title="">Analysis 3.9</a>), low density lipoprotein (LDL) (n = 57, 1 RCT, MD −0.10, 95% CI −0.50 to 0.30; <a href="./references#CD009555-fig-0027" title="">Analysis 3.9</a>), Apo A‐1 (n = 57, 1 RCT, MD −0.01, 95% C −0.14 to 0.12; <a href="./references#CD009555-fig-0027" title="">Analysis 3.9</a>) and Apo‐B levels (n = 57, 1 RCT, MD 0.10, 95% CI −0.14 to 0.34; <a href="./references#CD009555-fig-0027" title="">Analysis 3.9</a>). </p> </section> <section id="CD009555-sec-0170"> <h5 class="title">3.10 Adverse effects: 3. various effects – short term</h5> <p><a href="./references#CD009555-bbs2-0001" title="ChenYG , ZhaoJP , XieGR , ChenJD , ZhuRH , LiaoJD , et al. A study on serum concentration and clinical response of clozapine with different dose administration for treatment of schizophrenia. Chinese Journal of Psychiatry1998;31(2):104‐7. ">Chen 1998</a> found a significantly greater incidence in the standard compared to the low dose group for lethargy (n = 176, RR 0.77, 95% CI 0.60 to 0.97; <a href="./references#CD009555-fig-0028" title="">Analysis 3.10</a>), hypersalivation (n = 176, RR 0.70, 95% CI 0.57 to 0.84; <a href="./references#CD009555-fig-0028" title="">Analysis 3.10</a>), dizziness (n = 176, RR 0.56, 95% CI 0.39 to 0.81; <a href="./references#CD009555-fig-0028" title="">Analysis 3.10</a>) and tachycardia (n = 176, RR 0.57, 95% CI 0.45 to 0.71; <a href="./references#CD009555-fig-0028" title="">Analysis 3.10</a>). </p> </section> <section id="CD009555-sec-0171"> <h5 class="title">3.11 Adverse effects: 4. average endpoint score (TESS, high = poor) – short term</h5> <p>Meta‐analysis of two studies, <a href="./references#CD009555-bbs2-0001" title="ChenYG , ZhaoJP , XieGR , ChenJD , ZhuRH , LiaoJD , et al. A study on serum concentration and clinical response of clozapine with different dose administration for treatment of schizophrenia. Chinese Journal of Psychiatry1998;31(2):104‐7. ">Chen 1998</a> and <a href="./references#CD009555-bbs2-0002" title="ChenYH , CaoQ , ChenWQ . The effect of clozapine for patients with schizophrenia: a clinical trial [氯氮平治疗精神分裂症患者的临床研究]. Modern Diagnosis and Treatment [现代诊断与治疗]2013, issue 15:3460‐1. ">Chen 2013</a>, found total TESS scores were significantly lower in the low‐dose group compared to standard dose (n = 124, 2 RCTs, MD −3.99, 95% CI −5.75 to −2.24; <a href="./references#CD009555-fig-0029" title="">Analysis 3.11</a>). <a href="./references#CD009555-bbs2-0001" title="ChenYG , ZhaoJP , XieGR , ChenJD , ZhuRH , LiaoJD , et al. A study on serum concentration and clinical response of clozapine with different dose administration for treatment of schizophrenia. Chinese Journal of Psychiatry1998;31(2):104‐7. ">Chen 1998</a> found that TESS scores were significantly lower in the low‐dose group compared to standard dose on sub scores for behavioural toxicity (n = 176, 1 RCT, MD −1.00, 95% CI −1.51 to −0.49; <a href="./references#CD009555-fig-0029" title="">Analysis 3.11</a>), vegetative nervous system (n = 176, 1 RCT, MD −0.90, 95% CI −1.61 to −0.19; <a href="./references#CD009555-fig-0029" title="">Analysis 3.11</a>) and cardiovascular system (n = 176, 1 RCT, MD −0.60, 95% CI −0.98 to −0.22; <a href="./references#CD009555-fig-0029" title="">Analysis 3.11</a>). </p> </section> <section id="CD009555-sec-0172"> <h5 class="title">3.12 Leaving the study early</h5> <p>For this comparison, no participant left the study early in <a href="./references#CD009555-bbs2-0001" title="ChenYG , ZhaoJP , XieGR , ChenJD , ZhuRH , LiaoJD , et al. A study on serum concentration and clinical response of clozapine with different dose administration for treatment of schizophrenia. Chinese Journal of Psychiatry1998;31(2):104‐7. ">Chen 1998</a>. <a href="./references#CD009555-bbs2-0005" title="SimpsonGM . Correction. American Journal of Psychiatry2001;158(5):834. SimpsonGM , JosiassenRC , StanillaJK , deLeonJ , NairC , AbrahamG , et al. Double blind study of clozapine dose response in chronic schizophrenia. American Journal of Psychiatry1999;156(11):1744‐50. [MEDLINE: 10553738] deLeonJ , DiazFJ , JosiassenRC , CooperTB , SimpsonGM . Weight gain during a double‐blind multidosage clozapine study. Journal of Clinical Psychopharmacology2007;27(1):22‐7. [MEDLINE: 17224708] ">Simpson 1999</a> found no significant difference in numbers leaving the study early for any reason between the groups in the medium term (n = 34, 1 RCT, RR 0.20, 95% CI 0.01 to 3.88; <a href="./references#CD009555-fig-0030" title="">Analysis 3.12</a>). <a href="./references#CD009555-bbs2-0003" title="LiuSF , WangY , WangDP , WeiP , WangSG , MaHJ , et al. Effects of different doses clozapine on glucose metabolism in male schizophrenics. Chinese Journal of New Drugs and Clinical Remedies2005;24(2):98‐101. LiuSF , WeiP , WangSG , WangDP , WangY , MaHJ , et al. Effects of varied dosage of clozapine on blood lipid and glucometabolism in schizophrenia. Chinese Journal of Psychiatry2005;38(2):82‐5. ">Liu 2005</a> found no significant difference in numbers leaving the study early between the groups in the short term due to specific side effects (n = 60, 1 RCT, RR 0.50, 95% CI 0.05 to 5.22; <a href="./references#CD009555-fig-0030" title="">Analysis 3.12</a>). There was no difference between the groups in the overall analysis (n = 47, 2 RCTs, RR 0.35, 95% CI 0.06 to 2.21; <a href="./references#CD009555-fig-0030" title="">Analysis 3.12</a>). </p> </section> <section id="CD009555-sec-0173"> <h5 class="title">Missing outcomes</h5> <p>For this comparison, no studies reported on global state, death, behaviour, functioning, quality of life, satisfaction with treatment, service use and economic costs. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009555-sec-0174" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009555-sec-0174"></div> <section id="CD009555-sec-0175"> <h3 class="title" id="CD009555-sec-0175">Summary of main results</h3> <p>We included five studies with data from 452 participants suffering from schizophrenia and schizoaffective disorders diagnosed by any criteria. We categorised doses of clozapine into five categories: very low dose clozapine: up to 149 mg/day; low‐dose clozapine: 150 mg/day to 300 mg/day; standard‐dose clozapine: 301 mg/day to 600 mg/day; high‐dose clozapine: 601 mg/day to 900 mg/day; and very high dose clozapine: 901 mg/day and above. <a href="./references#CD009555-bbs2-0005" title="SimpsonGM . Correction. American Journal of Psychiatry2001;158(5):834. SimpsonGM , JosiassenRC , StanillaJK , deLeonJ , NairC , AbrahamG , et al. Double blind study of clozapine dose response in chronic schizophrenia. American Journal of Psychiatry1999;156(11):1744‐50. [MEDLINE: 10553738] deLeonJ , DiazFJ , JosiassenRC , CooperTB , SimpsonGM . Weight gain during a double‐blind multidosage clozapine study. Journal of Clinical Psychopharmacology2007;27(1):22‐7. [MEDLINE: 17224708] ">Simpson 1999</a> compared the effects of clozapine at doses of 100 mg/day (very low), 300 mg/day (low dose) and 600 mg/day (standard dose) over both short term (up to 12 weeks) and medium term (16 weeks). <a href="./references#CD009555-bbs2-0002" title="ChenYH , CaoQ , ChenWQ . The effect of clozapine for patients with schizophrenia: a clinical trial [氯氮平治疗精神分裂症患者的临床研究]. Modern Diagnosis and Treatment [现代诊断与治疗]2013, issue 15:3460‐1. ">Chen 2013</a> compared doses of 200 mg/day to 300 mg/day, 301 mg/day to 400 mg/day, and 401 mg/day to 500 mg/day over 12 weeks. <a href="./references#CD009555-bbs2-0004" title="ShengXQ , HuaK , YanH , LuoLH . Clozapine therapy in schizophrenia. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]1990; Vol. 16, issue 2:90‐2. ">Sheng 1990</a> compared doses of 300 mg/day and 600 mg/day over 12 weeks. <a href="./references#CD009555-bbs2-0003" title="LiuSF , WangY , WangDP , WeiP , WangSG , MaHJ , et al. Effects of different doses clozapine on glucose metabolism in male schizophrenics. Chinese Journal of New Drugs and Clinical Remedies2005;24(2):98‐101. LiuSF , WeiP , WangSG , WangDP , WangY , MaHJ , et al. Effects of varied dosage of clozapine on blood lipid and glucometabolism in schizophrenia. Chinese Journal of Psychiatry2005;38(2):82‐5. ">Liu 2005</a> compared effects of three different doses of clozapine: less than 150 mg/day (very low dose); 150 mg/day to 300 mg/day (low dose); and more than 300 mg/day (standard) over short term. </p> <p><a href="./references#CD009555-bbs2-0003" title="LiuSF , WangY , WangDP , WeiP , WangSG , MaHJ , et al. Effects of different doses clozapine on glucose metabolism in male schizophrenics. Chinese Journal of New Drugs and Clinical Remedies2005;24(2):98‐101. LiuSF , WeiP , WangSG , WangDP , WangY , MaHJ , et al. Effects of varied dosage of clozapine on blood lipid and glucometabolism in schizophrenia. Chinese Journal of Psychiatry2005;38(2):82‐5. ">Liu 2005</a> reported over six weeks on outcomes including leaving the study early, body weight, body mass index (BMI), lipid profile and blood glucose levels measured before meals, and one hour, two hours and three hours after meals. <a href="./references#CD009555-bbs2-0002" title="ChenYH , CaoQ , ChenWQ . The effect of clozapine for patients with schizophrenia: a clinical trial [氯氮平治疗精神分裂症患者的临床研究]. Modern Diagnosis and Treatment [现代诊断与治疗]2013, issue 15:3460‐1. ">Chen 2013</a> reported on mental state as clinical improvement (clinician assessed), and on TESS scale scores. Outcomes reported by <a href="./references#CD009555-bbs2-0004" title="ShengXQ , HuaK , YanH , LuoLH . Clozapine therapy in schizophrenia. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]1990; Vol. 16, issue 2:90‐2. ">Sheng 1990</a> were mental state as clinical improvement (clinician assessed), but the authors did not report BPRS scores or TESS scale scores. </p> <p><a href="./references#CD009555-bbs2-0001" title="ChenYG , ZhaoJP , XieGR , ChenJD , ZhuRH , LiaoJD , et al. A study on serum concentration and clinical response of clozapine with different dose administration for treatment of schizophrenia. Chinese Journal of Psychiatry1998;31(2):104‐7. ">Chen 1998</a> compared clozapine at doses of 200 mg/day (low dose) and 500 mg/day (standard dose) in short‐term and reported data over six weeks on outcomes including global state on clinically important response as defined by individual studies (curative rate: BPRS score &lt; 30% change = no improvement), mental state on the Brief Psychiatric Rating scale‐Anchored (BPRS‐A) and subscores of this scale, and adverse reaction using the TESS scale and the incidence of lethargy, hypersalivation, dizziness, and tachycardia. </p> <p><a href="./references#CD009555-bbs2-0005" title="SimpsonGM . Correction. American Journal of Psychiatry2001;158(5):834. SimpsonGM , JosiassenRC , StanillaJK , deLeonJ , NairC , AbrahamG , et al. Double blind study of clozapine dose response in chronic schizophrenia. American Journal of Psychiatry1999;156(11):1744‐50. [MEDLINE: 10553738] deLeonJ , DiazFJ , JosiassenRC , CooperTB , SimpsonGM . Weight gain during a double‐blind multidosage clozapine study. Journal of Clinical Psychopharmacology2007;27(1):22‐7. [MEDLINE: 17224708] ">Simpson 1999</a> reported on leaving the study early, BPRS‐A total scores. Though their report stated that they measured CGI and SANS, these data were not reported in the paper. Data on end body weight, weight gain and BMI over shorter term and medium term were reported in de Leon 2007. Data on BMI could not be used as it was not presented according to doses. We also could not use data on “clinically important response as defined by individual studies” as the details of responders were presented only at 48 weeks and not at 16 weeks (before cross‐over). In addition, it is reported that four people responded at end of 16 weeks, but it is unclear which dosage group these four patients belonged to. <a href="./references#CD009555-bbs2-0005" title="SimpsonGM . Correction. American Journal of Psychiatry2001;158(5):834. SimpsonGM , JosiassenRC , StanillaJK , deLeonJ , NairC , AbrahamG , et al. Double blind study of clozapine dose response in chronic schizophrenia. American Journal of Psychiatry1999;156(11):1744‐50. [MEDLINE: 10553738] deLeonJ , DiazFJ , JosiassenRC , CooperTB , SimpsonGM . Weight gain during a double‐blind multidosage clozapine study. Journal of Clinical Psychopharmacology2007;27(1):22‐7. [MEDLINE: 17224708] ">Simpson 1999</a> stated that data on CGI would be discussed in <a href="./references#CD009555-bbs2-0024" title="AbrahamG , NairC , TracyJI , SimpsonGM . The effects of clozapine on symptom clusters in treatment‐refractory patients. Journal of Clinical Psychopharmacology1997;17(1):49‐53. [MEDLINE: 9004057] ">Abraham 1997</a>, but we found this was not the case. We contacted the author for data on CGI, SANS, data on responders at 16 weeks and the details on which arm the four responders belonged to but we have not received the data at the time of writing. </p> <p>There were no studies comparing high dose or very high dose of clozapine and none of the reports identified presented outcomes in the longer term. </p> <section id="CD009555-sec-0176"> <h4 class="title">1 Comparison: clozapine: very low dose (up to 149 mg/day) versus low dose (150 mg/day to 300 mg/day) </h4> <section id="CD009555-sec-0177"> <h5 class="title">Short term</h5> <p>We found no evidence relating to clinical response. In terms of adverse effects, in one RCT of 59 participants there was no difference between the groups in BMI at endpoint with the very low dose group only 0.1 lower (0.95 lower to 0.75 higher) (<a href="./references#CD009555-bbs2-0003" title="LiuSF , WangY , WangDP , WeiP , WangSG , MaHJ , et al. Effects of different doses clozapine on glucose metabolism in male schizophrenics. Chinese Journal of New Drugs and Clinical Remedies2005;24(2):98‐101. LiuSF , WeiP , WangSG , WangDP , WangY , MaHJ , et al. Effects of varied dosage of clozapine on blood lipid and glucometabolism in schizophrenia. Chinese Journal of Psychiatry2005;38(2):82‐5. ">Liu 2005</a>). On other outcomes, the same study found low‐dose clozapine associated with lower serum triglycerides compared to very low dose, but no differences between the groups in other elements of the lipid profile, in blood glucose levels, in body weight at endpoint or in leaving the study early. </p> </section> <section id="CD009555-sec-0178"> <h5 class="title">Medium term</h5> <p>We found no evidence relating to clinical response. In one small RCT of 31 participants (<a href="./references#CD009555-bbs2-0005" title="SimpsonGM . Correction. American Journal of Psychiatry2001;158(5):834. SimpsonGM , JosiassenRC , StanillaJK , deLeonJ , NairC , AbrahamG , et al. Double blind study of clozapine dose response in chronic schizophrenia. American Journal of Psychiatry1999;156(11):1744‐50. [MEDLINE: 10553738] deLeonJ , DiazFJ , JosiassenRC , CooperTB , SimpsonGM . Weight gain during a double‐blind multidosage clozapine study. Journal of Clinical Psychopharmacology2007;27(1):22‐7. [MEDLINE: 17224708] ">Simpson 1999</a>), there was no difference between the groups in average BPRS‐A scores and no difference on change in mental state score. On other outcomes, no difference was found between the groups in terms of weight gain or number leaving the study early (<a href="./references#CD009555-bbs2-0005" title="SimpsonGM . Correction. American Journal of Psychiatry2001;158(5):834. SimpsonGM , JosiassenRC , StanillaJK , deLeonJ , NairC , AbrahamG , et al. Double blind study of clozapine dose response in chronic schizophrenia. American Journal of Psychiatry1999;156(11):1744‐50. [MEDLINE: 10553738] deLeonJ , DiazFJ , JosiassenRC , CooperTB , SimpsonGM . Weight gain during a double‐blind multidosage clozapine study. Journal of Clinical Psychopharmacology2007;27(1):22‐7. [MEDLINE: 17224708] ">Simpson 1999</a>). </p> </section> </section> <section id="CD009555-sec-0179"> <h4 class="title">2 Comparison: clozapine: very low (up to 149 mg/day) versus standard dose (301 mg/day to 600 mg/day) </h4> <section id="CD009555-sec-0180"> <h5 class="title">Short term</h5> <p>We found no evidence relating to clinical response in the short term. In terms of adverse effects, in one RCT of 58 participants there was no difference between the groups in BMI at endpoint with the very low dose group only 0.1 higher (0.76 lower to 0.96 higher) (<a href="./references#CD009555-bbs2-0003" title="LiuSF , WangY , WangDP , WeiP , WangSG , MaHJ , et al. Effects of different doses clozapine on glucose metabolism in male schizophrenics. Chinese Journal of New Drugs and Clinical Remedies2005;24(2):98‐101. LiuSF , WeiP , WangSG , WangDP , WangY , MaHJ , et al. Effects of varied dosage of clozapine on blood lipid and glucometabolism in schizophrenia. Chinese Journal of Psychiatry2005;38(2):82‐5. ">Liu 2005</a>). There was no difference in body weight at endpoint in the same study, although the very low dose group had less weight gain than the standard‐dose group at six and 12 weeks. On other outcomes, we found evidence in one study that the very low dose group had lower glucose levels one hour post meal compared to the standard‐dose group, but otherwise there was no difference between the groups in blood glucose measurements (<a href="./references#CD009555-bbs2-0003" title="LiuSF , WangY , WangDP , WeiP , WangSG , MaHJ , et al. Effects of different doses clozapine on glucose metabolism in male schizophrenics. Chinese Journal of New Drugs and Clinical Remedies2005;24(2):98‐101. LiuSF , WeiP , WangSG , WangDP , WangY , MaHJ , et al. Effects of varied dosage of clozapine on blood lipid and glucometabolism in schizophrenia. Chinese Journal of Psychiatry2005;38(2):82‐5. ">Liu 2005</a>); and no difference between the groups in numbers leaving the study early. In the same study, at six weeks standard dose was associated with lower serum triglycerides, serum total cholesterol and Apo‐B, but otherwise there was no difference between the groups in terms of lipid profile (<a href="./references#CD009555-bbs2-0003" title="LiuSF , WangY , WangDP , WeiP , WangSG , MaHJ , et al. Effects of different doses clozapine on glucose metabolism in male schizophrenics. Chinese Journal of New Drugs and Clinical Remedies2005;24(2):98‐101. LiuSF , WeiP , WangSG , WangDP , WangY , MaHJ , et al. Effects of varied dosage of clozapine on blood lipid and glucometabolism in schizophrenia. Chinese Journal of Psychiatry2005;38(2):82‐5. ">Liu 2005</a>). These results should be interpreted with caution as this trial was conducted only for six weeks with a small number of participants. </p> </section> <section id="CD009555-sec-0181"> <h5 class="title">Medium term</h5> <p>We found no evidence relating to clinical response in the medium term. On other outcomes, no differences between the groups were found in the medium term for weight gain or numbers leaving the study early (<a href="./references#CD009555-bbs2-0005" title="SimpsonGM . Correction. American Journal of Psychiatry2001;158(5):834. SimpsonGM , JosiassenRC , StanillaJK , deLeonJ , NairC , AbrahamG , et al. Double blind study of clozapine dose response in chronic schizophrenia. American Journal of Psychiatry1999;156(11):1744‐50. [MEDLINE: 10553738] deLeonJ , DiazFJ , JosiassenRC , CooperTB , SimpsonGM . Weight gain during a double‐blind multidosage clozapine study. Journal of Clinical Psychopharmacology2007;27(1):22‐7. [MEDLINE: 17224708] ">Simpson 1999</a>). </p> </section> </section> <section id="CD009555-sec-0182"> <h4 class="title">3. Comparison: clozapine: low dose (150 mg/day to 300 mg/day) versus standard dose (301 mg/day to 600 mg/day) </h4> <section id="CD009555-sec-0183"> <h5 class="title">Short term</h5> <p>We found no evidence relating to clinical response or to clinically significant response in global state in the short term. In one RCT of 57 participants there was no difference between the groups in BMI at endpoint with the low‐dose group only 0.2 higher (0.84 lower to 1.24 higher) (<a href="./references#CD009555-bbs2-0003" title="LiuSF , WangY , WangDP , WeiP , WangSG , MaHJ , et al. Effects of different doses clozapine on glucose metabolism in male schizophrenics. Chinese Journal of New Drugs and Clinical Remedies2005;24(2):98‐101. LiuSF , WeiP , WangSG , WangDP , WangY , MaHJ , et al. Effects of varied dosage of clozapine on blood lipid and glucometabolism in schizophrenia. Chinese Journal of Psychiatry2005;38(2):82‐5. ">Liu 2005</a>). On other outcomes, there was no difference between the groups on body weight at endpoint, lipid profile or blood glucose measurements. Side effects measured by TESS were less in the low‐dose group in two studies (<a href="./references#CD009555-bbs2-0001" title="ChenYG , ZhaoJP , XieGR , ChenJD , ZhuRH , LiaoJD , et al. A study on serum concentration and clinical response of clozapine with different dose administration for treatment of schizophrenia. Chinese Journal of Psychiatry1998;31(2):104‐7. ">Chen 1998</a>; <a href="./references#CD009555-bbs2-0002" title="ChenYH , CaoQ , ChenWQ . The effect of clozapine for patients with schizophrenia: a clinical trial [氯氮平治疗精神分裂症患者的临床研究]. Modern Diagnosis and Treatment [现代诊断与治疗]2013, issue 15:3460‐1. ">Chen 2013</a>), and the incidence of lethargy, hypersalivation, dizziness and tachycardia were also less in the low‐dose group in one study (<a href="./references#CD009555-bbs2-0001" title="ChenYG , ZhaoJP , XieGR , ChenJD , ZhuRH , LiaoJD , et al. A study on serum concentration and clinical response of clozapine with different dose administration for treatment of schizophrenia. Chinese Journal of Psychiatry1998;31(2):104‐7. ">Chen 1998</a>). </p> </section> <section id="CD009555-sec-0184"> <h5 class="title">Medium term</h5> <p>We found no evidence from one RCT of 34 participants that mental state at endpoint, numbers leaving the study early or weight gain differed between the groups (<a href="./references#CD009555-bbs2-0005" title="SimpsonGM . Correction. American Journal of Psychiatry2001;158(5):834. SimpsonGM , JosiassenRC , StanillaJK , deLeonJ , NairC , AbrahamG , et al. Double blind study of clozapine dose response in chronic schizophrenia. American Journal of Psychiatry1999;156(11):1744‐50. [MEDLINE: 10553738] deLeonJ , DiazFJ , JosiassenRC , CooperTB , SimpsonGM . Weight gain during a double‐blind multidosage clozapine study. Journal of Clinical Psychopharmacology2007;27(1):22‐7. [MEDLINE: 17224708] ">Simpson 1999</a>). </p> </section> <section id="CD009555-sec-0185"> <h5 class="title">4. Missing outcomes</h5> <p>There was no information available on other important outcomes such as clinically significant response in social or life skills, relapse, prolactin increase, service use, satisfaction with care or quality of life. </p> </section> <section id="CD009555-sec-0186"> <h5 class="title">5. Summary</h5> <p>We identified just three randomised controlled trials that met our inclusion criteria. We looked at a range of different doses including very low (up to 149 mg/day), low (150 mg/day to 300 mg/day), standard (301 mg/day to 600 mg/day), high (601 mg/day to 900 mg/day) and very high (901 mg/day and above). All trials identified compared very low dose, low dose and standard dose only. No trials were identified comparing high dose or very high dose to standard dose. Two studies were only of six weeks' and two were of 12 weeks' duration; one study relates to a trial of 48 weeks, but only for a 16‐week period before crossing over. The data for a number of outcomes could not be extracted. Four of the five included studies were based on a small number of participants. </p> <p>The quality of the evidence available was judged very low to low, and the following findings should be interpreted cautiously. We found no evidence relating to clinical response in the short or medium term. At the end of six weeks, incidence of lethargy, hypersalivation, dizziness and tachycardia was lower at low‐ compared to standard‐dose regimes; also side effects as measured by the Treatment Emergent Side Effect Scale (TESS) were less at low compared to standard dose. At six weeks, very low dose was associated with lower levels of blood glucose one hour post meal than standard dose and weight gain was the least in this group. At six weeks, standard dose was associated with lower serum triglycerides, serum total cholesterol and Apo‐B than very low dose, and low‐dose recipients had lower serum triglycerides than those on very low dose. This might suggest that the lipid variation may not be associated with doses of clozapine in the short term, such as six weeks' duration, but more trials are needed to validate the side effects of clozapine long term </p> </section> </section> </section> <section id="CD009555-sec-0187"> <h3 class="title" id="CD009555-sec-0187">Overall completeness and applicability of evidence</h3> <section id="CD009555-sec-0188"> <h4 class="title">Completeness</h4> <p>We suggest that the studies identified are insufficient to clearly identify what dose of clozapine is optimal for people suffering from schizophrenia and schizophreniform psychosis to gain a desired response to illness, attain remission and experience an improved quality of life. Important information on outcomes relevant to clinicians, consumers and policy makers (such as relapse, remission, social functioning and quality of life, service utilisation, cost‐effectiveness, satisfaction with care, and quality of life) is not currently available. </p> </section> <section id="CD009555-sec-0189"> <h4 class="title">Applicability</h4> <p>The five studies in our review reported on 14 outcomes and only on short‐term and medium‐term durations. We could not identify any studies which compared high and very high doses of clozapine or which considered outcomes long term. This can lead to difficulties in generalising our findings in the management of chronic illness such as schizophrenia. The evidence appears to be incomplete and there are various limitations in the applicability of the results from our review. </p> </section> </section> <section id="CD009555-sec-0190"> <h3 class="title" id="CD009555-sec-0190">Quality of the evidence</h3> <p>The quality of the evidence was poor. Only one of the included studies was clearly described as a double blind trial; the other studies were not clear about blinding status. In addition, data were selectively reported in some papers, which raises the possibility of bias. The quality of the evidence was also limited by the small number of participants reported on by <a href="./references#CD009555-bbs2-0005" title="SimpsonGM . Correction. American Journal of Psychiatry2001;158(5):834. SimpsonGM , JosiassenRC , StanillaJK , deLeonJ , NairC , AbrahamG , et al. Double blind study of clozapine dose response in chronic schizophrenia. American Journal of Psychiatry1999;156(11):1744‐50. [MEDLINE: 10553738] deLeonJ , DiazFJ , JosiassenRC , CooperTB , SimpsonGM . Weight gain during a double‐blind multidosage clozapine study. Journal of Clinical Psychopharmacology2007;27(1):22‐7. [MEDLINE: 17224708] ">Simpson 1999</a> (n = 31), <a href="./references#CD009555-bbs2-0002" title="ChenYH , CaoQ , ChenWQ . The effect of clozapine for patients with schizophrenia: a clinical trial [氯氮平治疗精神分裂症患者的临床研究]. Modern Diagnosis and Treatment [现代诊断与治疗]2013, issue 15:3460‐1. ">Chen 2013</a> (n = 90), <a href="./references#CD009555-bbs2-0004" title="ShengXQ , HuaK , YanH , LuoLH . Clozapine therapy in schizophrenia. Chinese Journal of Nervous and Mental Disorders [中国神经精神疾病杂志]1990; Vol. 16, issue 2:90‐2. ">Sheng 1990</a> (n = 51) and <a href="./references#CD009555-bbs2-0003" title="LiuSF , WangY , WangDP , WeiP , WangSG , MaHJ , et al. Effects of different doses clozapine on glucose metabolism in male schizophrenics. Chinese Journal of New Drugs and Clinical Remedies2005;24(2):98‐101. LiuSF , WeiP , WangSG , WangDP , WangY , MaHJ , et al. Effects of varied dosage of clozapine on blood lipid and glucometabolism in schizophrenia. Chinese Journal of Psychiatry2005;38(2):82‐5. ">Liu 2005</a> (n = 59). It is also of concern that two trials were conducted only for six weeks. Schizophrenia is a chronic illness and medications such as clozapine would need to be prescribed for a longer period of time so that these results may not generalise in the longer term. More good‐quality trials are therefore needed to allow findings to be substantiated and firm conclusions to be drawn. </p> </section> <section id="CD009555-sec-0191"> <h3 class="title" id="CD009555-sec-0191">Potential biases in the review process</h3> <p>We are not aware of any flaws in our review process. The search for trials was thorough and the review authors followed the criteria prespecified in the protocol. It is always possible, however, that we could have failed to identify relevant studies. </p> </section> <section id="CD009555-sec-0192"> <h3 class="title" id="CD009555-sec-0192">Agreements and disagreements with other studies or reviews</h3> <p>To our knowledge there has been no other systematic review or meta‐analysis comparing different doses of clozapine. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009555-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/urn:x-wiley:14651858:media:CD009555:CD009555-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_t/tCD009555-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Clozapine structure" data-id="CD009555-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Clozapine structure</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/full#CD009555-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009555-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/urn:x-wiley:14651858:media:CD009555:CD009555-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_t/tCD009555-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD009555-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/full#CD009555-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009555-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/urn:x-wiley:14651858:media:CD009555:CD009555-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_t/tCD009555-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009555-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/full#CD009555-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009555-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/urn:x-wiley:14651858:media:CD009555:CD009555-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_t/tCD009555-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009555-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/full#CD009555-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009555-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/urn:x-wiley:14651858:media:CD009555:CD009555-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_t/tCD009555-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150 to 300 mg/day), Outcome 1 Mental state: Average endpoint score (BPRS‐A, high = poor) ‐ medium term." data-id="CD009555-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150 to 300 mg/day), Outcome 1 Mental state: Average endpoint score (BPRS‐A, high = poor) ‐ medium term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/references#CD009555-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009555-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/urn:x-wiley:14651858:media:CD009555:CD009555-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_t/tCD009555-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150 to 300 mg/day), Outcome 2 Adverse effects: 1a. Weight ‐ BMI ‐ short term." data-id="CD009555-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150 to 300 mg/day), Outcome 2 Adverse effects: 1a. Weight ‐ BMI ‐ short term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/references#CD009555-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009555-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/urn:x-wiley:14651858:media:CD009555:CD009555-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_t/tCD009555-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150 to 300 mg/day), Outcome 3 Adverse effects: 1b. Weight ‐ weight gain." data-id="CD009555-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150 to 300 mg/day), Outcome 3 Adverse effects: 1b. Weight ‐ weight gain. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/references#CD009555-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009555-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/urn:x-wiley:14651858:media:CD009555:CD009555-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_t/tCD009555-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150 to 300 mg/day), Outcome 4 Adverse effects: 1c. Weight ‐ body weight at endpoint ‐ short term." data-id="CD009555-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150 to 300 mg/day), Outcome 4 Adverse effects: 1c. Weight ‐ body weight at endpoint ‐ short term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/references#CD009555-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009555-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/urn:x-wiley:14651858:media:CD009555:CD009555-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_t/tCD009555-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150 to 300 mg/day), Outcome 5 Adverse effects: 2a. Metabolic ‐ blood glucose ‐ short term." data-id="CD009555-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150 to 300 mg/day), Outcome 5 Adverse effects: 2a. Metabolic ‐ blood glucose ‐ short term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/references#CD009555-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009555-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/urn:x-wiley:14651858:media:CD009555:CD009555-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_t/tCD009555-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150 to 300 mg/day), Outcome 6 Adverse effects: 2b. Metabolic ‐ lipid profile ‐ short term." data-id="CD009555-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150 to 300 mg/day), Outcome 6 Adverse effects: 2b. Metabolic ‐ lipid profile ‐ short term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/references#CD009555-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009555-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/urn:x-wiley:14651858:media:CD009555:CD009555-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_t/tCD009555-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150 to 300 mg/day), Outcome 7 Leaving the study early." data-id="CD009555-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150 to 300 mg/day), Outcome 7 Leaving the study early. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/references#CD009555-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009555-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/urn:x-wiley:14651858:media:CD009555:CD009555-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_t/tCD009555-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus STANDARD DOSE (301‐600 mg/day), Outcome 1 Mental state: 1a. Average endpoint score (BPRS‐A, high = poor) ‐ medium term." data-id="CD009555-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus STANDARD DOSE (301‐600 mg/day), Outcome 1 Mental state: 1a. Average endpoint score (BPRS‐A, high = poor) ‐ medium term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/references#CD009555-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009555-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/urn:x-wiley:14651858:media:CD009555:CD009555-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_t/tCD009555-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus STANDARD DOSE (301‐600 mg/day), Outcome 2 Adverse effects: 1a. Weight ‐ BMI ‐ short term." data-id="CD009555-fig-0013" src="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus STANDARD DOSE (301‐600 mg/day), Outcome 2 Adverse effects: 1a. Weight ‐ BMI ‐ short term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/references#CD009555-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009555-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/urn:x-wiley:14651858:media:CD009555:CD009555-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_t/tCD009555-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus STANDARD DOSE (301‐600 mg/day), Outcome 3 Adverse effects: 1b. Weight ‐ weight gain." data-id="CD009555-fig-0014" src="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus STANDARD DOSE (301‐600 mg/day), Outcome 3 Adverse effects: 1b. Weight ‐ weight gain. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/references#CD009555-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009555-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/urn:x-wiley:14651858:media:CD009555:CD009555-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_t/tCD009555-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus STANDARD DOSE (301‐600 mg/day), Outcome 4 Adverse effects: 1c. Weight ‐ body weight at endpoint ‐ short term." data-id="CD009555-fig-0015" src="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus STANDARD DOSE (301‐600 mg/day), Outcome 4 Adverse effects: 1c. Weight ‐ body weight at endpoint ‐ short term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/references#CD009555-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009555-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/urn:x-wiley:14651858:media:CD009555:CD009555-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_t/tCD009555-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus STANDARD DOSE (301‐600 mg/day), Outcome 5 Adverse effects: 2a. Metabolic ‐ blood glucose ‐ short term." data-id="CD009555-fig-0016" src="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus STANDARD DOSE (301‐600 mg/day), Outcome 5 Adverse effects: 2a. Metabolic ‐ blood glucose ‐ short term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/references#CD009555-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009555-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/urn:x-wiley:14651858:media:CD009555:CD009555-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_t/tCD009555-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus STANDARD DOSE (301‐600 mg/day), Outcome 6 Adverse effects: 2b. Metabolic ‐ lipid profile ‐ short term." data-id="CD009555-fig-0017" src="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus STANDARD DOSE (301‐600 mg/day), Outcome 6 Adverse effects: 2b. Metabolic ‐ lipid profile ‐ short term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/references#CD009555-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009555-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/urn:x-wiley:14651858:media:CD009555:CD009555-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_t/tCD009555-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus STANDARD DOSE (301‐600 mg/day), Outcome 7 Leaving the study early." data-id="CD009555-fig-0018" src="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus STANDARD DOSE (301‐600 mg/day), Outcome 7 Leaving the study early. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/references#CD009555-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009555-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/urn:x-wiley:14651858:media:CD009555:CD009555-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_t/tCD009555-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 1 Mental state: 1a. Clinically important response as (BPRS score &gt; 30% change)." data-id="CD009555-fig-0019" src="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 1 Mental state: 1a. Clinically important response as (BPRS score &gt; 30% change). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/references#CD009555-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009555-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/urn:x-wiley:14651858:media:CD009555:CD009555-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_t/tCD009555-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 2 Mental state: 1b. Average endpoint score (BPRS‐A total, high = poor)." data-id="CD009555-fig-0020" src="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 2 Mental state: 1b. Average endpoint score (BPRS‐A total, high = poor). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/references#CD009555-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009555-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/urn:x-wiley:14651858:media:CD009555:CD009555-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_t/tCD009555-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 3 Mental state: 1c. Average endpoint score (BPRS‐A subscores, high = poor) ‐ short term." data-id="CD009555-fig-0021" src="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 3 Mental state: 1c. Average endpoint score (BPRS‐A subscores, high = poor) ‐ short term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/references#CD009555-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009555-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/urn:x-wiley:14651858:media:CD009555:CD009555-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_t/tCD009555-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 4 Mental state: 1e. Clinical improvement, clinician assessed." data-id="CD009555-fig-0022" src="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 4 Mental state: 1e. Clinical improvement, clinician assessed. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/references#CD009555-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009555-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/urn:x-wiley:14651858:media:CD009555:CD009555-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_t/tCD009555-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 5 Adverse effects: 1a. Weight ‐ BMI ‐ short term." data-id="CD009555-fig-0023" src="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 5 Adverse effects: 1a. Weight ‐ BMI ‐ short term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/references#CD009555-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009555-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/urn:x-wiley:14651858:media:CD009555:CD009555-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_t/tCD009555-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 6 Adverse effects: 1b. Weight ‐ weight gain." data-id="CD009555-fig-0024" src="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 6 Adverse effects: 1b. Weight ‐ weight gain. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/references#CD009555-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009555-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/urn:x-wiley:14651858:media:CD009555:CD009555-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_t/tCD009555-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 7 Adverse effects: 1c. Weight ‐ body weight at endpoint ‐ short term." data-id="CD009555-fig-0025" src="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 7 Adverse effects: 1c. Weight ‐ body weight at endpoint ‐ short term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/references#CD009555-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009555-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/urn:x-wiley:14651858:media:CD009555:CD009555-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_t/tCD009555-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 8 Adverse effects: 2a. Metabolic ‐ blood glucose ‐ short term." data-id="CD009555-fig-0026" src="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 8 Adverse effects: 2a. Metabolic ‐ blood glucose ‐ short term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/references#CD009555-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009555-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/urn:x-wiley:14651858:media:CD009555:CD009555-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_t/tCD009555-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 9 Adverse effects: 2b. Metabolic ‐ lipid profile ‐ short term." data-id="CD009555-fig-0027" src="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 9 Adverse effects: 2b. Metabolic ‐ lipid profile ‐ short term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/references#CD009555-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009555-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/urn:x-wiley:14651858:media:CD009555:CD009555-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_t/tCD009555-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 10 Adverse effects: 3. Various effects ‐ short term." data-id="CD009555-fig-0028" src="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 10 Adverse effects: 3. Various effects ‐ short term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/references#CD009555-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009555-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/urn:x-wiley:14651858:media:CD009555:CD009555-CMP-003-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_t/tCD009555-CMP-003-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 11 Adverse effects: 4. Average endpoint scores (TESS, high = poor) ‐ short term." data-id="CD009555-fig-0029" src="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-003-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 11 Adverse effects: 4. Average endpoint scores (TESS, high = poor) ‐ short term. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/references#CD009555-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-003-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009555-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/urn:x-wiley:14651858:media:CD009555:CD009555-CMP-003-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_t/tCD009555-CMP-003-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 12 Leaving the study early." data-id="CD009555-fig-0030" src="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-003-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3 CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day), Outcome 12 Leaving the study early. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/references#CD009555-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/media/CDSR/CD009555/image_n/nCD009555-CMP-003-12.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009555-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Clozapine: very low dose (up to 149 mg/day) versus low dose (150 mg/day to 300 mg/day) for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150‐300 mg/day) for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> <br/> <b>Intervention:</b> Clozapine: very low dose (up to 149 mg/day) versus low dose (150 mg/day to 300 mg/day) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Clozapine: very low dose (up to 149 mg/day) versus low dose (150 mg/day to 300 mg/day)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: clinically important response, as defined by individual studies</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: clinically important response, as defined by individual studies *</b> </p> <p>Follow‐up: 16 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean clinical response: mental state ‐ average scores ‐ medium term endpoint (BPRS‐A, high = worse) in the intervention group was<br/> <b>3.55 higher</b> <br/> (4.50 to 11.60 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>* Pre‐defined outcome not reported: Mental state measured as average endpoint scores (BPRS‐A, high = worse). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Functioning: clinically important change in general functioning, as defined by individual studies</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effect: clinically important adverse effect (weight ‐ BMI)</b> <br/> Follow‐up: 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean adverse effect ‐ any clinically important specific adverse effects ‐ BMI in the intervention group was<br/> <b>0.1 lower</b> <br/> (0.95 lower to 0.75 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Service use: number of days hospitalised</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Service use: time to hospitalisation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life: clinically important change in general quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias: rated as 'serious' (downgraded by 1) due to attrition bias, reporting bias, and sponsorship by Novartis Pharmaceuticals.<br/> <sup>2</sup> Indirectness: rated 'serious' (downgraded by 1) as proxy measure of pre‐defined outcome<br/> <sup>3</sup> Imprecision: rated 'serious' (downgraded by 1) as only one study providing data, small number of participants (less than 200) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Clozapine: very low dose (up to 149 mg/day) versus low dose (150 mg/day to 300 mg/day) for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/full#CD009555-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009555-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Clozapine: very low dose (up to 149 mg/day) versus standard dose (301 mg/day to 600 mg/day) for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus STANDARD DOSE (301‐600 mg/day) for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> <br/> <b>Intervention:</b> Clozapine: very low dose (up to 149 mg/day) versus standard dose (301 mg/day to 600 mg/day) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Clozapine: very low dose (up to 149 mg/day) versus standard dose (301 mg/day to 600 mg/day)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Global state: clinically important response, as defined by individual studies</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state: clinically important response, as defined by individual studies *</b> </p> <p>Follow‐up: 16 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean clinical response: mental state ‐ average scores ‐ medium term endpoint (BPRS‐A, high = worse) in the intervention group was<br/> <b>6.67 higher</b> <br/> (2.09 to 15.43 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>* Pre‐defined outcome not reported: Mental state measured as average endpoint scores (BPRS‐A, high = worse). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Functioning: clinically important change in general functioning, as defined by individual studies</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effect: clinically important adverse effect (weight ‐ BMI)</b> <br/> Follow‐up: 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean adverse effect ‐ any clinically important specific adverse effects ‐ BMI in the intervention group was<br/> <b>0.1 higher</b> <br/> (0.76 lower to 0.96 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Service use: number of days hospitalised</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Service use: time to hospitalisation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life: clinically important change in general quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias: rated as 'serious' (downgraded by 1) due to attrition bias, reporting bias, and sponsorship by Novartis Pharmaceuticals.<br/> <sup>2</sup> Indirectness: rated 'serious' (downgraded by 1) as proxy measure of pre‐defined outcome<br/> <sup>3</sup> Imprecision: rated 'serious' (downgraded by 1) as only one study providing data, small number of participants (less than 200) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Clozapine: very low dose (up to 149 mg/day) versus standard dose (301 mg/day to 600 mg/day) for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/full#CD009555-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009555-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Clozapine: low dose (150 mg/day to 300 mg/day) versus standard dose (301 mg/day to 600 mg/day) for schizophrenia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Clozapine: low dose (150 mg/day to 300 mg/day) versus standard dose (301 mg/day to 600 mg/day) for schizophrenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with schizophrenia<br/> <b>Settings:</b> <br/> <b>Intervention:</b> Clozapine: low dose (150 mg/day to 300 mg/day) versus standard dose (301 mg/day to 600 mg/day) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Clozapine: low dose (150 mg/day to 300 mg/day) versus standard dose (301 mg/day to 600 mg/day)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Global state: clinically important response, as defined by individual studies</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Mental state: clinically important response in mental state</b> <br/> BPRS score &gt;30% change<br/> Follow‐up: 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Low<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.93</b> <br/> (0.78 to 1.1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>176<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊝⊝<br/> low <sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>186 per 1000</b> <br/> (156 to 220) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>500 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>465 per 1000</b> <br/> (390 to 550) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>800 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>744 per 1000</b> <br/> (624 to 880) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Functioning: clinically important change in general functioning, as defined by individual studies</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0<br/> (0) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effect: clinically important adverse effect ( weight ‐ BMI)</b> <br/> Follow‐up: 6 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean adverse effect ‐ any clinically important specific adverse effects ‐ BMI in the intervention group was<br/> <b>0.2 higher</b> <br/> (0.84 lower to 1.24 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2,3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Service use: number of days hospitalised</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Service use: time to hospitalisation</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life: clinically important change in general quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0<br/> (0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No study reported this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Risk of bias rated as 'serious' (downgraded by 1) as allocation concealment, blinding status and trial sponsorship unclear<br/> <sup>2</sup> Indirectness: rated 'serious' (downgraded by 1) as proxy measure of pre‐defined outcome </p> <p><sup>3</sup> Imprecision: rated as 'serious' (downgraded by 1) as only one study providing data, small number of participants (less than 200) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Clozapine: low dose (150 mg/day to 300 mg/day) versus standard dose (301 mg/day to 600 mg/day) for schizophrenia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/full#CD009555-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009555-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Other reviews in the clozapine series</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Title</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reference</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clozapine versus other atypical antipsychotics for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009555-bbs2-0028" title="Asenjo LobosC , KomossaK , Rummel‐KlugeC , HungerH , SchmidF , SchwarzS , et al. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2010, Issue 11. [DOI: 10.1002/14651858.CD006633.pub2; PUBMED: 21069690] ">Asenjo 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009555-bbs2-0037" title="CiprianiA , BosoM , BarbuiC . Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD006324.pub2; PUBMED: 19588385] ">Cipriani 2009</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clozapine versus typical neuroleptic medication for schizophrenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009555-bbs2-0048" title="EssaliA , Al‐Haj HaasanN , LiC , RathboneJ . Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD000059.pub2; PUBMED: 19160174] ">Essali 2009</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pharmacological interventions for clozapine‐induced hypersalivation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD009555-bbs2-0086" title="SyedR , AuK , CahillC , DugganL , HeY , UduV , et al. Pharmacological interventions for clozapine‐induced hypersalivation. Cochrane Database of Systematic Reviews2008, Issue 3. [DOI: 10.1002/14651858.CD005579.pub2; PUBMED: 18646130] ">Syed 2008</a> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Other reviews in the clozapine series</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/full#CD009555-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009555-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150 to 300 mg/day)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mental state: Average endpoint score (BPRS‐A, high = poor) ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.55 [‐4.50, 11.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse effects: 1a. Weight ‐ BMI ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.95, 0.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse effects: 1b. Weight ‐ weight gain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.1 [‐3.93, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.3 [‐4.86, 2.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse effects: 1c. Weight ‐ body weight at endpoint ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐3.92, 3.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse effects: 2a. Metabolic ‐ blood glucose ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Before meal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐1.06, 0.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 1 hour after meal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.70 [‐2.01, 0.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 2 hours after meal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐0.98, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 3 hours after meal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.70 [‐1.59, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse effects: 2b. Metabolic ‐ lipid profile ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 triglycerides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.51, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 cholesterol ‐ total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [‐0.12, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 lipoprotein ‐ high density (HDL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.14, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 lipoprotein ‐ low density (LDL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.36, 0.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 Apo A‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.10, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6 Apo‐B</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [‐0.16, 0.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.09, 25.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 any reason ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.0 [0.31, 115.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 specific reason (alanine aminotransferase level) ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.01, 7.87]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus LOW DOSE (150 to 300 mg/day)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/references#CD009555-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009555-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus STANDARD DOSE (301‐600 mg/day)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mental state: 1a. Average endpoint score (BPRS‐A, high = poor) ‐ medium term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.67 [‐2.09, 15.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse effects: 1a. Weight ‐ BMI ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.76, 0.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse effects: 1b. Weight ‐ weight gain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.70 [‐5.38, ‐0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.10 [‐6.73, 0.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse effects: 1c. Weight ‐ body weight at endpoint ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [‐2.66, 4.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse effects: 2a. Metabolic ‐ blood glucose ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 one hour after meal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.60 [‐2.90, ‐0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 before meal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.68, 0.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 two hours after meal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐1.89, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 three hours after meal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐1.55, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse effects: 2b. Metabolic ‐ lipid profile ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 cholesterol ‐ total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.20, 1.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 triglycerides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.81, 1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Apo ‐ B</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.01, 0.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 lipoprotein ‐ high density (HDL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.13, 0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 lipoprotein ‐ low density (LDL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.39, 0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6 Apo A ‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.10, 0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.14, 3.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 any reason ‐ medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.20, 7.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 specific reason (neutropenia and tachycardia) ‐ short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.2 [0.01, 4.00]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">CLOZAPINE: VERY LOW DOSE (up to 149 mg/day) versus STANDARD DOSE (301‐600 mg/day)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/references#CD009555-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009555-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mental state: 1a. Clinically important response as (BPRS score &gt; 30% change) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.78, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mental state: 1b. Average endpoint score (BPRS‐A total, high = poor) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [‐1.26, 4.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.12 [‐4.20, 10.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mental state: 1c. Average endpoint score (BPRS‐A subscores, high = poor) ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.09, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 blunted affect</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.18, 0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 conceptual disorganisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐0.02, 0.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 excitement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.10, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 uncooperativeness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.21, 0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Mental state: 1e. Clinical improvement, clinician assessed <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>141</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.36, 1.61]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse effects: 1a. Weight ‐ BMI ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐0.84, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse effects: 1b. Weight ‐ weight gain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.60 [‐3.81, 0.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.80 [‐5.38, 1.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse effects: 1c. Weight ‐ body weight at endpoint ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [‐3.42, 5.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Adverse effects: 2a. Metabolic ‐ blood glucose ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 before meal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐0.23, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 one hour after meal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.90 [‐2.33, 0.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 two hours after meal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.90 [‐2.14, 0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 three hours after meal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [‐0.84, 1.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse effects: 2b. Metabolic ‐ lipid profile ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 cholesterol ‐ total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [‐0.29, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 triglycerides</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [‐0.12, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 lipoprotein ‐ high density (HDL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [‐0.16, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 lipoprotein ‐ low density (LDL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.50, 0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5 Apo A ‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.14, 0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.6 Apo ‐ B</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.14, 0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Adverse effects: 3. Various effects ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 lethargy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.60, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 hypersalivation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.57, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.39, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.45, 0.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Adverse effects: 4. Average endpoint scores (TESS, high = poor) ‐ short term <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 total</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>266</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.99 [‐5.75, ‐2.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 subscore ‐ behavioural toxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [‐1.51, ‐0.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 subscore ‐ vegetative nervous system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.90 [‐1.61, ‐0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.4 subscore ‐ cardiovascular system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐0.98, ‐0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.06, 2.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 any reason: short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 any reason: medium term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.01, 3.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 specific reason: short term</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [0.05, 5.22]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">CLOZAPINE: LOW DOSE (150 to 300 mg/day) versus STANDARD DOSE (301 to 600 mg/day)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009555.pub2/references#CD009555-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009555.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD009555-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD009555-note-0007">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009555-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD009555-note-0006">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD009555-note-0004">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD009555-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD009555-note-0005">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD009555-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD009555-note-0013">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009555\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009555\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009555\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009555\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009555\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009555\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009555\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009555\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009555\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009555\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009555\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009555\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009555\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009555\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009555\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009555\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009555\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009555\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1ljSZou6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009555.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009555.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009555.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009555.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009555.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728563859"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009555.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728563863"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009555.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ec78cec4af431',t:'MTc0MDcyODU2NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 